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Polysialic acid (PSA) is a linear homopolymer formed of chains of 2,8-linked sialic acid.  
Found predominantly attached to the neural cell adhesion molecule, PSA acts to reduce cell-
cell adhesion during development.  It is also found in some areas of the adult central 
nervous system (CNS) associated with persistent neuroplasticity.  Preliminary data from our 
laboratory indicated an inverse relationship between PSA expression and the formation of 
perineuronal nets (PNNs), specialised extracellular matrix structures with a role in limiting 
plasticity in the adult CNS.  The primary aims of this thesis were to investigate this 
relationship in more detail, using in vitro models of PNN formation and  in vivo.  Also, to 
evaluate whether lentiviral vector-mediated PSA expression can enhance locomotor 
recovery and neuroplasticity in a rodent model of spinal cord injury.  PNNs were 
heterogeneously distributed throughout the grey matter of the rat cervical spinal cord, and 
increased in numbers down the dorsoventral axis.  Induced expression of PSA in the spinal 
cord of either naïve or injured rats did not alter the number or density of PNNs.  Similarly, 
enzymatic removal of PSA from the surface of cultured embryonic neurons did not affect 
the formation of the PNNs.  In a rodent model of cervical spinal cord injury, induced PSA 
expression resulted in an improvement in hindlimb, but not forelimb, locomotor function 
compared to animals injected with control virus.  Interestingly, this was not associated with 
an increased density of serotonin or synaptophysin-labelled boutons in the areas of induced 
PSA expression.  Taken together, the data presented in this thesis suggests that while 
induced PSA expression may contribute to improved locomotor function in a model of 
cervical spinal cord injury, this is not due to a reduction in the density or number of PNNs in 
the spinal cord. 
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Chapter 1: Introduction 
 
1.1 The neuronal extracellular matrix  
The neuronal extracellular matrix (ECM) is a complex structure consisting of a large array of 
molecules that act to regulate cell growth and migration, in addition to synapse formation 
and plasticity.  During development, dynamic changes occur within the matrix to regulate 
axonal sprouting and the formation of new synapses.  When the majority of developmental 
neuroplasticity has occurred the composition of the ECM changes; molecules inhibitory to 
axonal growth are upregulated and the ECM plays a large part in the limitation of 
neuroplasticity in the adult central nervous system (CNS).   
The neuronal ECM can be subdivided into three distinct regions, namely, (i) the basement 
membrane, (ii) the interstitial matrix and (iii) the perineuronal net (PNN).  These subtypes 
are classified based on the ECM structure, in addition to location around neurons.  The 
basement membrane is a specialised form of extracellular matrix, located between 
endothelial cells that line the vasculature of the CNS and the parenchyma.  It is formed of 
type IV collagen, nidogen, agrin, heparin sulphate proteoglycan-2 (HSPG-2) and the 
glycoproteins laminin and fibronectin (reviewed by (Morris et al., 2014).  The interstitial 
matrix is found throughout the spinal cord parenchyma, providing structural support to cells 
within the CNS.  Containing structural molecules such as type IV collagen, laminin and 
fibronectin, the interstitial matrix differs from the basement membrane by containing a high 
proportion of chondroitin sulphate proteoglycans (CSPGs), supporting molecules hyaluronan 
and tenascin-R, but lacking HSPG-2 (Lau et al., 2013).  Conversely, the PNN is only found 
surrounding certain neuronal populations in the adult CNS and predominantly consists of 
CSPGs, in addition to supporting molecules (Deepa et al., 2006; Galtrey et al., 2008).  As the 
main scope of this thesis is to examine the relationship between the PNN and polysialic acid 
(PSA) in considerable detail, the distribution and composition of PNNs will be discussed 
further in section 1.1.1 below.  The composition of the basement membrane, interstitial 




Molecule Basement membrane Interstitial matrix Perineuronal net 
Fibronectin    
Laminin    
Type IV collagen    
Agrin    
Nidogen    
HSPGs    
CSPGs    
Hyaluronan    
Tenascin-R    
Cartilage link protein-1    
Semaphorin 3A    
Table 1.1.  Composition of the neuronal extracellular matrix. 
 
1.1.1 Perineuronal net structure 
First identified by Camillo Golgi in the late 19th century, the PNN was described as a reticular 
structure that envelopes the neuronal cell body.  Improvements in techniques allowed 
detailed visualisation of this structure and it was subsequently determined that PNNs are 
largely formed of CSPGs, a large family of molecules that have an essential role in the 
restriction of neuroplasticity in the adult CNS, in addition to a number of supporting 
molecules, which are summarised in Table 1.1, above.   
1.1.1.1 Chondroitin sulphate proteoglycans 
Structurally, CSPGs consist of a core protein, which is covalently attached to a number of 
sulphated glycosaminoglycan (GAG) side chains.  These GAG chains are post-translationally 
added to the core protein, the numbers of which are heterogeneous between CSPGs 
(Kjellen and Lindahl, 1991).  Up to 100 GAG chains can be added to the core protein (Dyck 
and Karimi-Abdolrezaee, 2015) and the length of individual GAG chains can vary (Kjellen and 
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Lindahl, 1991; Bartus et al., 2012).  Sulphation of CSPGs chains occurs via the action of 
chondroitin sulphotransferase enzymes, which add sulphate groups to specific residues of 
the GAG chains (Bartus et al., 2012).  Five sulphation locations have been determined, 
named CS-A to CS-E.  The pattern of sulphation varies on different CSPGs, at different stages 
of development and following trauma to the CNS (Bartus et al., 2012).  This, in combination 
with the number and length of GAG chains attached to the core protein, has been shown to 
modulate the inhibitory functions of CSPGs (Nandini and Sugahara, 2006).  For example, one 
study showed that CS-A is capable of inducing a more potent suppression of neurite 
outgrowth of cultured cerebellar granule neurons, compared with CS-C (Wang et al., 2008).  
However, other studies have disputed this finding and there are conflicting results as to 
which sulphation pattern can exert the strongest inhibition of axonal outgrowth. 
Broadly speaking, CSPGs can be sub-classified into 3 families: (i) the lecticans, (ii) the matrix-
associated proteoglycans and (iii) the cell-surface proteoglycans.  The lecticans are the 
largest family of CSPGs and the most abundant class of molecule found in the neuronal 
extracellular matrix (Howell and Gottschall, 2012).  Including neurocan, versican, aggrecan 
and brevican, they have distinct expression patterns in the developing CNS, which is 
believed in part to be due to their different structures (reviewed by (Howell and Gottschall, 
2012)).  The matrix-associated family contains the CSPG phosphacan, which is abundantly 
expressed throughout the developing and the adult CNS.  While members of the lectican 
and matrix-associated CSPG families are secreted by astrocytes and neurons, the cell-
surface proteoglycan NG2 is expressed by oligodendrocyte progenitor cells and 
microglia/macrophages, and shares little homology with other CSPGs (Siebert et al., 2014).  
Moreover, only members of the lectican and matrix-associated subgroups of CSPGs have 
been found condensed in PNNs (Deepa et al., 2006; Galtrey et al., 2008).  
Results from structural studies have suggested that CSPGs are bound to long chains of 
hyaluronan, via a link protein, cartilage link protein-1 (LN1) in PNNs (Tsien, 2013).  
Furthermore, CSPGs can aggregate together, via an intermediate protein, tenascin-R, and 




Two members of the tenascin family, tenascin-R and tenascin-C, are abundantly expressed 
in the CNS.  Tenascin-C is expressed during the development of the rodent CNS and is 
typically down-regulated in the adult nervous system, with the exception of a few limited 
brain regions associated with on-going neuroplasticity and following spinal cord injury 
(reviewed by Anlar 2012).  On the other hand, expression of tenascin-R persists into 
adulthood, where it is heavily distributed throughout the extracellular matrix.  Only 
tenascin-R has been localised to PNN structures in the rodent CNS, where it acts to stabilise 
connections between CSPGs (Aspberg et al., 1997).  The importance of tenascin-R in 
maintaining the structure of the PNN was shown in studies using mice deficient in this 
protein.  PNNs in the hippocampi and somatosensory cortex of tenascin-R deficient mice 
have an abnormal structure and contain reduced immunostaining for other PNN 
components, including hyaluronan, phosphacan, brevican and neurocan (Weber et al., 1999; 
Bruckner et al., 2000). 
1.1.1.3 Link proteins 
Out of the four identified link proteins only two have been observed in PNNs: LN1 and brain 
link protein 2 (BRAL2); they act to stabilise the connections between CSPGs and hyaluronan 
(Mörgelin et al., 1994; Carulli et al., 2010).  Mounting evidence is suggesting a crucial role 
for LN1 in maintaining the integrity of the PNN structure.  LN1 expression coincides with the 
formation of PNNs in vivo, therefore it has been proposed that LN1 acts as a ‘trigger’ for 
PNN formation in the CNS (Carulli et al., 2010).  While the brains of LN1 deficient mice 
contain similar amounts of aggrecan, phosphacan, brevican and versican compared to wild-
types animals, the condensation of these CSPGs into PNNs is reduced in LN1 knockout mice.  
PNNs in these mice appear thinner, and have a reduced amount of Wisteria Floribunda 
agglutinin (WFA; a lectin which binds to the N-acetylgalactosamine units found within the 
side chains of CSPGs) labelling (Carulli et al., 2010).  In a separate study, LN1 deficiency led 
to the abnormal structure of PNN-like formations surrounding HEK293 cells in vitro (Kwok et 
al., 2010).  Similarly to the brain of LN1 deficient mice, those lacking BRAL2 do not have a 
general reduction in CSPG expression in their brains, but condensation of these molecules 




Hyaluronan is a glycosaminoglycan and is ubiquitously distributed throughout the neuronal 
extracellular matrix during development.  While expression is generally reduced in the adult 
CNS it persists in PNNs, where it is believed to bind to CSPGs (Deepa et al., 2006; McRae and 
Porter, 2012).  Hyaluronan is synthesised by the enzymes hyaluronan synthases (HAS), 
transmembrane proteins that are found on the surface of all PNN-expressing neurons (Kwok 
et al., 2010).  Three HAS enzymes have been identified, HAS1-3, which are all differentially 
expressed during postnatal development in the CNS (Galtrey et al., 2008).  As all PNNs have 
been shown to contain hyaluronan, it is likely that the PNN is anchored to the neuronal 
extracellular membrane via HAS enzymes and hyaluronan. To date only one study 
investigating the structure of the PNN in mice lacking one or more of the HAS enzymes has 
been conducted.  Mice lacking the HAS3 isoform do not show any abnormalities in the 
structure or the number of WFA-labelled PNNs in their cortex or hippocampus (Arranz et al., 
2014).  However, the appearance of ‘normal’ PNNs in HAS3 knockout mice may be due to 
the continued expression of hyaluronan by other HAS isoforms.  In an interesting in vitro 
study, HAS3, in addition to LN1 and aggrecan expression by a cell line that does not normally 
produce a pericellular matrix, led to the formation of a PNN-like structure surrounding 
HEK293 cells.  Cells expressing LN1 and aggrecan only, in the absence of hyaluronan 
produced by HAS3, did not form this PNN-like structure (Kwok et al., 2010).  
  
1.1.1.5 Semaphorin 3A 
Recent work has identified the chemorepulsive axon guidance protein semaphorin 3A as a 
component of PNNs in the adult CNS.  The semaphorins are the largest family of axon 
guidance molecules and are abundantly distributed throughout the CNS during 
development (Fiore and Püschel, 2003).  Thus far, only semaphorin 3A has been identified in 
PNNs, where it interacts with the GAG side chains of CSPGs, as enzymatic removal of these 
GAG chains using chondroitinase ABC (ChABC) abolished semaphorin 3A immunolabelling 
within the PNN (Vo et al., 2013).  As the finding of the presence of semaphorin 3A in PNNs 
was only recently discovered, there are no published studies on the structure of PNNs in 
mice lacking this protein.  As current research suggests semaphorin 3A binds exclusively to 
the GAG chains of the CSPG molecules, it may be that knocking out this protein has minimal 




Figure 1.1.  Structure of the perineuronal net. 
PNNs predominantly consist of CSPGs, such as aggrecan, versican, neurocan and brevican, 
which are anchored to the extracellular membrane by HAS enzymes, which secrete 
hyaluronan molecules.  CSPGs bind to hyaluronan via LN1, and are cross-linked via 
interactions with tenascin-R.  Semaphorin 3A, a recently discovered component of PNNs, is 
speculated to bind to the GAG side chains of CSPGs.  Adapted from Tsien 2013. 
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1.1.2 Distribution of perineuronal nets in the CNS 
To date there have only been a handful of studies that have investigated the detailed 
distribution of PNNs in specific regions of the rodent CNS, including the cerebellum and 
spinal cord.  For the most part, PNNs are detected using a combination of WFA labelling and 
antibodies raised against various members of the CSPG family.  Generally, PNN 
immunolabelling detected by WFA lectin can be observed from the end of the first and 
second postnatal weeks in most brain regions.  Cortical regions including the parietal, 
occipital and temporal cortices typically form PNNs at the end of the second postnatal week, 
with the appearance of adult-like PNNs observed at the end of the fifth week (Koppe et al., 
1997).  While the emergence of PNN structures in subcortical regions also occurs during the 
second week of postnatal development, some structures, such as the inferior colliculus and 
the red nucleus, form PNNs earlier.  Adult-like PNNs are consistently observed by the end of 
the third week throughout all examined subcortical regions (Koppe et al., 1997).  PNN 
formation in the deep cerebellar nuclei and spinal cord is observed from the first postnatal 
week (Carulli et al., 2007), and in the spinal cord, reaches adult levels by the third week 
(Galtrey et al., 2008). 
To date, two studies have provided a thorough review of PNN formation in the cerebellum 
and spinal cord, by looking at the immunolabelling of individual PNN components, such as 
the CSPGs aggrecan and phosphacan, in addition to supporting molecules such as LN1 and 
hyaluronan (Carulli et al., 2007; Galtrey et al., 2008).  As previously mentioned, WFA-PNN 
immunolabelling can be detected in the cerebellum from the end of the first postnatal 
week.  Interestingly, while the lectican CSPG versican also condenses to form PNN structures 
at this time, it is not until the end of the second postnatal week that other lectican CSPGs, 
such as aggrecan and neurocan, in addition to supporting molecules LN1 and hyaluronan, 
are condensed into PNN structures (Carulli et al., 2007).  Furthermore, although the general 
timescale of PNN development is similar in the deep cerebellar nuclei and the spinal cord, 
the temporal deposition of individual PNN components onto the neuronal surface is 
variable.  For example, versican PNN immunolabelling can be detected in the cerebellum at 
the end of the first postnatal week; however, it is only observed in PNNs in the spinal cord 
from the third week.  Aggrecan PNN immunolabelling however, is detected in the spinal 
cord from the end of the first postnatal week, but is not observed in the cerebellar PNNs 
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until the end of the second week.  A tabular review of the two studies is shown below in 
Table 1.2.   
 
 
Table 1.2. Expression of PNN components in cerebellum and spinal cord at different 
developmental periods. 
 
Until recently, little data was available on the composition of PNNs and the phenotype of 
PNN-expressing neurons in the human CNS.  One recent study has partly addressed this 
issue, and has provided a thorough histological examination of PNNs in the human spinal 
cord.  Similarly to rodents, PNNs in the human spinal cord are heterogeneously distributed 
throughout the grey matter and contain a high proportion of CSPGs, in addition to 
hyaluronan, LN1 and tenascin-R (Jager et al., 2013).   
 
1.1.3 Function of PNNs 
Formation of PNNs has been shown to correspond to the postnatal time points at which 
developmental neuroplasticity is reduced throughout the nervous system.  Consequently, 
this led to the hypothesis that the PNN may be involved in the restriction of neuroplasticity 
in the adult CNS.  The first direct evidence to support this hypothesis came following the 
enzymatic degradation of the PNN using the bacterial enzyme ChABC, which cleaves the 
GAG side chains from the CSPG core protein.  During postnatal development, but not in the 
adult CNS, monocular deprivation (that is, depriving one eye of visual input) results in a shift 
in the response of cortical neurons (situated in the visual cortex), such that the response to 








Link protein (LN1) P14 P21
Tenascin-R n/a P14
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inputs from the deprived eye are reduced and responses to inputs from the undeprived eye 
are increased - known as an ocular dominance shift.  Administering ChABC to the visual 
cortex of adult rats led to an ocular-dominance shift following monocular deprivation, 
similar to the effect normally only observed in postnatal rats (Pizzorusso et al., 2002).  
Moreover, in vitro studies using ChABC to degrade PNNs resulted in an increase in the 
density of synaptic boutons contacting embryonic hippocampal neurons (Pyka et al., 2011).   
Further evidence supporting the role of the PNN in the limitation of the neuroplasticity 
came from a combination of research using mice lacking one or more of the PNN 
components.  Typically, these mice possess abnormalities in axonal rewiring or synaptic 
plasticity.  For example, mice lacking LN1 have persistent ocular-dominance plasticity and 
elevated axonal sprouting following injury to the spinal cord (Carulli et al., 2010).  
Interestingly, although LN1-deficient mice have abnormal PNNs, the levels of inhibitory 
CSPGs in the brains of these mice is similar to wild-type mice, suggesting, it is the PNN, not 
the overall amount of inhibitory molecules in the brain that is critical for neuroplasticity 
(Carulli et al., 2010; Oohashi et al., 2015).  BRAL2-deficient mice also possess PNNs with an 
abnormal structure, and have a reduction in the density of synapses in the deep cerebellar 
nuclei (Bekku et al., 2012).  Interestingly, mice lacking the glycoprotein tenascin-R have 
normal synaptic structures of net-bearing neurons in the brain (Bruckner et al., 2000).  
However, additional studies have revealed a reduction in synaptic plasticity in the 
hippocampus (Bukalo et al., 2001).   
Increasingly, a number of research groups are studying the effects of PNN degradation on 
neuroplasticity in the CNS.  Using ChABC, mounting evidence suggests ChABC-mediated PNN 
breakdown can promote plasticity and behavioural recovery in rodent models of spinal cord 
injury (Bradbury et al., 2002; Barritt et al., 2006; Alilain et al., 2011).  Moreover, ChABC-
mediated PNN degradation in the spinal cord following stroke led to enhanced plasticity and 
locomotor recovery (Soleman et al., 2012).  In the brain, PNNs have been associated with 
memory, as ChABC treatment enhanced memory and plasticity in mice (Romberg et al., 
2013), in addition to increased plasticity and improvements in object recognition memory in 
two mouse models of tauopathy (Yang et al., 2015b).  PNNs have also been shown to be 
involved in the maintenance of fear memories in the adult brain (Gogolla et al., 2009). 
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In addition to a critical role in the restriction of neuroplasticity in the adult CNS, recent 
findings have also indicated the PNNs may be involved in some sort of neuroprotection in 
pathological states.  CSPGs have been shown to induce neuroprotection against the 
glutamate-mediated excitotoxicity of cultured neurons and in a separate study, PNN-
expressing neurons were associated with reduced degeneration following oxidative stress, 
compared to neurons lacking PNNs (Cabungcal et al., 2013).  The mechanism responsible for 
this is currently unknown and requires further research.  Moreover, PNNs have been shown 
to prevent the lateral diffusion of AMPA receptors in vitro (Frischknecht et al., 2009). 
 
1.1.4 Formation of PNNs 
While it is now generally well-accepted that the formation of PNNs coincides with the 
timepoint at which most of the developmental neuroplasticity is concluding, there is little 
data available regarding the molecular events that underlie the formation of these 
structures in vivo.  One thing that is known, however, is that neuronal activity correlates 
with the formation of PNNs, as chronic depolarisation has been shown to enhance PNN 
formation in a number of in vitro studies (Brückner and Grosche, 2001; Giamanco and 
Matthews, 2012).  Moreover, a reduction in the formation of PNNs in animals raised with 
visual deprivation also suggests that neuronal activity in vivo can regulate the formation of 
PNNs (Brückner and Grosche, 2001; McRae et al., 2007).  Linking in with this, the 
morphology of PNNs (meaning, the intensity of WFA labelling) in the deep cerebellar nuclei 
is dependent on presynaptic inputs to these neurons from Purkinje cells (Foscarin et al., 
2011), such that reduced inputs from Purkinje cells results in less neurons with a PNN and a 
reduction in the thickness of PNNs (Carulli et al., 2013).  Furthermore, it has been postulated 
that LN1 upregulation is important for the development of PNNs, as LN1 upregulation 
correlates with the timepoint of PNN formation, and animals lacking this molecule have 
deficits in PNN formation in vivo (Carulli et al., 2010).  Other factors that can modulate the 
PNN include environmental stimuli, such as housing animals in an enriched environment. 
Interestingly, housing animals in an enriched environment results in a decrease in the 
proportion of neurons with a PNN in the deep cerebellar nuclei and reduces the intensity of 
WFA labelling of these PNNs, compared with controls (Foscarin et al., 2011). 
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As previously mentioned, upregulation of PNNs is associated with the closure of the critical 
period for neuroplasticity in the developing visual cortex (Pizzorusso et al., 2002).  
Interestingly, this phenomenon also coincides with the downregualtion of polysialic acid 
(PSA), a post-translational modification found preferentially attached to the neural cell 
adhesion molecule (NCAM) in the developing CNS (Di Cristo et al., 2007a).  Moreover, 
closure of the critical period can be delayed by the continued expression of PSA in the visual 
cortex (Di Cristo et al., 2007a).  This suggests that PSA expression is also a key regulator of 
neuroplasticity, and may exert this effect by modulating the formation of PNNs in vivo.   
Preliminary research from our laboratory suggests a spatiotemporal relationship between 
PSA and PNNs in the postnatal rat spinal cord.  During the first two weeks of postnatal 
development, PSA is abundantly distributed throughout the spinal cord and is found in both 
the grey and white matter.  During this time, PNNs are not observed in the spinal cord.  
Towards the end of the second week of postnatal development, PSA expression is reduced 
and WFA-labelled PNNs can be detected in the spinal cord, the numbers of which continue 
to increase during the third and fourth postnatal weeks.  By the end of the third week, PSA 
expression is solely confined to the anterior corticospinal tract, lamina X and the superficial 
dorsal horn (Figure 1.2). 
 
Figure 1.2.  Inverse relationship between PSA and the expression of WFA-labelled PNNs in 
the postnatal rat spinal cord. 
(A-B) During the first week of postnatal development, PSA expression is high throughout all 
regions of the spinal cord (yellow arrows).  (C) Towards the end of the second postnatal 
week, PSA expression is reduced throughout the grey matter and weakly WFA-labelled PNNs 
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can be observed surrounding occasional neurons in the grey matter (white arrows).  (D) By 
the end of the third postnatal week, PSA is only maintained in regions that continue to 
express PSA in the adult spinal cord, and the number of WFA-labelled PNNs is increased. 
Images courtesy of Dr Xuenong Bo. 
 
As mounting evidence supports the critical role of PNNs in the limitation of plasticity in the 
adult nervous system, and that degrading this structure can induce significant recovery of 
function in preclinical models of SCI and stroke, in addition to mice with memory deficits, it 
is clear that PNNs require much further research.  With little known about the molecular 
events that underlie PNN formation in vivo, this also requires further study.  The inverse 
relationship between PSA expression and formation of PNNs in the spinal cord, in addition 
to the antagonistic effects of these molecules with respect to the closure of the critical 
period, suggests that PSA expression may be able to regulate the formation of PNNs in vivo.  
This will be examined in more detail in this thesis. 
 
 
1.2 Polysialic acid 
 
1.2.1. Neural cell adhesion molecule and polysialic acid - structure and biochemistry 
As briefly mentioned, PSA is predominantly found attached to NCAM during the 
development of the nervous system.  NCAMs are membrane-associated proteins and 
members of the immunoglobulin superfamily of adhesion molecules.  Ubiquitously 
expressed throughout both the developing and adult CNS, NCAMs are found as three main 
isoforms: 180, 140 and 120 kDa (Bonfanti, 2006).  The two larger isoforms are large, 
transmembrane proteins that consist of a cytoplasmic C-terminal domain and an 
extracellular N-terminal domain, that consists of five immunoglobulin-like domains and two 
fibronectin III domains (Figure 1.3A, Bonfanti, 2006).  The smaller, 120 kDa isoform of NCAM 
does not possess a cytoplasmic domain but instead is attached to the extracellular 
membrane via a glycosylphosphatidylinositol anchor (Bonfanti, 2006). 
A homophilic interaction between the 1st and 2nd Ig-like domains of the extracellular 
domains of NCAMs on opposing cell membranes leads to the formation of homodimers, 
which facilitates cell adhesion and neuronal differentiation.  Conversely, this reduces cell 
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proliferation (Bonfanti, 2006).  The formation of NCAM heterodimers is also common and 
has thus far been observed with the fibroblast growth factor receptor (FGFR) and the 
neurotrophin receptor TrkB. In addition, NCAM forms heterodimers with extracellular 
matrix molecules such as heparin sulphate proteoglycans (HSPGs) and CSPGs, such as 
neurocan and phosphacan (Kallapur and Akeson, 1992; Grumet et al., 1993; Friedlander et 
al., 1994; Kiselyov et al., 2003).  Interactions between CSPGs and NCAM are thought to 
occur between the sulphated glycosaminoglycan side chains, as enzymatic digestion of 
these glycans using ChABC reduces the formation of NCAM-neurocan heterodimers 
(Friedlander et al., 1994). 
One of the most frequent post-translational modifications of NCAM involves the addition of 
long chains of PSA to the 5th immunoglobulin (Ig)-like domain, in a process known as 
polysialylation.  PSA is a linear homopolymer of 2, 8-linked sialic acid and is added to NCAM 
in the Golgi apparatus by the action of two polysialyltransferase enzymes; 
polysialyltransferase (PST) and sialyltransferase X (STX), which can also be referred to as 
ST8SiaIV and ST8SiaII, respectively (Eckhardt et al., 1995; Nakayama and Fukuda, 1996).  
These enzymes bind to NCAM at the 1st fibronectin type III (FN-III) domain, and catalyse the 
addition of PSA to the 5th Ig-like domain (Figure 1.3A, Mendiratta et al., 2005; Maness and 
Schachner, 2007).  The extent of NCAM polysialylation is directly regulated by expression of 
the polysialyltransferase enzymes (Oka et al., 1995), which have distinct expression patterns 
throughout the CNS.  The expression of STX is high during development, but expression is 
down-regulated in the adult CNS; but the opposite is true of PST (Hildebrandt et al., 1998; 
Ong et al., 1998).   
Brains harvested from NCAM knockout mice have almost a complete loss of PSA expression, 
suggesting that the majority of PSA found in the CNS is bound to NCAM.  Nonetheless, 
subsequent studies have revealed a number of other molecules that can be polysialylated, 
such as neuropilin-2, α subunit of the rat brain voltage-sensitive sodium channel, synaptic 
adhesion molecule and the polysialyltransferase enzymes themselves (Zuber et al., 1992; 
Mühlenhoff et al., 1996; Close and Colley, 1998; Curreli et al., 2007; Galuska et al., 2010).  
While much less is known about the effect of polysialylation on the function of these 
proteins, it is generally agreed that polysialylation of the sialyltransferase enzymes can 
regulate their ability to catalyse the addition of PSA onto NCAM (Close et al., 2000).   
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PSA has unusual biochemical properties; it occupies a large spatial area and has a large 
hydrated volume (Rutishauser, 1998; Johnson et al., 2005).  When bound to NCAM it can 
increase its relative molecular mass by up to 30% and leads to a reduction in the homophilic 
interactions between NCAMs on opposing cellular membranes (Figure 1.3B-C).  
Consequently, this leads to a reduction in the adhesive force between cells and can increase 
the spacing between adjacent cells up to 15 nm (Yang et al., 1992).  In addition to its effect 
on NCAM homophilic interactions, PSA has been shown to alter heterophilic interactions 
between NCAM and its binding partners (Storms and Rutishauser, 1998; Hane et al., 2015).  
One example of this is the association between NCAM and HSPGs (Storms and Rutishauser, 
1998).  Additionally, PSA binding to NCAM has been shown to enhance BDNF signalling via 
its TrkB receptors, and has been shown to impair the processing of proBDNF by plasmin 






Figure 1.3. Structure and mechanism of PSA-NCAM.   
(A) A member of the immunoglobulin superfamily of adhesion molecules, NCAM is formed 
of 5 immunoglobulin (Ig)-like domains and 2 fibronectin type-III (FN-III) domains.  The 
polysialyltransferase enzymes bind to NCAM at the 1st FN-III domain, which catalyses the 
addition of PSA onto NCAM at the 5th Ig-like domain.  (B) NCAMs on opposing cellular 
membranes can form homophilic interactions, leading to strong cell-cell adhesion.  (C) In the 
presence of PSA the adhesive force of NCAMs on opposing membranes is reduced, leading 
to an increase in the size of the extracellular space.  Adapted from Rutishauser (2008). 
 
1.2.2. Expression of polysialic acid in the nervous system 
 
1.2.2.1. Development 
Generally absent during early developmental stages, PSA expression increases during mid-
late embryonic development and is maintained during early post-natal development 
(Chuong and Edelman, 1984; Aaron and Chesselet, 1989; Nait Oumesmar et al., 1995b; Di 
Cristo et al., 2007a).  Studies using mice deficient for one or more of the isoforms of NCAM 
have revealed the importance of PSA expression during development of the CNS.  Mice 
deficient in NCAM have virtually no PSA in their brains and present with a minor reduction 
in body weight.  Examining brain morphology revealed abnormalities in a number of brain 
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structures, such as a reduced size of the olfactory bulb and hippocampus (Tomasiewicz et 
al., 1993; Cremer et al., 1994b), in addition to behavioural deficits such as depression 
(Cremer et al., 1994a) and a reduction in spatial learning in NCAM-deficient mice (Cremer et 
al., 1994b).  The relative reduction in size of the olfactory bulb in NCAM-deficient mice was 
revealed to be due to a deficit in migration of precursors from the subventricular zone to 
the olfactory bulbs (Hu et al., 1996).   
Mice deficient in both polysialyltransferase enzymes lack expression of PSA in the brain, but 
expression of unpolysialylated NCAM is unchanged (Weinhold et al., 2005).  PSA deficient 
mice present with a reduced body mass, precocious death and severe motor deficits, 
compared with wild-type mice.  Examining brain morphology revealed abnormalities in a 
number of brain structures in PSA deficient mice, including a reduced olfactory bulb size, the 
accumulation of cells in the proximal rostral migratory stream, a smaller cross-sectional area 
of the corticospinal tract (at the level of the pyramids) and abnormal development of the 
mossy fibre tract of the hippocampus.  Additionally, more than 80% of the PST/STX 
knockouts suffered from progressive hydrocephalus, due to enlargement of the lateral and 
third ventricles (Weinhold et al., 2005).  The similarities in the phenotypes of NCAM or PSA 
knockout mice indicates that the deficits in brain structure and behaviour are most likely 
due to the lack of PSA, resulting in poor regulation of the adhesive properties of NCAM (Giza 
and Biederer, 2010).   
Further evidence revealing the roles of PSA during development came from studies using 
the enzyme endoneuraminidase N (endo-N), to selectively remove PSA from the surface of 
NCAMs.  In the developing corticospinal tract, PSA immunoreactivity is generally confined to 
regions associated with the formation of collateral axons, for example the entry of 
corticospinal axons into the spinal grey matter (Daston, Bastmeyer et al. 1996).  Removing 
PSA from the developing corticospinal tract did not result in aberrant projections away from 
the typical path of the corticospinal tract but did, however, result in a reduced number of 
collateral branches into the spinal grey matter (Daston et al., 1996).  In the visual cortex PSA 
is strongly expressed up to the end of the second postnatal week, following which 
expression steadily declines until it is virtually absent by postnatal day 28.  Selectively 
removing PSA during the third postnatal week using endo-N resulted in early maturation of 
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inhibitory synapses in the visual cortex, in addition to the early onset of ocular dominance 
plasticity (Di Cristo et al., 2007a). 
Taken together, these studies using NCAM, or PSA-deficient mice, or using endo-N to 
remove PSA in vivo, revealed the important role of PSA in neurodevelopment. 
 
1.2.2.2. Adult 
Although expression of PSA in the CNS is generally reduced during late stages of postnatal 
development, expression is maintained in areas typically associated with ongoing 
neuroplasticity and neurogenesis.  In the adult brain there are two primary regions with 
sustained neurogenesis: the subgranular zone of the hippocampus and subventricular zone 
(SVZ) of the lateral ventricles. 
Early research noted a population of PSA-expressing cells located in the granule cell layers of 
the dentate gyrus.  Subsequent studies revealed these cells to be newly generated neurons, 
produced in the subgranular layer (Seki and Arai, 1991, 1993).  Removing PSA from this 
region using endo-N resulted in the differentiation of these neural progenitor cells into 
neurons in the subgranular zone (Burgess et al., 2008).  The SVZ is the most heavily studied 
area of neurogenesis in the adult brain.  Newly generated neuronal precursors in the SVZ 
migrate to the olfactory bulbs of rodents, where they differentiate into inhibitory 
interneurons that form the granule cell layers of the olfactory bulb (Bonfanti et al., 1997).  
PSA expression is found on the neuronal precursors in the SVZ and persists as the cells 
migrate to the olfactory bulb.  Upon reaching the olfactory bulb, PSA expression is reduced 
and these cells differentiate into inhibitory interneurons that form the granular cell layers 
(Bonfanti et al., 1997; Rockle et al., 2008).  Removing PSA from this pathway using endo-N 
revealed the crucial role of PSA in the organisation and migration of cells from the SVZ to 
the olfactory bulb.  These mice had smaller olfactory bulbs than controls and a disorganised 
rostral migratory stream (Battista and Rutishauser, 2010).  Additionally, newly generated 
inhibitory interneurons were found in aberrant locations, such as the cortex and striatum, 
indicating a reduction in migration of progenitor cells out of the rostral migratory stream 
(Battista and Rutishauser, 2010). 
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While largely confined to the two main areas of ongoing neurogenesis, PSA expression can 
also be observed in a number of regions in the temporal lobe, such as the entorhinal and 
piriform cortices and other regions of the hippocampus such as CA1 and CA3 (Nacher et al., 
2002).  However, the function of continued PSA expression in these structures is poorly 
understood.  Structures in the hypothalamus can also continue to express PSA, such as the 
suprachiasmatic nucleus (Glass et al., 1994), where PSA is believed to have a role in the 
regulation of circadian rhythms; and in the axons of neurosecretory cells and pituicytes that 
make up the hypothalamo-neurohypophysial system (Theodosis et al., 1994).  In the spinal 
cord, PSA immunoreactivity is observed in the superficial layers of the dorsal horns and also 
surrounding the central canal.  Interestingly, cells surrounding the central canal can share 
some characteristics with those in the SVZ (Hamilton et al., 2009), but there is no 
neurogenesis under normal physiological conditions.  Nonetheless, in vitro, these cells are 
capable of producing neurospheres which can differentiate into neurons and glial cells 
(Dromard et al., 2008), suggesting that these cells may harbour a latent neurogenic ability.  
These findings further established the role of PSA in neurogenesis in the adult CNS. 
 
1.2.2.3. Involvement in injury and disease  
An increasing number of studies have noted an increase in levels of polysialylation following 
traumatic injury to the brain or spinal cord.  PSA is transiently upregulated on both the ipsi- 
and contralateral sides of the spinal cord 4 days following dorsal rhizotomy lesion, in 
neurons, and levels are also elevated in astrocytes on the ipsilateral side of the spinal cord, 
12 days post-injury (Bonfanti et al., 1996).  Lesioning the entorhinal cortex resulted in a 
continuous elevation in PSA-NCAM levels in the denervated region of the dentate gyrus, 
starting 2 days post-lesion and the expression is maintained for over 60 days (Miller et al., 
1994).  The spatiotemporal relationship between PSA expression and axonal sprouting in the 
denervated dentate gyrus led to the hypothesis that re-expression of PSA following CNS 
injury may act as a pro-regenerative response, which may facilitate axonal sprouting and 
synaptogenesis.  Subsequent studies have also noticed a relationship between PSA 
expression following CNS injury and attempts at axonal sprouting.  PSA is upregulated in a 
number of cells in the perilesional area 7 days following controlled cortical impact injury 
(Harris et al., 2010; Budinich et al., 2012).  These cells have a glial-like morphology and are 
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associated with sprouting axons positive for growth associated protein-43 (GAP-34) (Harris 
et al., 2010). 
While much of this research has focused on PSA expression following traumatic injury to the 
CNS, one study has also noted alterations in PSA in a model of chemically-induced spinal 
cord injury.  Lysolecithin-induced demyelination of the mouse spinal cord results in transient 
expression of PSA in Schwann cells, astrocytes and oligodendrocyte precursors, in and 
around the lesion site (Nait Oumesmar et al., 1995a).  The novel finding of PSA upregulation 
in areas of demyelination has also been verified in human tissue samples using post-mortem 
brain samples from patients with multiple sclerosis (Charles et al., 2002). 
With significant evidence supporting the role of PSA in plasticity in both the developing and 
adult CNS, and the evidence supporting a spatiotemporal correlation between PSA 
expression and axonal sprouting after injury, this led to a number of studies investigating 
whether induced PSA expression could lead to enhanced sprouting or regeneration, in 
addition to functional improvement in rodent models of CNS injury.  Predominantly, these 
studies have relied on rodent models of spinal cord injury (SCI).  The ability of induced PSA 
expression to mediate locomotor recovery in a rodent model of SCI will also be examined in 
this thesis, therefore, the pathophysiology of SCI, in addition to current research strategies 
to target neuroplasticity and axonal regeneration, including PSA, will be discussed in detail 
below. 
 
1.3 Spinal cord injury – facts, figures and clinical manifestation 
SCI is a devastating condition that affects an estimated 40,000 people in the United 
Kingdom, with a new occurrence every 8 hours (BackUp, 2016).  Males are twice as likely to 
develop SCI and injuries are more prevalent in younger people, specifically, between the 
ages of 15 and 38 (SpinalResearch, 2016).  Injuries are commonly caused by falls or road 
traffic accident (SpinalResearch, 2016), the impact of which can break one or more of the 
vertebrae thereby contusing or compressing the spinal cord.  Additional causes of SCI, albeit 
those far less common, include stab injuries which directly penetrate the spinal cord, sports 
injuries and tumours (SpinalResearch, 2016). The annual cost of SCI in the UK is estimated at 
£1 billion, making this a large public health concern (SpinalResearch, 2016).  
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SCI patients may display a wide neurological deficit including loss of sensory, motor and 
autonomic functions.  The extent of these deficits is dependent on both the location and 
size of the spinal cord lesion.  For example, injuries occurring at the thoracic level will result 
in paralysis of the lower limbs (paraplegia) and loss of autonomic functions (bowel, bladder 
and sexual).  In contrast, injuries occurring at the cervical level will result in paralysis of both 
upper and lower limbs (quadriplegia) and loss of autonomic functions.  Injuries in the 
cervical region may also be associated with loss of respiratory function.  Additional 
complications of SCI include autonomic dysreflexia, neuropathic pain, spasticity, frequent 
urinary tract infections (due to loss of bladder voiding reflexes) and depression.  While these 
consequences of injury result in a drastic change to a patient’s quality of life, a fraction of 
patients may have some preserved function due to the presence of spared spinal cord tissue 
that was not damaged by the injury.   
 
1.4 Spinal cord injury pathophysiology 
SCI pathophysiology is broadly subdivided into two stages, primary and secondary injury.  
The primary injury refers to the initial damage to the spinal cord and is frequently caused by 
the dislodgement of one or more of the vertebrae, which then contuses or compresses the 
spinal cord.  This injury results in a focal area of cell death and haemorrhage, and initiates a 
cascade of secondary injury mechanisms, which results in the propagation of the injury and 
ultimately, a worsening of neurological outcome.  There are a number of processes involved 
in the secondary injury phase, including inflammation, vascular disturbances and oxidative 
stress, which will be discussed in more detail in subsequent sections. 
 
1.4.1 Vascular disturbances and the inflammatory response 
The inflammatory response to SCI commences minutes after injury, persists for months, and 
involves a number of immune cells, both intrinsic to the spinal cord and originating in the 
periphery (Bowes and Yip, 2014).  Of those found in the spinal cord, the first cellular 
responders are microglia, the resident immune cells of the CNS (David and Kroner, 2011).  
Typically, microglia exist in a quiescent state in the uninjured spinal cord, but are rapidly 
activated minutes after the initial spinal cord trauma (Davalos et al., 2005).  Migrating to the 
injury epicentre, activated microglia act to seal off the injury site and clear away cellular 
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debris in an attempt to prevent the spread of damage to other parts of the spinal cord 
(Hines et al., 2009; Greenhalgh and David, 2014; Stirling et al., 2014).  Activated microglial 
cells are still observed in the spinal cord weeks after the initial injury and are believed to be 
involved in the regulation of infiltration of peripheral immune cells into the spinal cord, in 
addition to the secretion of proinflammatory cytokines (Kigerl et al., 2009). 
Secondary cellular responders to SCI include astrocytes, which rapidly proliferate, 
hypertrophy and increase production of intermediate filament proteins such as vimentin 
and glial fibrillary acidic protein (GFAP), in a process known as gliosis (Silver and Miller, 
2004; Sofroniew and Vinters, 2010).  Astrocytes also migrate to the lesion site, where they 
secrete CSPGs, molecules which aggregate with reactive astrocytes, to form a glial scar 
(Silver and Miller, 2004; Yuan and He, 2013).  Early research suggested that the glial scar 
acts as a barrier to axonal growth and may be responsible for the poor recovery observed 
following SCI (Fawcett and Asher, 1999; Cregg et al., 2014).  However, subsequent studies 
have suggested the glial scar may also have a beneficial role post-SCI by sealing off the 
lesion site, to prevent the spread of injury and enhance tissue preservation (Rolls et al., 
2009).  This was investigated in more detail in a novel study that investigated the 
development of gliosis and the extent of neurological improvement in a rodent model of 
SCI, using mice with ablated gliosis (due to the selective deletion of reactive astrocytes).  
Interestingly, these mice had a significantly worse neurological outcome post-injury, 
compared to control mice (Faulkner et al., 2004).  Furthermore, histological examination 
revealed a significant reduction in the number of neurons and an increase in degenerating 
white matter, leucocyte infiltration and lesion size in these mice, compared with controls 
(Faulkner et al., 2004).  Further details regarding the development of the glial scar and its 
contribution to poor neurological recovery following SCI will be discussed in section 1.4.4. 
 
Under normal circumstances, the blood-spinal cord barrier (BSCB) consists of tightly 
compacted endothelial cells, ensheathed by perivascular cells (known as pericytes) and a 
basal lamina, which is contacted by the processes of astrocytes (Bartanusz et al., 2011).  
Collectively, these cellular populations compose the BSCB, which regulates the influx of 
molecules and cells from the blood into the spinal cord parenchyma (Echeverry et al., 2011).  
Within the first 24 hours post-SCI, there is a drastic upregulation of a number of matrix 
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metalloproteinases (MMPs), a family of zinc-dependent endopeptidases, which have a 
crucial role in extracellular matrix remodelling (reviewed by (Zhang et al., 2011).  Following 
injury, the upregulation of MMPs such as MMP-3, -9 and -12 has been shown to promote 
the breakdown of the BSCB, via degradation of the endothelial tight junctions and basal 
lamina (Noble et al., 2002; Wells et al., 2003; Lee et al., 2014).  This leads to an increase in 
the permeability of the BSCB, resulting in the influx of circulating inflammatory cells, such as 
macrophages/monocytes, neutrophils and leucocytes into the spinal cord (Trivedi et al., 
2006). 
Neutrophils, generally absent in the spinal cord, can cross the disrupted BSCB and enter the 
spinal cord parenchyma within a few hours after injury.  Correlating with the extent of SCI 
damage, the number of neutrophils in the injured spinal cord peaks after 24 hours, but 
neutrophils are still observed in the cord three months post-injury (Beck et al., 2010).  While 
initially acting to clear the injury site of cellular debris, neutrophils also secrete pro-
inflammatory cytokines, which results in the recruitment of additional inflammatory cells, 
such as circulating monocytes, to the injury site.  For a long while, this was believed to 
strongly contribute to secondary tissue damage and worsening neurological outcomes 
following SCI (Neirinckx et al., 2014).  Interestingly, however, subsequent data has disputed 
this, and has suggested that the infiltration of neutrophils into the injured spinal cord may 
actually promote neurological recovery.  For example, depleting the number of circulating 
neutrophils (and consequently reducing the number entering the injured spinal cord) was 
found to increase the amount of oxidised proteins observed in the injured spinal cord (de 
Castro et al., 2004).  Moreover, in a separate study, this was shown to worsen locomotor 
function following SCI (Stirling et al., 2009).  However, even considering these findings, 
neutrophils are generally still viewed to be a hindrance to spinal cord repair as the evidence 
supporting their role in the exacerbation of secondary tissue damage outweighs that 
supporting a beneficial role for neutrophils in the conservation of neurological function. 
As previously mentioned, degradation of the BSCB also allows circulating 
monocytes/macrophages to enter the injured spinal cord (Glomsda et al., 2003).  Migrating 
to the lesion epicentre, macrophages act in a similar capacity to microglial cells, where they 
act to phagocytose cellular debris in an attempt to prime the spinal cord for attempts at 
regeneration (David and Kroner, 2011; Greenhalgh and David, 2014).  Additionally, however, 
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macrophages can contribute to axonal dieback, post-injury (Horn et al., 2008; Zhou et al., 
2014b).  The diverse functions of these cells led to the suggestion that there may be 
multiple phenotypes of macrophages that underlie each of these different roles.  This has 
subsequently been demonstrated in a number of studies, which have noted two distinct 
subtypes of macrophages post-SCI; the classically activated M1 or the alternatively activated 
M2 phenotypes (Kigerl et al., 2009).  M1 macrophages are considered pro-inflammatory and 
neurotoxic, while the M2 subset acts to promote tissue remodelling and axonal growth 
(David and Kroner, 2011).  Activated microglia may therefore exacerbate secondary injury or 
promote repair of the spinal cord, based on which phenotype is predominantly expressed.  
A number of studies have revealed the predominance of M1 macrophages in the injured 
spinal cord for months after injury, which is believed to, in part, underlie the poor recovery 
of function following SCI (Kigerl et al., 2009; Chen et al., 2015).  Attempts at driving 
macrophage polarisation towards the M2 phenotype in rodent models of SCI has resulted in 
improved tissue sparing and a significant neurological improvement (Gensel and Zhang, 
2015; Zhang et al., 2015). 
 
Figure 1.4.  Macrophage polarisation. 
Macrophages have diverse functions after injury to the spinal cord.  Characterising 
macrophage polarisation has led to the identification of two distinct subtypes known as M1 
and M2.  These subtypes have a role in the pro-inflammatory and anti-inflammatory 
responses to SCI, respectively.  Adapted from David and Kroner, 2011. 
 
 45 
Responses of the adaptive immune system to SCI include infiltration of both B- and T-cells to 
the spinal cord, following breakdown of the BSCB (Jones et al., 2005; Bowes and Yip, 2014).  
Both B- and T-cell infiltration peaks approximately one week post-injury, however, B-cells 
display a biphasic response after SCI as a secondary peak is observed after four weeks 
(Bowes and Yip, 2014).  After injury, both T- and B-cells are involved in a process known as 
SCI-induced autoimmunity, which involves these cells becoming ‘autoreactive’ and 
contributing to further secondary damage (Popovich et al., 1996; Ankeny et al., 2006).  
Improvement in locomotor function has been observed in mice devoid of mature T- and B-
cells and is associated with enhanced axonal sprouting, remyelination and a reduced 
number of microglia/macrophages in the spinal cord (Wu et al., 2012).  Despite some 
evidence suggesting a negative role of T-cells following injury to the nervous system, other 
studies have suggested that CD4+ T-cells can induce neuroprotection of facial motor 
neurons after transection of the facial nerve in mice (Serpe et al., 2003; Deboy et al., 2006). 
 
1.4.2 Excitotoxicity and oxidative stress 
Damage to the spinal cord vasculature can result in ischaemia in the injured cord.  This, 
coupled with membrane depolarization can result in glutamate release, which can reach 
toxic levels within minutes of SCI (McAdoo et al., 1999).  Activation of glutamate receptors 
on the cell surface, namely N-methyl-D-aspartate (NMDA) receptors can result in elevated 
cytoplasmic calcium concentrations, due to an influx of calcium from the extracellular space 
into the cell, in addition to calcium release from intracellular stores (Hausmann, 2003).  This 
elevation in cytoplasmic calcium can activate a number of pathways that ultimately result in 
the apoptotic death of the cell (Hausmann, 2003).   
In addition to glutamate-mediated excitotoxicity, post-SCI ischaemia can also lead to a rapid 
increase in the production of reactive oxygen species (ROS).  ROS production peaks 
approximately 12 hours following SCI but is elevated for weeks post-injury (Xu et al., 2005).  
Polyunsaturated fatty acids make up a high proportion of cellular membranes and are highly 
sensitive to lipid peroxidation by ROS, which leads to cell death (Hall and Braughler, 1986).   
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1.4.3 Cell death 
The primary injury to the spinal cord results in an immediate zone of necrotic cell death, 
including both neurons and glial cells such as oligodendrocytes (Liu et al., 1997).  Secondary 
injury cascades amplify this cell death, which can worsen neurological outcomes following 
injury.  For example, secondary injury mechanisms have been speculated to be responsible 
for the apoptotic death of neurons, observed between 4 and 6 hours after injury in the rat 
spinal cord (Crowe et al., 1997).  Moreover, neuronal death has been shown to continue for 
up to 1 month post-SCI, both at the initial injury site and further along the spinal cord 
(Huang et al., 2007).  This amplified neuronal death leads to the expansion of the lesion site, 
and worsening neurological outcomes.   
Death of oligodendrocytes has been observed within 15 minutes of SCI in the rat and can 
persist for up to 3 weeks (Crowe et al., 1997).  Similarly to neurons, the initial impact of the 
mechanical insult to the spinal cord results in a focal area of oligodendrocyte death (Liu et 
al., 1997).  Following this, oligodendrocyte cell death continues in the days post-injury and is 
thought to be mediated by the high sensitivity of these cells to a number of secondary injury 
mechanisms, including glutamate and ATP-mediated excitotoxicity, oxidative stress and the 
release of pro-inflammatory cytokines from activated microglia and neutrophils (Crowe et 
al., 1997; Almad et al., 2011).  Apoptotic oligodendrocytes have been observed up to 3 
weeks following SCI in the rodent spinal cord, located both rostral and caudal to the lesion 
epicentre and associated with axons undergoing Wallerian degeneration (Crowe et al., 
1997; Warden et al., 2001).  This acute and delayed death of oligodendrocytes results in 
large areas of demyelinated axons.  However, the extent of these and their contribution to 
the poor neurological recovery observed after SCI is debated due to conflicting data on the 
extent of remyelination of these fibres (Totoiu and Keirstead, 2005; Lasiene et al., 2008; 
Hesp et al., 2015).  
 
1.4.4 Inhibitory molecules and the glial scar 
Even following severe SCI, patients can regain some functional neurological improvement 
(Fawcett et al., 2007).  One contributing mechanism to this functional improvement is that 
some axons can retain the capacity to regrow, or ‘sprout’.  However, the ability of these 
sprouting fibres to reform substantial functional connections is severely limited and this is 
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believed to be at least partly due to the dynamic changes that occur in the neuronal 
extracellular matrix following SCI.  The primary injury to the spinal cord results in immediate 
death of oligodendrocytes at the lesion site, and as previously mentioned, secondary injury 
mechanisms such as oxidative stress, and glutamate excitotoxicity, contribute to a second, 
delayed death of oligodendrocytes, which typically occurs 1 week post-injury (Crowe et al., 
1997; Warden et al., 2001).  Degenerating oligodendrocytes release a number of molecules, 
collectively known as the myelin-derived inhibitors, which are capable of restricting the 
neurite outgrowth of cultured neurons (Schwab and Caroni, 2008).  These molecules are 
myelin-associated glycoprotein (MAG), oligodendrocyte-myelin glycoprotein (OMgp), 
neurite outgrowth inhibitor (Nogo), ephrin B3 and semaphorin 4D (GrandPré et al., 2000; 
Hunt et al., 2002; Huebner and Strittmatter, 2009).  Following release from degenerating 
oligodendrocytes, MAG, OMgp and Nogo can bind to a range of receptors on the neuronal 
surface, such as members of the tumour necrosis factor family and LINGO-1, while ephrinB3 
and semaphorin 4D signal via the EphA4 and plexin B1 receptors, respectively (Fournier et 
al., 2001; Wang et al., 2002; Mi et al., 2004; Benson et al., 2005).  One of the first receptors 
to be identified was the Nogo-66 receptor, which can bind to MAG, OMgp and Nogo 
(Fournier et al., 2001; Liu et al., 2002).  Downstream effects of Nogo-66 receptor activation 
are suppression of the Akt signalling pathway and activation of the Rho/ROCK signalling 
pathway, which ultimately initiates growth cone collapse via dysregulation of the actin 
cytoskeleton (Yiu and He, 2006).   
In addition to the release of the myelin-derived inhibitory molecules from degenerating 
oligodendrocytes, as previously mentioned, a secondary class of molecules, known as CSPGs 
are secreted by reactive astrocytes (Silver and Miller, 2004).  In the uninjured CNS, CSPGs 
are ubiquitously distributed throughout the adult spinal cord, both in the neuropil and 
within specialised ECM structures known as PNNs (see chapter 1.1 for more details on the 
neuronal extracellular matrix).  After SCI, reactive astrocytes coupled with secreted CSPGs 
and infiltrating macrophages and fibroblasts, condense around the lesion site to form a glial 




Figure 1.5.  Classical glial scar structure. 
Infiltrating macrophages, which act to clear the immediate lesion site from cellular debris 
are surrounded by reactive astrocytes, which secrete CSPGs.  These cellular components and 
CSPGs form the glial scar, which acts as a barrier to axonal growth.  Upon entering the 
environment of the scar, sprouting axons will lose their capacity for growth due to the 
formation of dystrophic growth cones (Silver and Miller, 2004). 
 
Initially, the glial scar acts to limit the spread of secondary damage but its continued 
presence in the spinal cord has been shown to be a significant inhibitor of axonal sprouting 
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and/or regeneration.  Upon reaching the glial scar, sprouting axons lose their capacity for 
growth as their growth cones become ‘dystrophic’, i.e. they take on a swollen appearance 
and contain a disorganised cytoskeleton (Li and Raisman, 1995; Tom et al., 2004).  The high 
CSPG content of the glial scar has been proposed to be directly responsible for the 
formation of dystrophic growth cones and abortive axonal sprouting.  In support of this 
hypothesis, a study revealed the poor neurite outgrowth of cultured dorsal root ganglion 
(DRG) neurons when plated on alternating strips of CSPGs and a growth-promoting 
substrate, such as laminin (Snow et al., 1990).  Interestingly, neurites that extended onto 
the CSPG substrate were either repelled, or ceased to grow further and their growth cones 
became dystrophic (Snow et al., 1990).  Building on these early experiments, subsequent 
studies modified this in vitro system to more accurately represent the concentration 
gradient of CSPGs within the glial scar, since typically, the concentration of CSPGs is at its 
highest at the inner-most regions (Tom et al., 2004).  In this study, growth cones from 
cultured DRG neurons also formed swollen end bulbs following entry into the CSPG region, 
characteristic of the dystrophic growth cones which are observed in vivo (Tom et al., 2004).   
For a long time, the mechanism underpinning the CSPG-induced formation of dystrophic 
growth cones was unknown.  However, recent work has highlighted a number of different 
receptors that can bind to these molecules.  One such receptor is protein tyrosine 
phosphatase sigma (PTPσ), which has been shown to interact with the CSPG GAG side chains 
(Shen et al., 2009).  Additional receptors include members of the Nogo receptor family, 
NgR1, NgR3 and LAR (Dickendesher et al., 2012).  Currently, the downstream effects of 
CSPG-receptor activation are poorly understood; however, activation of LAR is believed to 
activate the Rho/ROCK signalling pathway, which interestingly, is also activated by the 
binding of myelin-derived inhibitory molecules to their receptors (Fisher et al., 2011). 
 
 
1.5 Strategies to promote spinal repair 
For many years, the primary aim of therapies targeting repair of the injured spinal cord was 
to promote regeneration of damaged axons across the lesion site, with the hope of these 
axons forming functional connections beyond the lesion (Silver and Miller, 2004; Cregg et 
al., 2014).  Whilst some regenerating axons are able to grow a few millimetres in the rodent 
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spinal cord following targeted pharmacological interventions, the translational ability of 
these drugs is under question, due to the difference in size between human and rodent 
spinal cords.  In the human, regenerating fibres must grow centimetres to bridge the lesion 
site, then find appropriate target neurons and form functional synapses, compared to the 1 
or 2 mm axonal growth required to bridge a spinal cord lesion in the rat.   
Over the past decade it has become more apparent that the injured spinal cord is capable of 
spontaneous axonal sprouting and these sprouting fibres can connect with neurons spared 
by the initial injury to bypass the lesion site and form novel spinal circuits (Bareyre et al., 
2004).  Harnessing and amplifying this neuroplasticity to specific neuronal phenotypes could 
therefore lead to successful repair of the spinal cord in the absence of long-distance axonal 
regeneration.  Because of this, a number of research laboratories are aiming to enhance this 
axonal sprouting by removing the inhibitory extracellular matrix molecules from the spinal 
cord and using rehabilitation to maintain these new synaptic connections.  The next sections 
will discuss ways to promote regeneration and plasticity within the injured spinal cord. 
 
1.5.1 Overcoming inhibition  
 
1.5.1.1. Myelin-derived inhibitory molecules 
As previously mentioned, a number of in vitro studies have highlighted the growth-
restricting effects of the myelin-derived inhibitors and have suggested that removing or 
neutralising the inhibitory effect of these molecules may promote axonal growth, and thus, 
neurological recovery from SCI.  However, attempts at confirming this data in vivo using 
knockout mice devoid of one or more of these molecules, and experimental models of SCI, 
has been met with mixed success.  For example, inconsistent results have been observed in 
experiments using mice deficient in Nogo, with some studies noting poor regeneration 
following spinal lesions (Zheng et al., 2003; Lee et al., 2009) and others revealing a 
significant enhancement of regeneration in Nogo deficient mice (Kim et al., 2003).  What is 
now clear is the differences between these studies may be due to differences in the 
underlying genetics of the mouse strains used to produce these knockouts (Dimou et al., 
2006; Akbik et al., 2012).  While studies using knockout mice yielded inconclusive data, 
interestingly, studies inhibiting downstream signalling of these molecules, or using function-
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blocking antibodies to restrict their function, has resulted in promising results, showing an 
improvement in axonal regeneration and associated neurological function.  
The discovery that Nogo, MAG and OMgp all bind to a common receptor, Nogo-66 receptor, 
led to the commencement of a series of studies utilising receptor antagonists in an attempt 
to block the action of these three molecules.  Initial data noted enhanced regeneration of 
the corticospinal tract, sprouting of serotonergic fibres and associated locomotor recovery 
(GrandPré et al., 2002; Li and Strittmatter, 2003).  However, an attempt at replicating this 
early study as part of the NIH “Facilities of Research-Spinal Cord Injury” project, yielded 
conflicting results (Steward et al., 2008).  In a similar line of research, some groups have also 
investigated the effect of blocking LINGO-1, a co-receptor in the Nogo-receptor complex.  
These studies have noted enhanced regeneration of corticospinal and rubrospinal fibres, in 
addition to locomotor improvements, following intrathecal delivery of LINGO-1 antagonist 
in rodent models of SCI (Ji et al., 2006).  
The convergence of the myelin-derived inhibitors on the Rho/ROCK signalling pathway led 
to the assumption that blocking this pathway would prevent the downstream effects of 
these molecules (i.e. prevent growth cone collapse).  The enzyme C3 transferase, a potent 
inhibitor of the Rho signalling pathway, was initially shown to promote a significant recovery 
of locomotor function in a rodent model of injury, associated with enhanced regeneration of 
the corticospinal tract (Dergham et al., 2002).  Subsequent studies have shown the efficacy 
of this enzyme in a number of different injury models and in both rats and mice, in addition 
to using an enzyme activity-deficient version of the protein (Boato et al., 2010). 
Additional studies have targeted individual myelin-derived inhibitors by the use of, for 
example, function-blocking antibodies, and have shown promise in rodent models of SCI.  
Antibodies targeting Nogo-A were found to enhance axonal regeneration in the injured 
spinal cord, which was associated with an improvement in locomotor recovery (Liebscher et 
al., 2005).  Subsequent studies have confirmed this data and have also shown a reduction in 
injury-related muscle spasms in rats following Nogo-A antibody treatment (Gonzenbach et 
al., 2010; Gonzenbach et al., 2012).  The success of these rodent studies led to the 
development of experiments in non-human primate models of SCI, results of which 
mirrored those observed in rodents; enhanced regeneration of corticospinal neurons and 
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improvements in locomotor function were observed in the Nogo-A blocking antibody 
treated groups (Freund et al., 2006, 2009). 
Although a partial recovery of function has been observed following neutralisation or 
blocking of the myelin-derived inhibitors, the lack of functional sprouting in mice lacking one 
or all three of these proteins after SCI indicates that these molecules may not be one of the 
main inhibitors of axonal regeneration after injury.  Nonetheless, recently, the anti-Nogo 
antibody (ATI355) was tested for safety in patients with SCI.  This was completed in 2011, 
but results of trials exploring the efficacy of this drug have not yet been published.  
 
1.5.1.2. Glial-derived inhibitory molecules 
Following results from early studies that noted the inhibitory effect of the glial scar on 
axonal growth and regeneration, a number of groups aimed to elucidate the main causes of 
this inhibition by examining the cellular molecular components of the glial scar in more 
detail.  Initial observations suggested the CSPG molecules that form a large proportion of 
the glial scar are responsible for this limitation of axonal regeneration, and much research 
was performed to try to degrade CSPGs in the hope of promoting regeneration and spinal 
cord repair.   
The finding that ChABC could remove the inhibitory GAG side chains from CSPGs in vivo and 
in culture, allowed the development of a pioneering study in 2002.  In these experiments, 
ChABC was injected intrathecally following mid-cervical SCI, and was found to promote 
regeneration of lesioned corticospinal and sensory axons into the lesion site.  This was also 
associated with a significant improvement in forelimb motor function (Bradbury et al., 
2002).  Subsequent studies have built on these initial experiments to investigate the use of 
ChABC in other models of SCI and using different delivery methods to the spinal cord.  To 
date, ChABC-mediated axonal sprouting of both injured and uninjured spinal pathways has 
been observed, including the corticospinal (Barritt et al., 2006; Wang et al., 2011; Starkey et 
al., 2012), raphe-spinal (Barritt et al., 2006) and reticulospinal (Garcia-Alias et al., 2015) 
tracts.  Further work has also investigated the efficacy of ChABC treatment on respiratory 
function following high-cervical SCI (Alilain et al., 2011) and on bladder function (Caggiano 
et al., 2005), and results have been promising.  While earlier studies used a purified version 
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of the bacterial enzyme, this has been associated with some issues, including the lack of 
long-term stability of this enzyme in vivo (Lin et al., 2008; Bartus et al., 2014).  In response to 
this, recent studies have commenced testing of viral vectors to drive expression of the 
ChABC gene in vivo, with results from these studies showing enhanced axonal regeneration, 
neuroplasticity and locomotor recovery following ChABC treatment (Zhao et al., 2011; 
James et al., 2015). 
Interestingly, while previously thought to act to primarily promote regeneration and/or 
neuroplasticity, recent evidence also suggests ChABC treatment can modulate the 
phenotype of macrophages following SCI.  Lentiviral vector-mediated ChABC treatment 
resulted in a significant increase in the density of M1-type macrophages 3 days post-injury, 
whereas, 2 weeks following injury, the density of M1 macrophages was reduced, but M2 
macrophages were increased, compared to control groups (Bartus et al., 2014).  More 
recent data also suggests that ChABC may increase the expression of anti-inflammatory 
cytokines, such as IL-10 (Didangelos et al., 2014).  
With the success of ChABC in promoting regeneration and/or plasticity, in addition to a 
partial restoration of locomotor function in injured rodents, a number of studies have 
investigated the efficacy of ChABC combinatorial therapies, using, for example, another 
targeted therapeutic intervention.  A popular combination is that of ChABC and 
administration of neurotrophins, or other growth factors.  However, these studies have 
been met with mixed success.  Combining ChABC and neurotrophin-3 (NT-3) administration 
following SCI resulted in improved locomotor function, enhanced serotonergic and 
corticospinal fibre sprouting, in addition to strengthening newly formed connections 
between corticospinal tract fibres and motor neurons (Hunanyan et al., 2013).  Conversely, 
no long-term locomotor improvement was observed with ChABC administration in 
combination with a cocktail of growth factors and neurorehabilitation, although, there was 
noted to be enhanced sprouting of serotonergic and corticospinal fibres in this study (Alluin 
et al., 2014).  Interestingly, a study utilising peripheral nerve grafts, to guide regenerating 
axons across the lesion site into distal regions of the spinal cord, in combination with brain-
derived neurotrophic factor (BDNF) delivery and ChABC treatment showed no improvement 
in axonal regeneration or locomotor recovery (Tom et al., 2013).  Other combinatorial 
therapies have included ChABC, Nogo-A function-blocking antibodies and 
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neurorehabilitation, which resulted in a synergistic improvement in locomotor function, 
with enhanced axonal regeneration and sprouting (Zhao et al., 2013), and ChABC and the 
adhesion molecule L1, which also showed improvements in locomotor function and 
anatomical plasticity (Lee et al., 2012).  Following the success of ChABC treatment in 
promoting locomotor recovery in a number of rodent models of SCI, recently, a study 
involving ChABC in a canine model of severe chronic SCI has been approved (SpinalResearch, 
2016). 
The identification of a variety of CSPG receptors led a number of groups to try and promote 
axonal sprouting by blocking these receptors, or their downstream signalling mediators. 
Promising results were obtained from PTPσ knockout mice, which are capable of long-
distance regeneration of the injured corticospinal tract (Fry et al., 2010).  To date, two 
studies have aimed to modulate the PTPσ receptor, by either lentiviral-mediated delivery of 
RNA interference or creation of a PTPσ blocking peptide.  Using a lentiviral vector to 
knockdown PTPσ in vivo resulted in improved hindlimb motor function post-SCI, compared 
with control-treated rats (Zhou et al., 2014a).  Systemic administration of PTPσ blocking 
peptide led to improved motor function and bladder voiding and was associated with 
elevated sprouting of serotonergic fibres caudal to the lesion site, compared to control 
animals (Lang et al., 2015).  Similarly, following the discovery of another CSPG receptor, LAR, 
studies aiming to block receptor activity using function-blocking peptides led to enhanced 
locomotor function following SCI, in addition to elevated regeneration of serotonergic fibres 
(Fisher et al., 2011).  Comparable results were found in mice lacking LAR, in addition to 
enhanced regeneration of the corticospinal tract (Xu et al., 2015). 
While most research targeting CSPGs and SCI uses the application of either function-
blocking peptides or bacterial enzyme, to either block the activity of, or degrade CSPGs, 
respectively, some studies are investigating the endogenous molecules that are involved in 
the normal turnover of CSPGs in vivo.  The ADAMTS family of proteases has been implicated 
in the degradation of CSPGs in the CNS, and expression of a number of these proteases has 
been found to increase following SCI in rodents (Tauchi et al., 2012a; Demircan et al., 2013).  
While research investigating these proteases is not as prolific as studies using ChABC, some 
groups have suggested ADAMTS-4 is capable of digesting CSPGs in the injured spinal cord, 
and administration of recombinant ADAMTS-4 has been shown to improve neurological 
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outcomes following injury, in addition to enhanced sprouting of serotonergic fibres (Tauchi 
et al., 2012b; Lemarchant et al., 2014).  
Further strategies targeting CSPGs include attempts to neutralise the signalling of these 
molecules.  As previously mentioned, activation of RhoA/ROCK signalling pathways occurs 
following receptor binding of the myelin-derived inhibitory molecules, and it was discovered 
that CSPGs also activate this pathway (Monnier et al., 2003).  As strategies targeting this 
pathway were discussed in section 1.5.1.1, it will not be discussed in more detail here. 
 
1.5.1.3 Intracellular inhibition 
It is now generally well-established that most neuronal subtypes lose the capacity to fully 
regenerate in the injured adult CNS.  While a large part of this is caused by extracellular 
factors, such as inhibitory extracellular matrix molecules and the down-regulation of several 
important growth-promoting molecules, mounting evidence suggests that a number of 
intracellular molecules may be at least partly responsible for the poor axonal regeneration 
of neurons observed in the adult CNS.   
One of the best characterised intrinsic modulators of the regenerative function of neurons is 
the level of cyclic AMP (cAMP).  Early studies noted that the growth-promoting effect on 
myelin of neurons isolated from early postnatal rat pups was due to high intracellular cAMP 
levels (Cai et al., 2001).  Conversely, neurons from later postnatal time points showed a 
reduction in cAMP levels, and showed a drastic reduction in axonal outgrowth following 
contact with myelin.  Increasing cAMP levels overcame this myelin-based inhibition of 
axonal outgrowth (Cai et al., 2001).  Building from this initial study, it was noted that pre-
conditioning peripheral nerve injury, previously shown to enhance regeneration of injured 
sensory axons in vivo, resulted in increased cAMP levels in DRG neurons, and direct 
administration of cAMP to DRG neurons prior to SCI mimicked the effect of a 
preconditioning lesion (Neumann et al., 2002; Qiu et al., 2002).  Although an interesting 
observation, this is obviously clinically non-viable, so new studies were aimed at elucidating 
a pharmacological intervention that could be used post-SCI to raise intracellular cAMP 
levels.  One of the first studies to do this used the phosphodiesterase 4 inhibitor, rolipram 
(Nikulina et al., 2004).  Administered 2 weeks following SCI and embryonic spinal tissue 
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transplant, rolipram was found to improve axonal regeneration into the transplant, which 
was accompanied by an improvement in locomotor function and reduced levels of gliosis 
(Nikulina et al., 2004).  Subsequent research has built on this initial experiment, to include 
other models of SCI (Kajana and Goshgarian, 2009; Costa et al., 2013) and different 
combinations of rolipram administration, including combinatorial therapies with cell 
transplantation (Dai et al., 2009; Bretzner et al., 2010), neurorehabilitation (Dai et al., 2009), 
and neurotrophin delivery (Lu et al., 2004). 
A number of studies have characterised a relatively recently discovered intracellular 
inhibitor of axonal regeneration, namely PTEN.  A negative regulator of mTOR, PTEN is 
highly expressed in adult corticospinal neurons, which undergo limited axonal regeneration 
following injury to the spinal cord (Liu et al., 2010).  Conditional deletion of PTEN in 
corticospinal neurons was found to promote sprouting of the uninjured corticospinal tract, 
in addition to enhancing regeneration of injured corticospinal fibres through the lesion site 
in two distinct models of SCI (Liu et al., 2010).  Since this was published, there have been a 
number of studies confirming the link between ablation or knockdown of PTEN and 
enhanced regeneration of corticospinal fibres in a number of different injury models, and 
also showing improved locomotor recovery in these animals (Zukor et al., 2013; Danilov and 
Steward, 2015; Du et al., 2015).  Interestingly, strong regeneration of injured corticospinal 
neurons was observed following conditional ablation of PTEN one year following SCI (Du et 
al., 2015).  
Following the promising results observed by deletion of PTEN alone, some groups have 
started investigating combinatorial therapies, to try to target multiple factors that have 
been shown to restrict recovery from SCI.  As previously mentioned, Nogo is a myelin-
derived inhibitory molecule found to exert a significant restriction on neuronal regeneration 
in vivo.  Interestingly, double-mutant mice lacking all isoforms of Nogo and with conditional 
PTEN deletion, do not show an increase in compensatory sprouting following 
pyramidotomy, compared to animals lacking PTEN alone (Geoffroy et al., 2015).  Conversely, 
regeneration of injured corticospinal fibres past the caudal border of the lesion following 
thoracic-level SCI was enhanced in double-mutant mice, compared to those lacking PTEN 
deletion alone, however, this was not associated with significant locomotor recovery 
(Geoffroy et al., 2015).  Additionally, one notable study co-deleted PTEN and SOCS3, 
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another intrinsic regulator of regeneration, which promoted elevated sprouting of uninjured 
corticospinal neurons and partial restoration of locomotor recovery, compared to single 
deletion of SOCS3 (Jin et al., 2015). 
Other strategies showing success in improving the intrinsic growth capacity of neurons, 
thereby allowing axonal growth in non-permissive environments, include targeting 
microtubule stabilisation using the cancer drug Taxol and overexpression of neuronal 
calcium sensor-1 (NCS-1) in the sensorimotor cortex (Yip et al., 2010; Hellal et al., 2011). In 
addition, targeting the repulsive guidance molecule – an inhibitor of axonal growth that is 
expressed in neurons, leucocytes and the glial scar after SCI (Schwab et al., 2005) – or its 
receptor, neogenin, has been shown to promote regeneration and locomotor recovery in 
rodent models of SCI (Hata et al., 2006; Tassew et al., 2014). 
 
1.5.2 Cell transplantation 
As previously mentioned, one of the immediate consequences of SCI is the necrotic death of 
neurons at the injury epicentre.  Secondary pathological mechanisms lead to further death 
of neurons distal from the injury site, which also contributes to the death of other cells such 
as oligodendrocytes.  Although numerous studies have documented the ability of 
neuroplasticity to promote significant recovery of function lost by a SCI in rodent models, a 
number of groups believe full recovery will not be possible unless there is a replacement of 
the cells lost by the injury. 
 
1.5.2.1. Schwann cells 
As previously mentioned, there is typically a perimeter of spared tissue following SCI.  Axons 
in this spared region can undergo demyelination due to the on-going apoptosis of 
oligodendrocytes that persists for up to 3 weeks post-injury (Crowe et al., 1997; Warden et 
al., 2001).  While remyelination of these axons is common, their myelin sheath remains thin 
which leads to reduced neuronal function (Crowe et al., 1997).  
Schwann cells, the myelinating cell type in the peripheral nervous system, have been shown 
to be able to remyelinate rodent CNS axons in vivo (Zhang et al., 2013).  Therefore, the 
primary aim of these studies is to remyelinate the demyelinated axons following SCI, to 
promote the recovery of locomotor function.  In addition to this myelinating ability of 
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transplanted Schwann cells, following ex vivo engineering to express, for example, growth 
factors, Schwann cells have also been shown to increase axonal regeneration and sprouting.  
The ex vivo engineering of Schwann cells to selectively over-express the neurotrophin glial-
derived neurotrophic factor (GDNF) resulted in the regeneration of descending 
propriospinal neurons beyond the spinal cord lesion, which was accompanied by a partial 
improvement in locomotor function (Deng et al., 2013).  In a separate study, a synergistic 
effect was observed following the transplantation of Schwann cells engineered to express 
both neurotrophins and ChABC into the injured spinal cord (Kanno et al., 2014).  Animals 
receiving these transplants had significant locomotor recovery, which was associated with 
regeneration of corticospinal, serotonergic and propriospinal fibres, compared to animals 
that received control transplants (Kanno et al., 2014). 
The ability of Schwann cells to both remyelinate demyelinated fibres, enhance axonal 
regeneration and promote partial locomotor recovery suggests they may be very useful as 
part of a combinatorial therapy to treat SCI in the future.  Based on the thorough preclinical 
data showing the efficacy of transplanted Schwann cells in promoting locomotor recovery 
following SCI, recently, a phase I clinical trial was approved to investigate the safety of 
autologous Schwann cells isolated from the sural nerve in acute and chronic SCI. 
 
1.5.2.2. Olfactory ensheathing cells 
A specialised population of glial cells in the olfactory mucosa, known as olfactory 
ensheathing cells (OECs), have been trialled in rodent models of SCI.  These cells can be 
purified from either the olfactory bulb or the olfactory mucosa and are believed to provide 
channels through which regenerating neurons can grow and eventually form functional 
connections with target cells (Raisman and Li, 2007).  Early studies noted the enhanced 
regeneration of the injured corticospinal tract and a partial recovery of locomotor function 
in rats that received OEC transplantation, either at the time of injury or up to 2 months post-
lesion (Lu et al., 2002; Keyvan-Fouladi et al., 2003). In addition, OEC transplants promoted 
the restoration of supraspinal control of breathing in rats with a high cervical injury (Li et al., 
2003).  Since the publication of these studies there has been a large volume of research 
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conducted using these cell transplants, with variable results (Takami et al., 2002; Steward et 
al., 2006; Stamegna et al., 2011). 
Based on the success of many of the rodent studies described above, a small study 
investigating the therapeutic benefit of OEC transplantation in companion dogs with chronic 
SCI was performed.  Results from this study showed a modest improvement in interlimb 
coordination in dogs that received OEC transplants, compared to those that received control 
treatments.  However there was no improvement in long-tract functionality.  Importantly, 
there were no long-term adverse effects of this treatment (Granger et al., 2012).  Following 
on from this translational study, another research group recently performed a small clinical 
trial investigating the use of OEC transplantation, the results of which received widespread 
media attention.  A single patient with an ASIA-classified complete SCI received an 
autologous OEC transplant into the lesion site, in addition to surgical removal of scar tissue, 
autologous peripheral nerve graft and extensive neurorehabilitation (Tabakow et al., 2014).  
Nineteen months post-surgery, the patient showed improved trunk stability, voluntary 
movement of the lower limbs and partial recovery of sensation (Tabakow et al., 2014).  It 
was speculated that this functional recovery is due to long-distance axonal regeneration 
facilitated by the OEC transplantation (Tabakow et al., 2014).  However, the results from this 
study should be treated with caution, as this was only performed on one patient, who 




While selective drugs targeting the promotion of regeneration or plasticity after SCI  
have resulted in modest improvement in functional recovery in animal models, combining 
these therapeutic interventions with motor rehabilitation has, in some cases, produced 
extensive recovery of function.  Rehabilitation protocols include enriched cages, treadmill 
training, or pellet retrieval tasks and can, as previously mentioned, be used in combination 
with targeted pharmacological interventions or can be used as a monotherapy (Houle and 
Côté, 2013; Sandrow-Feinberg and Houlé, 2015).  Exercise and rehabilitation procedures 
have been shown to modify the spinal cord, to make it more permissible for plasticity and 
regeneration in many ways, including down-regulation of PTEN, increased levels of 
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neurotrophins and a reduction in inflammation (Hutchinson et al., 2004; Ying et al., 2005; 
Liu et al., 2012).  Interestingly, exercise has been shown to increase expression of PNNs in 
the spinal cord of injured rats (Wang et al., 2011; Smith et al., 2015). 
One notable example of the beneficial effect of exercise is a study investigating the 
combination of ChABC and neurorehabilitation.  While ChABC treatment alone has been 
shown to promote locomotor recovery and enhanced axonal sprouting in a number of 
different injury models, combining treatment with rehabilitative therapy resulted in a 
significant improvement in forelimb function after C4 level dorsal column lesion in rats 
(García-Alías et al., 2009).  Conflicting results have been obtained with a Nogo-A function 
blocking antibody and rehabilitation; one study noted a reduction in muscle spasms, 
however, the other noted no benefit of dual treatment on locomotor recovery (Maier et al., 
2009; Gonzenbach et al., 2010). 
Interestingly, there are also some beneficial effects of rehabilitative therapy, in the absence 
of targeted drug therapies (Houle and Côté, 2013).  However, rehabilitation must be 
approached carefully.  Mounting evidence suggests that targeted rehabilitation to improve a 
specific feature of motor function can lead to impairments in other functions.  One key 
example of this was highlighted in another study combining ChABC and either task-specific 
or general rehabilitation.  This study noted that general locomotor rehabilitation resulted in 
a worsening of performance on a pellet-reaching task, compared to animals treated with 
ChABC only (García-Alías et al., 2009). 
Thus, for studies investigating neurorehabilitation, the type of rehabilitation used (general 
locomotor versus task-specific), must be carefully decided upon before the study 
commences.  Other research has revealed that the time and duration of rehabilitation can 
have a significant effect on locomotor outcomes, therefore must also be carefully 
investigated.   
 
1.5.4 Adhesion molecules 
Many classes of adhesion molecules have been examined in preclinical models of SCI to 
determine their efficacy at supporting axonal regeneration and/or neuroplasticity.  This 




The integrins are a large family of transmembrane proteins that primarily function to 
mediate cell-ECM interactions.  Composed of an alpha and beta subunit, of which there are 
18 and 8, respectively, 24 integrins can be generated in total, each with specific roles (Eva 
and Fawcett, 2014).  In the CNS, integrins are ubiquitously expressed and found on both 
neurons and glial cells (Eva and Fawcett, 2014).  Recent evidence suggests that the growth-
restrictive effects of the myelin-derived inhibitory molecules, in addition to CSPGs, may be 
partially mediated by integrin signalling (Goh et al., 2008; Hu and Strittmatter, 2008; Tan et 
al., 2011).  
The ubiquity of integrins throughout both the injured and naïve nervous system means that 
directly modulating integrin function can have multiple effects post-lesion.  Many studies 
targeting integrins, such as D2 (also called CD11d/CD18) and v3 integrin, have been 
shown to reduce the systemic immune response to spinal cord injury, with some vasculature 
effects (Gris et al., 2004; Han et al., 2010; Bao et al., 2011).  There is less data, however, to 
support the pro-regenerative consequences of integrin manipulation within the damaged 
spinal cord.  While it is generally well-established that integrin signalling is necessary for 
axonal growth within the CNS, data showing enhanced axonal regeneration as a 
consequence of integrin expression post-SCI is limited (Lemons and Condic, 2008; Eva and 
Fawcett, 2014).  One notable study, however, noted increased regeneration of damaged 
sensory axons into the lesion site of a dorsal column crush injury, following transgenic 
expression of 9 integrin (Andrews et al., 2009).  However, it should be noted that 
regeneration beyond the lesion site was not observed in this study.  More recent work has 
shown that co-expressing 9 integrin and kindlin-1 (which binds to the integrin  subunit to 
regulate integrin activation) in DRG neurons can promote long-distance regeneration of 
sensory axons into the spinal cord after dorsal root crush (Cheah et al., 2016). 
 
1.5.4.2 Immunoglobulin superfamily  
Members of the immunoglobulin superfamily of adhesion molecules have been shown to 
promote axonal regeneration and/or neuroplasticity and associated locomotor 
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improvement in a number of rodent models of SCI.  The L1 cell adhesion molecule is widely 
expressed in the CNS during development and is believed to be associated with axon 
guidance and cell migration (Maness and Schachner, 2007).  Early research noted 
administering L1-Fc (a soluble dimer composed of L1 and immunoglobulin Fc) could improve 
locomotor recovery following contusion injury to the thoracic spinal cord (Roonprapunt et 
al., 2003).  Subsequent studies have utilised an adeno-associated viral vector to induce 
expression of L1, and a function-triggering monoclonal antibody to stimulate L1 activation in 
vivo, which have both promoted locomotor recovery following thoracic level compression 
injury in mice (Chen et al., 2007; Loers et al., 2014).  Histological data from these studies 
indicated that L1-mediated locomotor recovery may be associated with enhanced 
regeneration, or axonal sprouting of serotonergic fibres, a reduction in astrogliosis and 
secretion of the inhibitory proteoglycan NG2, when administered focally using a viral vector 
(Chen et al., 2007).  Interestingly, L1-mediated locomotor recovery was associated with 
neuroprotection of motor neurons and parvalbumin-positive interneurons, in addition to a 
reduction in the size of the glial scar, and enhanced growth of dopaminergic fibres caudal to 
the lesion following treatment with L1 monoclonal antibody (Loers et al., 2014).   
The close homologue of L1 (CHL1), another member of the immunoglobulin superfamily of 
adhesion molecules, is upregulated within 24 hours post-SCI, at and around the lesion site 
(Jakovcevski et al., 2007; Wu et al., 2011).  Found in NG2-positive cells, and at later time 
points in reactive astrocytes, elevated CHL1 expression persists for up to 8 weeks post-
lesion (Wu et al., 2011).  While studies in CHL1 knockout mice have shown an improvement 
in locomotor function following mid-thoracic level SCI, there have been no studies to date 
that have tried to knock down CHL1 post-lesion to evaluate this in more detail (Jakovcevski 
et al., 2007).  To date, up- or down-regulation of other members of the L1 family, such as 
neurofascin and the neuronal cell adhesion molecule (NrCAM), have not been investigated 
in rodent models of SCI. 
The distribution and function of neural cell adhesion molecules (NCAMs) have been 
extensively studied in the CNS, and can be modulated to promote significant locomotor 
recovery in rodent models of SCI.  As previously mentioned, the main scope of this thesis is 
to investigate polysialylation of NCAM so studies investigating PSA and SCI will be discussed 
in extensive detail in section 1.5.4.4 below. 
 63 
 
1.5.4.3 Other molecules 
Other classes of adhesion molecules include cadherins, calpains and neuroligins. However, 
currently, there is little data available regarding their involvement in the pathophysiology of 
SCI, or how modulation of their function is correlated with functional improvement. 
 
1.5.4.4 Polysialic acid  
Utilising the unique biochemical properties of PSA to promote recovery in experimental 
models of SCI has progressed in two main directions.  Firstly, transplantation of genetically 
modified Schwann cells that were engineered ex vivo to express polysialyltransferase, or 
secondly, direct expression of polysialyltransferase in the injured spinal cord.  Each of these 
approaches will be discussed in detail below. 
The ability of transplanted Schwann cells to myelinate CNS axons following trauma to the 
spinal cord has been well documented and has been shown to promote some behavioural 
improvement in experimental models of SCI (Yang et al., 2015a).  However, these studies 
have a number of important caveats, such as the death of Schwann cells following 
transplantation and the poor integration of surviving cells into the host spinal cord (Pearse 
et al., 2007).  The ability of PSA to facilitate cell migration during development of the CNS 
led to the hypothesis that engineering PSA expression on cultured Schwann cells may enable 
transplanted cells to migrate further into the host spinal cord.  
Preliminary work utilised a retroviral vector to express the STX transgene in cultured 
Schwann cells isolated from the rat sciatic nerve.  Cells transduced by the viral vector were 
strongly immunopositive for PSA and survived well in vitro.  Importantly, PSA-Schwann cells 
migrated approximately 50% further than wild-type cells in a scratch assay and retained 
their myelinating ability (Lavdas et al., 2006).  Subsequent studies aimed to transplant PSA-
expressing Schwann cells into the injured mouse spinal cord to assess locomotor recovery.  
Animals that received transplants of PSA-Schwann cells rostral to SCI had improved motor 
function, compared to mice that received either control Schwann cells or no transplant at 
all.  Interestingly, these animals had a significant increase in the density of serotonergic 
axons caudal to the injury, but not in the lesion site, and an increase in remyelination by 
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resident Schwann cells (Papastefanaki et al., 2007).  Further research has built on this initial 
study and has investigated the therapeutic potential of PSA-Schwann cells in different 
models of SCI.  In one study, PSA-Schwann cells showed improved survival up to 30 days 
following transplantation caudal to T8 dorsal column crush injury.  PSA-Schwann cells 
migrated a further distance than control counterparts, and reduced the reactive response of 
astrocytes that is normally observed following Schwann cell transplantation into the injured 
spinal cord (Luo et al., 2010).  A more recent study revealed similar findings following 
transplantation of PSA-Schwann cells into the injury epicentre, one week following 
moderate contusion at T8/9 spinal level.  PSA-Schwann cells migrated significantly further 
than control cells. However, no difference was observed in the reactivity of astrocytes at the 
injury epicentre between cell types.  Interestingly, there was also a significant increase in 
the density of serotonergic axons in the centre of the graft and an increase in corticospinal 
axons both in the centre of the graft and caudal to the leading edge of the transplant.  Rats 
that received PSA-Schwann cells had a modest improvement in hindlimb function, 
compared to those that received control cells (Ghosh et al., 2012). 
The ability of PSA expression to promote axonal regeneration following SCI has been 
documented in a number of rodent models.  The first study to do this used a lentiviral vector 
carrying the polysialyltransferase gene to selectively express PSA in astrocytes following 
thoracic corticospinal tract lesion.  Mice that received injections of PST lentivirus had 
elevated sprouting of corticospinal axons crossing the caudal border of the lesion, than 
those treated with control virus (El Maarouf et al., 2006).  Detailed histological assessment 
also revealed a large number of non-dystrophic growth cones associated with regions of PSA 
expression (El Maarouf et al., 2006).  Following on from this work, other groups have used 
lentiviral vectors to express PSA at the lesion site in a number of rodent models of injury.  
Injecting lentivirus carrying the PST gene (LV/PST) into the lesion site after dorsal column 
transection resulted in increased regeneration of sensory axons, compared with animals 
that received LV/GFP (Zhang et al., 2007b).  In a separate group of LV/PST treated animals, 
the sciatic nerve was crushed immediately following SCI to initiate a pro-regenerative 
response in these neurons.  Animals that received sciatic nerve crush, in addition to LV/PST 
treatment had significantly more CTB-labelled sensory axons in and rostral to the lesion site, 
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compared to those that received crush and treatment with control virus (Zhang et al., 
2007b).  
One of the limitations of using viral vectors to selectively express PSA in the spinal cord after 
injury is the relatively small area transduced by the virus.  To obtain a large area of 
expression, multiple injections need to be performed to the spinal cord, which may be 
counter-productive.  Recent research has identified two 9 amino acid peptides that can 
mimic the role of PSA in culture and in the developing chick retina.  Soaking a collagen gel in 
this peptide, followed by subsequent transplantation into the lesion site after thoracic-level 
dorsal column hemisection promoted a significant improvement in hindlimb motor function, 
compared to mice that received control peptide.  Additionally, these mice regained 
controlled bladder voiding faster and showed an increase in the density of serotonergic 
fibres both in the lesion site and in the caudal side of the lesion (Marino et al., 2009).  These 
findings were verified in another study, in which mice received continuous infusion of PSA 
mimetic for 2 weeks post-T8 compression injury.  Mice treated with one of the two different 
PSA mimetics had a significant improvement in hindlimb motor function, compared with 
animals that received control peptide (Mehanna et al., 2010; Pan et al., 2014).  Interestingly, 
a PSA mimetic has also been shown to preserve neurons in the ventral horn, both rostral 
and caudal to the lesion and induce sprouting of serotonergic and catecholinergic neurons 
above and below the injury epicentre (Mehanna et al., 2010; Pan et al., 2014).  Recent work 
has revealed another two mimetic peptides, vinorelbine and epirubicin, however, their 
efficacy at promoting repair and locomotor improvements in SCI has not yet been examined 
(Loers et al., 2016). 
 
1.6. Hypotheses and aims 
Based on the previously mentioned preliminary data, we hypothesise that PSA expression 
can restrict the formation of the PNN.  Moreover, we speculate that the large, hydrated 
volume of PSA can prevent WFA-binding to its site within the PNN.  
There are three main aims for this thesis.  Firstly, to map the distribution of two PNN 
components, neurocan and LN1, and the PNN-binding lectin WFA, in the adult rat cervical 
spinal cord.  We hypothesise that these components will be heterogeneously distributed 
throughout different laminae of the spinal cord and we also expect to see high levels of co-
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localisation between these markers within PNN structures.  Secondly, to investigate the 
proposed relationship between PSA and the PNN, using both in vitro and in vivo models.  It 
is speculated that removal of PSA from primary neuronal cultures will increase development 
of the PNN, which will be associated with a reduction in the density of synapses contacting 
PNN-expressing neurons in vitro.  Furthermore, we hypothesise that in vivo, induced PSA 
expression using a lentiviral vector carrying the transgene for the polysialyltransferase 
enzyme (LV/PST) will reduce binding of the WFA to its specific site within the PNN.  Finally, 
we will investigate the behavioural effects of induced PSA expression rostral and caudal to a 
mid-cervical lateral hemisection lesion, using LV/PST, in adult rats.  Synaptic inputs to 
transduced neurons will be examined 6 weeks following injection of LV/PST.  We 
hypothesise that LV/PST treated rats will show a significantly elevated locomotor recovery, 
compared with animals that received injections of control virus, carrying the transgene for 
green fluorescent protein (LV/GFP) only.  Additionally, we expect the density of synaptic 
inputs to transduced neurons to be increased in animals that received LV/PST injections, 














Chapter 2: Materials and methods 
 
2.1. Cell culture 
 
2.1.1. Primary cortical and hippocampal cell culture 
Timed-pregnant Wistar rats (Charles River UK), gestation day 18, were sacrificed by CO2 
asphyxiation followed by decapitation.  Embryos were rapidly removed and placed in ice-
cold Hank’s buffered salt solution (HBSS) (Sigma-Aldrich, UK).  Embryos were decapitated 
and the heads placed in fresh HBSS.  Skin and skull were removed from each head and the 
brain transferred into a fresh dish filled with HBSS.  After each brain was split into 2 cerebral 
hemispheres with the dura removed, the hippocampi and cortices were collected in 
separate tubes containing fresh HBSS.  Brain tissue was chemically dissociated using 0.125% 
trypsin-EDTA solution (Sigma-Aldrich, UK) for 8 minutes at 37°C.  Modified medium which 
contained Neurobasal medium, 100 units/ml penicillin / 100 g/ml streptomycin, 1% B27 
supplement without vitamin A, 0.5 mM GlutaMAX and 10% foetal bovine serum (FBS) (all 
Life Technologies, UK) was added to each tube to inactivate the trypsin.  The tissue was 
mechanically dissociated using a 1 ml pipette tip and the resulting cell suspension was 
filtered through a sterile 70 µm cell strainer (VWR, UK).  Cells were collected by 
centrifugation at 1000 rpm for 5 minutes, then resuspended in modified Neurobasal 
medium without any FBS.  Cells were plated at a density of 50,000 or 100,000 cells/cm2 on 
13 mm poly-D-lysine with or without laminin coated glass coverslips. 
 
2.1.2. Preparation of coverslips for culture 
For poly-D-lysine coating, 13 mm glass coverslips were sterilised in 70% ethanol and then 
autoclaved in an enclosed container.  Coverslips were coated with 100 µg/ml poly-D-lysine 
solution, overnight at 37°C and 5% CO2 and then were washed in sterile distilled water four 
times and once in sterile PBS, before cell plating. 
For coating with poly-D-lysine and laminin, coverslips were initially incubated in poly-D-
lysine, as above. After several washes in sterile distilled water, the poly-D-lysine- treated 
coverslips were incubated in laminin (2 g/ml, Life Technologies) for three hours at 37°C 
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and 5% CO2.  Coverslips were rinsed four times in sterile distilled water and then once in 
sterile PBS, prior to cell plating.  
 
2.1.3. Treatment of primary cells with endoneuraminidase-N 
To investigate the effect of PSA on the development of PNNs and synaptogenesis in vitro, 
PSA was removed from the surface of cultured hippocampal cells using endoneuraminidase-
N (endo-N, ABC Scientific).  Endo-N was diluted in modified Neurobasal medium to 
concentrations of 40, 80, 160 or 200 ng/ml.  4 days after plating, cells received a 50% 
medium change with endo-N containing medium, resulting in final endo-N concentrations of 
20, 40, 80 or 100 ng/ml, respectively.  All subsequent medium changes contained endo-N.  
Control cells received medium changes containing vehicle only (phosphate-buffered saline).   
 
2.1.4. HEK293T cell culture 
Human embryonic kidney 293 (HEK293T) cells were plated at a density of 40,000 cells/cm2.  
Cells were maintained in modified Dulbecco's Modified Eagle Medium (DMEM, Life 
Technologies) supplemented with 100 units/ml penicillin / 100 µg/ml streptomycin and 10% 
FBS, at 37°C and 5% CO2.  Cells were split at a ratio of 1:3 when they reached a confluency of 
approximately 80%.   
 
2.2. Lentiviral vector production  
2.2.1. Preparation of transfer vector 
Green fluorescent protein (GFP) cDNA was fused to the C-terminal of mouse 
polysialyltransferase (PST) cDNA, to generate PST-GFP.  PST-GFP and mCherry cDNAs were 
subcloned into the transfer vector pRRL, with each cDNA under the control of an 
independent human synapsin I promoter.  GFP cDNA was subcloned into two separate pRRL 
transfer vectors, one under the control of a human synapsin I promoter and the other under 
the control of a cytomegalovirus (CMV) promoter (Figure 2.1). 
Plasmid vectors were transformed into DH5α competent cells (Life Technologies, UK) using 
the heat shock method according to the manufacturer’s instructions. The bacteria were 
then streaked on Lysogeny broth agar plates containing 50 μg/ml ampicillin and incubated 
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overnight at 37°C.  Single colonies were selected and grown in terrific broth overnight at 
37°C.  Plasmid DNA was isolated using QIAprep Miniprep kits and QIAprep Midiprep kits 
(Qiagen).  To verify insertion of cDNA into plasmids, isolated DNA was digested using 
appropriate restriction enzymes and fragments were separated on a 0.8% agarose gel. 
Concentration of plasmid DNA was determined using a NanoDrop UV spectrophotometer.  
Plasmid DNA was diluted to a final concentration of 1 μg/μl and stored at -20°C until needed 
for production of lentiviral vectors.  
 
 
Figure 2.1.  Schematic of transfer vectors for lentiviral vectors. 
CMV: cytomegalovirus promoter sequence, GFP: green fluorescent protein, hSyn-1: human 
synapsin I promoter sequence, PST: polysialyltransferase. 
 
2.2.2. Production of lentiviral vectors 
HEK293T cells were expanded as described previously (see section 2.1.4).  To package the 
lentivirus, cells that were passaged at least 3 times after thawing from liquid nitrogen 
storage were re-plated at a density of 3 x 106 cells per 10 cm dish, which had been pre-
coated with 10 μg/ml poly-D-lysine.  When cells reached 80-85% confluency, transfection 
was carried out using the calcium precipitation method.  Two hours before transfection, 
cells received a full medium change.  Sterile water, 0.1 X Tris-EDTA (TE) and envelope, pack 
and transfer plasmids (Table 2.1) were mixed together by gentle vortexing.  Calcium chloride 
(2.5 M, CaCl2) was added and the solution was mixed.  An equal volume of 2 X HEPES-
buffered saline (HBS) was added to the mixture at a rate of two drops per second, while the 
solution was vortexed at high speed.  1 ml was immediately added to each 10 cm dish, 





Reagent Amount of solution (µl) 
    
H20 1080 
0.1 X TE 1500 
    
ENV plasmid  
(1 µg/µl) 
21 
PACK plasmid  
(1 µg/µl) 
39 
Transfer vector  
(1 µg/µl) 
60 
    
2.5M CaCl2 300 
    
Table 2.1.  Composition and volumes of transfection mixture for production of lentiviral 
vectors for six 10 cm dishes.   
 
Cells were incubated for 14 hours before the medium was replaced with 9 ml DMEM-
GlutaMAX supplemented with 2% FBS and 100 units/ml penicillin / 100µg/ml streptomycin.  
Medium containing the viral vectors was harvested 48 hours after transfection.  Cell debris 
was removed by centrifugation at 1000 x g for 10 minutes and then filtered through a sterile 
0.45 µm syringe filter. 
To concentrate the lentiviral vectors for use in vivo, supernatant from three dishes was 
decanted into sterile Ultracone centrifugation tubes (28 ml size) and centrifuged using the 
Sorvall SureSpin 630/36 swing bucket rotor for 2.5 hours at 25,000 x g at 4°C.  After 
centrifugation, the supernatant was carefully aspirated and the pellet re-suspended in 60 µl 
sterile 0.01 M phosphate buffered saline (PBS).  The virus was stored in 10 l aliquots at -
80°C until required. 
 
2.2.3. Titration of lentiviral vectors  
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To titrate lentiviral vectors, HEK293T cells were seeded at a density of 5 x 105 cells into each 
well of a 6-well plate, which was pre-coated with poly-D-lysine.  Viral stocks were serially 
diluted to 0.1, 0.01 and 0.001 µl/ml in modified DMEM (see section 2.1.4), and 1 ml diluted 
virus and 1 ml medium was added to cells.  24 hours later, the medium was replaced with 
modified DMEM.  Cells were fixed after a further 24 hours and the number of transduced 
cells was counted using an inverted fluorescence microscope using a 10x objective lens.  The 
number of viral transducing units (TU) was calculated according to the formula below. 
 
TU/ml = Number transduced cells (at 10x objective lens) x dilution x 
700 fields of view 
  
Lentiviral vectors driven by the synapsin I promoter (LV/Synapsin I-GFP and LV/Synapsin I-
PST) were not titered as this titration method did not work, seemingly due to the lack of 
synapsin I expression in HEK293T cells.  The titre of LV/CMV-GFP was 1.7 x 1010 TU/ml. 
 
2.3. Animals and surgeries 
All surgical procedures were performed in accordance with the Animals (Scientific 
Procedures) Act 1986.  Adult Wistar rats (weight 125-200 g, Charles River UK) were used to 
optimise surgical procedures and test lentivirus transduction.  Adult female Wistar rats 
(weight 200-225g, Charles River UK) were used for the spinal cord injury experiments.  All 
animals were housed in groups under a 12 hour light/dark cycle with ad libitum access to 
food and water. 
To prepare for surgery, all animals (unless otherwise stated) were anaesthetised using a 
combination of ketamine (60 mg/kg, Ketaset®, Fort Dodge) and medetomidine (0.25 mg/kg, 
Dormitor®, Pfizer).  The surgical area was shaved and cleansed with iodine solution. 
 
2.3.1. Optimising surgical procedures 
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2.3.1.1. Lentiviral vector delivery to cortex 
To optimise the procedure for injecting lentiviral vectors into the CNS, animals (n=2) were 
deeply anaesthetised with 4% isoflurane (IsoFlo®) and positioned in a stereotaxic frame.  A 2 
cm midline incision was made to reveal the skull.  Each animal received 3 injections into the 
left sensorimotor cortex at coordinates defined as anteroposterior (AP) and mediolateral 
(ML): (i) AP: 1.0 mm ML: -1.5 mm (ii) AP: 1.5 mm, ML: -2.5 mm (iii) AP: 2.0 mm, ML: -3.5 
mm, relative to bregma.  The lentiviral vector used carried a GFP cDNA under the control of 
a cytomegalovirus (CMV) promoter (LV/CMV-GFP).  Another 3 injections of lentiviral GFP 
vector under the control of a synapsin I promoter (LV/Synapsin I-GFP) were carried out at 
coordinates: (i) AP: 1.0 mm, ML: 1.5 mm (ii) AP: 1.5 mm, ML: 2.5 mm (iii) AP: 2.0 mm, ML: 
3.5 mm, relative to bregma.  All injections were carried out at the depth of 2 mm from the 
surface of the skull.  To assess the optimal procedure for injecting viral vectors into the CNS, 
lentiviral vectors were delivered using a Hamilton syringe via a directly attached 33-gauge 
steel needle or a glass microneedle.  All injections were performed at a flow rate of 0.2 
μl/min and 1 μl vector was delivered per site. 
In a second study, animals received unilateral injections of lentiviral vector carrying PST-GFP 
and mCherry cDNAs (LV/Synapsin I-PST) into the forelimb sensorimotor cortex, at 
coordinates: AP: 1.5 mm, ML: -2.5 mm, relative to bregma.  Injections were performed using 
a glass microneedle at a depth of 2 mm from the surface of the skull and a flow rate of 0.2 
μl/min.   
In a third study, animals (n=6) received two LV/Synapsin I-GFP injections at coordinates: (i) 
AP: 1.5 mm, ML: -2.5 mm (ii) AP: -1.5 mm, ML: -2.5 mm, relative to bregma, and two 
LV/Synapsin I-PST injections at coordinates: (i) AP: 1.5 mm, ML: 2.5 mm (ii) AP: -1.5 mm, ML: 
2.5 mm, relative to bregma.  All injections were performed at a depth of 2 mm below the 
skull surface.  Injections were performed at a flow rate of 0.2 μl/min (2 μl/site) using a glass 
microneedle.  The wound was sutured and animals were allowed to recover in a heated 
chamber.  
 
Animals from the first two studies were deeply anaesthetised with pentobarbital (50 mg/kg, 
Euthatal®, intraperitoneal, Merial Animal Health Ltd) then underwent perfusion-fixation 
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(see section 2.3.3) at 2 weeks post-surgery, before brains were harvested for 
immunofluorescent staining.  Animals from the third study were deeply anaesthetised with 
pentobarbital (50 mg/kg, Euthatal®, intraperitoneal, Merial Animal Health Ltd) then 
underwent perfusion-fixation (see section 2.3.4) at either 4 weeks (n=3) or 6 weeks (n=3) 
post-surgery, before brains were harvested for immunofluorescent staining.  
 
 
2.3.1.2. Lentiviral vector delivery to the cervical spinal cord 
To identify cell types transduced by lentiviral vectors in the spinal cord, animals (n=2) 
received unilateral injections of LV/CMV-GFP into the cervical spinal cord.  A dorsal midline 
incision was made between the 4th and 7th cervical laminae and the vertebral column was 
exposed.  A hemi-laminectomy on the left hand side was performed at C6 and C7, following 
which the dura was cut to expose the dorsal surface of the spinal cord.  Injections were 
delivered using a glass micropipette attached to a Hamilton syringe via a water-filled 
polyethene tube, into the intermediate grey matter.  All injections were performed at a flow 
rate of 0.2 μl/min (2 μl/site).  After injection, the muscle and skin were sutured and animals 
received buprenorphine (0.01 mg/kg) and saline subcutaneously, twice daily for 2 days.   
In another experiment, animals (n=2) received injections of viral vectors immediately 
following cervical lateral hemisection injury.  A hemi-laminectomy was performed on the 
left side between the 4th and 7th cervical spinal cord segments, following which an incision 
was made in the dura to expose the dorsal surface of the spinal cord.  A sharp microblade 
was used to make an incision at the spinal cord midline between the 5th and 6th cervical 
segments, which was then extended laterally using microscissors.  Immediately following 
injury, rats received 1 injection of LV/Synapsin I-PST rostrally and 1 injection of LV/Synapsin-
I-GFP caudally to the injury. 
Animals from these studies underwent perfusion fixation at 2 weeks post-surgery and the 
spinal cords were collected for histological analysis.  
 
2.3.2. Spinal cord injury and intraspinal lentiviral vector injections study 
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2.3.2.1. Experimental timeline 
Animals received training at behavioural tasks for up to two weeks prior to surgery (see 
chapter 2.4 for details) and baseline values for all behavioural assessments were obtained 
up to three days prior to surgery.  Animals were assigned into one of five groups; (i) 
hemisection + LV/Synapsin I-PST, (ii) hemisection + LV/Synapsin I-GFP, (iii) LV/Synapsin I-PST 
injection only, (iv) LV/Synapsin I-GFP injection only, (v) sham (laminectomy only).  Testing of 
locomotor function was carried out on the next day following surgery and weekly for the 
duration of the experiment.  All animals received unilateral injections of the anterograde 
neuronal tracer, biotin dextran amine (BDA) into the primary sensorimotor cortex two 






 Figure 2.2.  Timeline and schematic for SCI experiments 
(A) Animals were trained on the Montoya staircase test daily for 2 weeks prior to surgery. 
Furthermore, during this time, animals were also habituated to a number of other 
behavioural tasks (see chapter 2.4 for details).  Surgery (including laminectomy, lesion and 
delivery of lentiviral vectors) was performed on day 0, and then locomotor function was 
examined for 6 weeks.  Two weeks prior to sacrifice, animals received injections of the 
anterograde neuronal tracer biotin dextran amine (BDA) to the cortex that was ipsilateral to 
the injury.  (B) Animals received lateral hemisection injury at C5/6, followed with 4 
intraspinal injections of either LV/Synapsin I-PST or LV/Synapsin I-GFP alone without the 
injury.  The control surgery group received a laminectomy only. All animals received 
unilateral injections of BDA into the ipsilateral sensorimotor cortex.    
 
2.3.2.2. Cervical lateral hemisection 
A dorsal midline incision was made between the second and seventh cervical laminae and 
the vertebral column was exposed.  A hemi-laminectomy was performed on the left side 
between the C4 and C7, following which an incision was made in the dura to expose the 
dorsal surface of the spinal cord.  A sharp microblade was used to make an initial incision at 
C5/C6, which was extended laterally to ensure complete lateral hemisection of the spinal 
cord (Figure 2.3A).   
 
2.3.2.3. Intraspinal injections of lentiviral vectors 
Immediately following the hemisection lesion animals were prepared for intraspinal 
injections.  Each animal received four injections of either LV/Synapsin I-GFP (n=8) or 
LV/Synapsin I-PST (n=12), at two sites rostral and two sites caudal to the lateral hemisection 
site (approximately 0.5 and 1.5 mm rostral and caudal to the lesion).  Injections were 
delivered using a glass micropipette attached to a Hamilton syringe via a water-filled 
polyethene tube at a flow rate of 0.2 μl/min (1 μl/site).  After injection, muscle and skin 
were sutured and animals were left to recover in a warm chamber. 
A separate group of animals received LV/Synapsin I-GFP (n=6) or LV/Synapsin I-PST (n=5) 
injections in the absence of hemisection injury (Figure 2.3B), or sham surgery (laminectomy 
only, n=4).   
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Figure 2.3.  Representative surgical images of the lateral hemisection and microinjection 
of lentiviral vector into the spinal cord. 
(A) Laminectomy was performed between C4-C7 and lateral hemisection (Hx) injury was 
performed at C5/6.  (B) A representative image showing lentiviral vector injection sites into 
the uninjured spinal cord. (C) A representative image showing lentiviral vector at the end of 
the glass microneedle being delivered into the uninjured cervical spinal cord.  * denotes 
blood vessel. 
 
2.3.2.4. Post-operative care 
All animals received buprenorphine (0.01 mg/kg, subcutaneous) and sterile saline (3ml, 
Vetivex), immediately following surgery and twice daily for 4 days.  In agreement with Home 
Office instructions, animals that lost 20% body mass were immediately culled.  Paws were 
inspected daily for signs of autotomy.  If observed, rats received topical treatment of anti-
chew spray and Fuciderm® (Dechra) gel, 3 times per day until the skin healed.  If autotomy 




2.3.2.5. Anterograde tract tracing 
To investigate whether lentiviral vector-mediated PSA expression can promote sprouting of 
the uninjured corticospinal tract, rats received unilateral injections of BDA (10%; 10 000 
MW, Life Technologies, UK).  Rats were anaesthetised with 4% isoflurane and placed in a 
stereotaxic frame.  Seven burr holes (0.7 mm diameter) were drilled through the skull, 
ipsilateral to the site of lateral hemisection, at coordinates defined as anteroposterior (AP) 
and mediolateral (ML): (i) AP: -1.5 mm, ML: 2.5 mm; (ii) AP: -0.5 mm, ML: 3.5 mm (iii) AP: - 
0.5 mm, ML: 2.5 mm; (iv) AP: + 0.5 mm, ML: 3.5 mm; (v) AP: + 1.0 mm, ML: 1.5 mm; and (vi) 
AP: 1.5 mm, ML: 2.5 mm; and (vii) AP: 2.0 mm, ML: 3.5 mm, relative to bregma.  BDA (0.8 
µl/site) was injected at a flow rate of 0.2 µl/min using a 26 G needle attached to a Hamilton 
syringe via a water-filled polyethene tube.  Injections were carried out at a depth of 2 mm 
below the skull.  Animals were left to recover in a warm chamber before being transferred 
to clean cages.  Animals received buprenorphine (0.01 mg/kg, subcutaneous) and saline (3 
ml, subcutaneous) twice daily, for two days. 
 
2.3.2.6. Exclusion criteria 
A total of 6 animals in the hemisection + LV/Synapsin I-PST group were excluded from the 
study.  Three animals developed severe autotomy of the contralateral hindlimb, between 2 
and 3 weeks post-surgery and were culled as per Home Office instructions.  Another two 
animals were excluded due to incomplete lesions and a further did not recover from BDA 
injections.  
One animal from the hemisection + LV/Synapsin I-GFP group did not recover from surgery. 
Thus, final group sizes for this study were as follows: hemisection + LV/Synapsin 1-PST (n=6), 
hemisection + LV/Synapsin I-GFP (n=7), LV/Synapsin I-PST alone (n=5), LV/Synapsin I-GFP 
(n=6), and laminectomy alone (n=3). 
 
2.3.3. Perfusion-fixation 
At the end of the study, the animals were deeply anaesthetised using pentobarbital (50 
mg/kg, Euthatal®, intraperitoneal, Merial Animal Health Ltd). The thoracic cavity was 
opened and a needle was inserted into the ascending aorta, via the left ventricle.  The right 
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atrium was cut and perfused with 0.9% saline followed by 4% paraformaldehyde in 0.1 M 
phosphate buffer, for 8 minutes.  The brain and spinal cord were collected and post-fixed in 
4% paraformaldehyde overnight at 4°C.  Tissue was cryoprotected in 20% sucrose in 0.1 M 
phosphate buffer for at least two days at 4°C. 
 
2.3.4. Tissue processing (spinal cord) 
Following cryoprotection in 20% sucrose, spinal cords were cut into 15 mm tissue blocks, 
containing the lesion and injection sites.  Tissue was embedded in optimum cutting 
temperature (OCT) mounting medium (VWR, UK), rapidly frozen on dry ice and stored at -
20°C until further processed. 
Spinal cords were sectioned serially (15 μm thick) in the horizontal plane and thaw-mounted 
onto Superfrost Plus microscope slides.  Sections were air dried and stored at -20°C until 
further processed. 
 
2.3.5. Tissue processing (brain) 
Large brain sections (3-5 mm thick) containing the injection regions were embedded in OCT 
mounting medium, rapidly frozen on dry ice and stored at -20°C until needed.  Coronal 
sections (20 µm thick) were collected and thaw-mounted on to Superfrost Plus slides.  
Tissue sections were air dried and stored at -20°C until further processed. 
 
2.4 Behavioural testing 
All behavioural testing and analysis was done by a blinded assessor. 
 
2.4.1 Open field locomotor assessment 
Rats were habituated to the open field (approximately 1 metre diameter) daily, starting 1 
week prior to surgery.  For the behavioural testing, animals were placed in the open field 
and allowed to freely explore for 4 minutes.  Fore- and hindlimb locomotor function was 
assessed in real-time using the forelimb locomotor scale (FLS) and Basso, Beattie, Bresnahan 
scale (BBB), respectively.  Open field locomotor assessment was performed daily for 7 days 
post-surgery, then every other day for the remainder of the study.   
 
 81 
2.4.2 Montoya staircase 
Skilled forelimb reaching was assessed using the Montoya staircase test.  Animals were 
trained to retrieve food pellets from the staircase daily for 2 weeks before surgery.  Baseline 
testing values were obtained 2 days before surgery then animals were tested twice weekly, 
beginning 3 days post-surgery.  Animals were placed in the staircase for 20 minutes, with 
one food pellet per step.  The number of pellets consumed and displaced was recorded.   
 
 
Figure 2.4.  Montoya staircase test. 
(A-D).  Animals were placed inside the Montoya staircase and allowed to grab a food pellet 
from the steps.  The number of food pellets displaced and eaten was recorded.  Images 
provided courtesy of Dr Zhuo-Hao Liu. 
 
2.4.3 Grid exploratory test 
Animals were habituated to the grid exploratory apparatus daily, for 1 week prior to 
surgery.  Baseline data was obtained 2 days before surgery and then animals were tested 
once per week starting 7 days post-surgery.  Rats were placed on a metal grid (1 metre x 1 
metre with gaps measuring 50 x 50 mm) and allowed to freely explore for 35 steps.  This 
was recorded using a video camera and the number of hindlimb missteps (when the entire 
surface of the foot misses the wire and protrudes through the bottom of the grid, Figure 
2.5) was counted retrospectively. 
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Figure 2.5.  Grid exploratory test. 
Animals were left to roam on a metal grid and the number of missteps was manually 
counted by a blinded assessor.  (A) Generally, animals can place paws on the metal grid 
while exploring.  (B) Missteps were defined as when the entire paw missed the grid and 
protruded through the grid.  
 
2.4.4 Automated gait analysis 
Automated gait analysis was performed using the Catwalk-XT system (Noldus).  This consists 
of an enclosed linear glass walkway, which emits LED light that is completely internally 
reflected.  When an animal moves down the walkway, the LED light is refracted at the areas 
where the paw contacts the glass surface.  This refracted light is detected by a video camera 
attached underneath the walkway, which inputs to a computer for data analysis.   
Animals were habituated to the Catwalk-XT apparatus daily, for 3 days before surgery.  
Individual animals were placed at one end of the walkway, and allowed to walk freely until 
they entered their home cage, which was placed at the other end of the walkway.  Baseline 
data was obtained 2 days before surgery and then animals were tested once per week, 
starting 3 weeks post-lesion.  Three complete runs were analysed per animal at each time 
point.  A complete run was defined as between 1.5 and 10 seconds in duration, during 
which the animal did not pause when it was moving along the walkway.  Data was analysed 
using the Catwalk-XT software provided by the manufacturer.      
 
2.4.5 Plantar heat test (Hargreave’s method) 
Hindlimb responses to thermal stimuli were assessed using the plantar heat test 
(Hargreave’s method).  Rats were habituated in plastic boxes over a glass plate for 20 
minutes.  An infrared heat source (Ugo Basile) was placed beneath the glass plate, which 
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was situated over the centre of the plantar surface of the hind paw.  The heat source was 
switched on and the latency to paw withdrawal was recorded.  Each hind paw was tested 3 
times, with at least 5 minutes resting time in between each test. 
 
2.4.6 Von Frey 
Hindlimb responses to tactile stimuli were assessed by Von Frey filaments (Ugo Basile 
37450/277, Linton Instruments) using a simplified up-down method (Bonin et al., 2014).  
Animals were habituated in plastic boxes placed over a wire mesh, for 20 minutes.  Each 
hindpaw was tested 5 times using Von Frey filaments of various diameters and responses to 
each filament were recorded. 
 
2.5 Immunofluorescence 
2.5.1 Immunohistochemistry (tissue sections) 
Slides containing the tissue sections were rinsed three times in 0.01 M PBS then incubated 
in blocking solution (10% normal goat, or normal donkey, serum in 0.01 M PBS + 0.2% 
Triton-X-100 (PBS-T)) for 2 hours.  The blocking solution was removed and slides were 
incubated in the appropriate primary antibodies (Table 2.2), overnight at room 
temperature.  Next day, slides were washed in PBS and incubated in the appropriate 
fluorescent (Alexa Fluor®, Life Technologies)-conjugated secondary antibody, diluted in PBS-
T, for 2 hours.  Unbound secondary antibody was removed from slides by washing in PBS 
and slides were cover slipped using DAPI Fluoromount-G (Southern Biotech, UK). 
 
2.5.2 Wisteria floribunda agglutinin labelling 
Lectin from Wisteria floribunda agglutinin (WFA) was used to detect perineuronal nets 
(PNNs) in tissue sections.  Sections were washed in Tris buffered saline (TBS) then incubated 
in biotinylated WFA lectin (Sigma Aldrich) diluted in TBS + 0.2% Triton-X-100 (TBS-T) to a 
final concentration of 50 g/ml, overnight at room temperature.  Unbound lectin was 
removed by washing with TBS then labelling was detected by incubation with fluorescence-
conjugated streptavidin (Life Technologies), for two hours.  Slides were washed in TBS and 
cover slipped with DAPI Fluoromount-G. 
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2.5.3 Immunocytochemistry (cell cultures) 
Coverslips were rinsed once in TBS and incubated in 10% normal donkey serum in TBS-T, for 
1 hour at room temperature.  Coverslips were incubated in either WFA-lectin or primary 
antibody (for dilutions see Table 2.2), overnight at room temperature.  The following day 
coverslips were washed in TBS and incubated in secondary antibody for 35 minutes, at room 
temperature.  Unbound secondary antibody was removed by washing in TBS then coverslips 
were mounted using DAPI Fluoromount-G. 
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GFAP (rabbit) Dako 1:1000 1:1000 
Iba1 (rabbit) Wako - 1:500 
Cartilage link 
protein-1 (goat) 
R & D Systems 1:100 1:100 
Neurocan (sheep) R & D Systems 1:500 1:500 
Parvalbumin Swant - 1:1000 


























PSA (mouse IgM) Hybridoma Bank 1:500 1:500 
Lectin for PNN labelling 
WFA Sigma, L1766 10 g/ml 50 g/ml 
Table 2.2.  Concentrations of primary antibodies used for immunofluorescence.  
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2.6 Data analysis and statistics 
All data and statistical analysis was performed by a blinded assessor.  All images were 
captured using a Leica Epifluorescence microscope (unless otherwise stated) and all analysis 
was performed using ImageJ (National Institute for Health).   
 
2.6.1 Percentage of neurons with a PNN  
 
2.6.1.1 Dissociated hippocampal cultures 
To quantify the percentage of neurons with a PNN in dissociated hippocampal cultures, the 
number of WFA, LN1 or neurocan-positive PNNs was expressed as a percentage of the 
number of MAP2-labelled neurons.  Forty images taken with a 20x objective were analysed 
per experiment and three independent experiments were analysed.  Statistical significance 
was determined using a two-way ANOVA. 
2.6.1.2 Following lentiviral vector injection to spinal cord 
The number of GFP or mCherry-positive neurons was manually counted using the Cell 
Counter Plugin on ImageJ.  The number of WFA, LN1 or neurocan-labelled PNNs surrounding 
transduced neurons was also counted and expressed as a percentage of the total number of 
transduced neurons.  For each animal, three spinal cord sections were quantified, 
encompassing the intermediate grey matter and the ventral horn.  Statistical significance 
was determined using a two-way ANOVA. 
   
2.6.2 Density of synaptic inputs to neurons 
 
2.6.2.1. Dissociated hippocampal cultures 
The density of synaptophysin-labelled boutons contacting individual PNN-expressing 
hippocampal neurons was quantified using a custom script on ImageJ created by Prof. John 
Priestley.  Thirty images of PNN-expressing neurons taken at 40x objective lens were 
captured per experiment and three independent experiments were quantified in total.  The 
synaptophysin labelling is overlapped with the MAP2 labelling, to assess the area occupied 
by synaptophysin immunolabelling that was in contact with a MAP2-positive neuronal cell 
body.  The area occupied by synaptophysin labelling was presented as a percentage of the 
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area of the neuronal cell body.  Statistical significance was determined using a two-way 
ANOVA. 
 
2.6.2.2. Following lentiviral vector injection into the spinal cord 
The density of synaptophysin and serotonin-positive boutons on individual transduced 
neurons was quantified using the same script described above.  For each animal, three 
spinal cord sections were quantified, encompassing the intermediate grey matter and the 
ventral horn.  Statistical significance was determined using a two-way ANOVA. 
 
2.6.3 Density of individual PNNs 
 
2.6.3.1. Dissociated hippocampal cultures 
The density of individual PNNs was analysed using a custom script on Image J created by 
Prof. John Priestley.  Thirty high magnification (40x objective) images were captured per 
experiment and the area occupied by PNN labelling was manually thresholded using Image 
J.  The area occupied by individual PNNs was converted into m2 and three independent 
experiments were analysed in total.  Statistical significance was determined using a two-way 
ANOVA.   
 
2.6.3.2. Following lentiviral vector delivery into the spinal cord 
The density of WFA, LN1 or neurocan-labelled PNNs surrounding transduced neurons was 
quantified using the same script that measured the density of synaptic inputs to transduced 
neurons.  Data was obtained from three spinal cord sections per animal, encompassing the 
intermediate grey matter and the ventral horn.  Statistical significance was determined 
using a two-way ANOVA. 
 
2.6.4 PSA expression 
 
2.6.4.1. Dissociated hippocampal cultures 
Twenty images were captured per experiment using a 20x objective.  The area occupied by 
PSA immunolabelling was quantified in a 500 m x 500 m box, using a custom script 
designed for Image J.  The area occupied by PSA was reported as a percentage of the area of 
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the quantification box and three independent experiments were quantified.  Statistical 
significance was determined using a one- or a two-way ANOVA. 
 
2.6.4.2. Lentiviral vector delivery into the spinal cord 
For each animal, images encompassing all injection sites were taken using a 20x objective 
lens on three spinal cord sections (intermediate grey matter and ventral horn).  The area 
occupied by PSA labelling was manually thresholded on Image J and quantified using the 
‘measure’ function.  The values obtained were converted into m2.  Statistical significance 
was determined using a two-way ANOVA. 
 
2.6.5 Behavioural tests 
A two-way repeated measures ANOVA was used to compare open field locomotor function, 
performance at the grid exploratory test and performance at the Montoya staircase test in 
animals that received either lateral hemisection injury or laminectomy only, and either 
injections of LV/PST or LV/GFP.  A two-way ANOVA was used to compare the responses to 
thermal and mechanical stimuli in these animals.  
 
2.6.6. Statistical analysis 
All data in this thesis is presented as mean  standard error of the mean (SEM) and 
statistical analysis was performed using GraphPad Prism software.  Statistical significance 
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Chapter 3: Distribution of perineuronal net molecules in the 




3.1.1 The neuronal extracellular matrix 
As previously mentioned in section 1.1.1, the neuronal extracellular matrix can be 
subdivided into three distinct regions, namely (i) basement membrane (ii) the interstitial 
matrix and (iii) the PNN, which are classified based on their localisation and structure 
(Barros et al., 2011).  With different molecular components found in each type of 
extracellular matrix, they all have varying functions and can respond differently to injury or 
diseases of the nervous system (Barros et al., 2011).  As the detailed structure and function 
of the extracellular matrix was previously described in detail, it will only be touched upon 
here. 
The PNN is a specialised form of extracellular matrix, which has previously been observed to 
surround some populations of neurons during early postnatal development stages in the 
CNS, and throughout adulthood (Carulli et al., 2007; Galtrey et al., 2008).  Compared to both 
the basement membrane and the interstitial matrix, the PNN does not contain the ‘classical’ 
extracellular matrix molecules such as collagen, laminin and fibronectin, but contains a high 
proportion of CSPGs and supporting molecules (Carulli et al., 2007; Galtrey et al., 2008).  
This underlies the main function of the PNN, which is the restriction of neuroplasticity and 
the stabilisation of synapses in the adult CNS (Pizzorusso et al., 2002). 
The PNN can be detected in brain and spinal cord tissue sections using lectin from WFA, 
which binds to N-acetylgalactosamine units that compose the GAG side chains of CSPGs 
(Rhodes and Fawcett, 2004).  Additionally, antibodies have been raised against a number of 
components of the PNN, such as LN1, tenascin-R, semaphorin 3A and individual CSPGs such 
as neurocan, aggrecan, brevican, phosphacan and versican (Carulli et al., 2007; Galtrey et 
al., 2008).  The hyaluronan backbone of the PNN can be reliably detected using a 
biotinylated hyaluronan binding protein (Carulli et al., 2007; Galtrey et al., 2008).  
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To date, there have been a number of studies that have examined the distribution and 
development of PNNs in the CNS, using a combinatorial approach of immunohistochemistry 
and in situ hybridization.  While the general structure and composition of these structures 
are consistent between the brain and the spinal cord, there are regional differences in the 
subtypes of CSPGs expressed in PNNs (Galtrey et al., 2008).  Additionally, some studies have 
investigated the phenotype of PNN-expressing neurons (Vitellaro-Zuccarello et al., 2007).  
What is lacking in these studies is a quantitative assessment of the types and relative 
amounts of synaptic inputs to PNN-expressing neurons.  As mounting evidence suggests 
enzymatic degradation of PNNs following SCI can enhance both axonal regeneration and 
sprouting, in addition to the density of synaptic boutons, understanding the type of synaptic 
connections to PNN-expressing neurons is crucial. 
 
3.1.2 Aims 
The primary aim of this study was to investigate the distribution of WFA-labelled PNNs in 
the rat cervical spinal cord, and to compare this with PNNs immunolabelled using antibodies 
raised against LN1 and neurocan.  LN1 and neurocan were selected as PNN markers as 
mounting evidence supports the vital role of LN1 for PNN formation, and as neurocan has 
previously been shown to bind to NCAM (Friedlander et al., 1994; Carulli et al., 2010). 
Additionally, the relative density of synaptic inputs to PNN-expressing neurons was studied. 
 
3.2 Results 
3.2.1 General characteristics of perineuronal net labelling in the cervical spinal cord 
Epifluorescence images of adult rat cervical spinal cord sections revealed the close 
association between the pericellular PNN and the neuronal cell body (Figure 3.1A-C), and 
under higher-power confocal microscopy it was possible to visualise the ‘honeycomb’ 
structure of the PNN on the surface of ventral horn neurons (Figure 3.1D-F).  To determine 
whether PNNs are found heterogeneously distributed throughout the grey matter of the 
spinal cord, different regions of the cervical spinal cord were analysed for PNNs.  
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Figure 3.1.  Structure of PNNs in the cervical spinal cord. 
PNNs were detected in spinal cord tissue using antibodies against link protein (LN1) and 
neurocan, or lectin from WFA.  (A-C) In the grey matter, PNNs are found surrounding the 
neuronal cell body (single plane).  (D-F) High magnification confocal imaging of single 
neurons revealed the ‘honeycomb’ structure of the PNN on the neuronal surface. 
 
 
3.2.2 PNN expression in the dorsal horn 
To investigate the proportion of neurons with a PNN in the cervical spinal cord dorsal horn, 
sections were double-labelled using antibodies against neuronal nuclei antigen (NeuN), to 
label neuronal cells, and the PNN components; LN1 or neurocan, or WFA (Figure 3.2A-C).  In 
the dorsal horn, WFA labelling was sparse and the percentage of neurons surrounded by a 
PNN was low (5.2 ± 0.6 %, Figure 3.2C, D).  LN1 or neurocan-positive PNNs were found at a 
similar frequency to those labelled with WFA (LN1, 4.4 ± 1.1 %; neurocan, 7.0 ± 2.9 %, 
Figures 3.2A-D).  A comparison of PNN density detected by each marker, calculated as a 
percentage of NeuN labelling, showed no significant difference between the density of LN1-
positive or WFA-labelled PNNs in the dorsal horn (LN1, 38.5 ± 2.3%; WFA 37.9 ± 1.8% Figure 
3.2E).  Interestingly, the density of neurocan-positive PNNs was significantly less compared 
with those positive for LN1 or WFA (28.0 ± 2.4 %, Figure 3.2E). No significant difference was 
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observed in the mean size of neurons expressing LN1, neurocan or WFA-labelled PNNs 
(Supplementary Figure 1A).   
 
Figure 3.2 PNNs in the dorsal horn. 
(A-C) Double fluorescent labelling was used to assess the proportion of neurons surrounded 
by PNNs in the dorsal horn.  LN1, neurocan or WFA-labelled PNNs were associated with 
NeuN-positive neuronal cell bodies.  (D) Quantification of the percentage of neurons with a 
PNN revealed no difference between the three PNN markers (n=3, p>0.05, one-way 
ANOVA).  (E) Quantification of the area of the neuronal cell body occupied by PNN labelling 
revealed a significant difference between neurocan-containing PNNs, compared with LN1-
positive or WFA-labelled PNNs.  n=3, * p < 0.05, one-way ANOVA, Tukey’s post hoc. 
 
To assess the relationship between WFA-labelled and LN1 or neurocan-positive PNNs, 
double fluorescent labelling was performed using WFA and either LN1 or neurocan 
antibody.  WFA labelling within PNNs ranged in intensity, as did LN1 or neurocan staining 
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intensity (Figure 3.3).  LN1-immunoreactivity was strong in 71% of WFA-labelled PNNs 
(Figure 3.3A, arrows) and neurocan was strong in 67% of WFA-labelled PNNs (Figure 3.3B, 
arrows, Summary Figure 3.20).   
 
 
Figure 3.3.  Co-localisation of WFA-labelled PNNs with LN1 or neurocan in the dorsal horn.   
Double-labelling was used to reveal the association between WFA-labelled PNNs and LN1 or 
neurocan in the dorsal horn region of the spinal cord.  (A’-A’’’) WFA-labelled PNNs 
contained high levels of LN1 (arrows).  Remaining PNNs are weak for LN1 (asterisks).  (B‘-
B’’’) Some WFA-labelled PNNs are strong for neurocan while others are weakly labelled 
(asterisks).  Scale bar 100 m. 
 
To assess the density of synaptic boutons in contact with PNN-expressing neurons, sections 
stained with WFA were double-labelled with ChAT (cholinergic fibres), 5-HT (serotonergic 
fibres) or GAD67 (GABAergic fibres).  The area occupied by immunopositive synaptic 
boutons was calculated as a percentage of the size of the cell surface.  The density of 
inhibitory terminals in contact with the surface of PNN-expressing dorsal horn neurons was 
relatively high (GAD67, 14.5 ± 1.4 % Figure 3.4A).  The density of serotonergic and 
cholinergic immunopositive boutons contacting PNN-expressing neurons was low (5-HT, 4.7 
± 1.2 %; ChAT, 1.1 ± 0.3 %, Figure 3.4B-C, Summary Figure 3.20).  To investigate whether a 
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relationship existed between the density of synaptic input and the size of the PNN, a linear 
regression analysis was performed for the PNN size with density of synaptic inputs to 
individual PNN-expressing neurons.  There was no correlation between the extent of WFA 
labelling versus the density of synaptic input on PNN-expressing neurons for GABAergic, 




Figure 3.4.  Synaptic inputs to PNN-expressing neurons in the dorsal horn.   
Double-labelling using WFA lectin and antibodies against GAD67, 5-HT or ChAT was used to 
assess the relationship between the PNN and the density of synaptic input to PNN-
expressing neurons.  (A) neurons with a PNN received moderate levels of inhibitory input.  
(B, C) PNN-expressing neurons received sparse serotonergic and cholinergic input.  (D-F) the 
density of inhibitory, serotonergic or cholinergic synaptic inputs to PNN-expressing neurons 
does not correlate with the density of WFA labelling (linear regression, R2 = 0.09, 0.02 and 
0.03, respectively). 
 
3.2.3 Intermediate grey matter 
For this study the intermediate grey matter (IMG) has been subdivided into three regions; (i) 
dorsal IMG encompasses lamina VI and the dorsal region of VII, (ii) lamina X, as defined by 
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Bror Rexed, (iii) ventral IMG, which includes the ventral region of lamina VII and dorsal 
regions of lamina VIII.  Each region of the IMG will be discussed in separate sections in this 
subchapter.  
3.2.3.1 PNN expression in the dorsal IMG  
PNNs were found throughout the dorsal IMG and could be detected by LN1 and neurocan 
antibodies, or WFA (Figures 3.5A-C, respectively).  No significant difference was observed 
between the percentage of neurons with a LN1-positive PNN or those labelled by WFA (LN1, 
9.5 ± 1.0 %; WFA, 12.3 ± 0.6 %, Figure 3.5D).  The proportion of neurons with a neurocan-
positive PNN was significantly reduced, compared to WFA-labelled PNNs (7.4 ± 0.1 %, p < 
0.05; one-way ANOVA, Tukey’s post hoc, Figure 3.5D).  Although there was a difference in 
the number of neurocan and WFA PNNs in the dorsal IMG, the density of individual PNNs 
was unchanged for all examined markers (Figure 3.5E).  No significant difference was 
observed in the size of neurons with PNNs positive for LN1, neurocan or labelled by WFA 
(Supplementary Figure 1B) 
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Figure 3.5.  PNN expression in the dorsal IMG. 
(A-C) LN1, neurocan or WFA-labelled PNNs were found surrounding neurons in the dorsal 
IMG region of the spinal cord.  (D) Analysis of the proportion of neurons with a PNN 
revealed a significant reduction in the percentage of neurons with a neurocan-positive PNN, 
compared to those labelled by WFA (n =3, p < 0.05, one-way ANOVA, Tukey’s post hoc).  (E) 
No significant difference in the densities of PNNs with the three markers (n=3, p>0.05, one-
way ANOVA).  Scale bar = 100 m. 
 
The density of individual WFA-labelled PNNs was variable in the dorsal IMG (Figure 3.6).  
Strong LN1 immunolabelling was present in 65% of WFA-labelled PNNs (Figure 3.6A, 
arrows).  Similar number of PNNs contained strong neurocan immunoreactivity (61%, Figure 
3.6B, arrows, Summary Figure 3.20).  A subpopulation of PNNs were strongly labelled by 




Figure 3.6.  Colocalisation of different PNN components in neurones located in the dorsal 
IMG.   
(A) Intensity of LN1 staining was variable between WFA-labelled PNNs.  WFA-labelled PNNs 
can display weak (asterisks) or strong (arrows) LN1 immunoreactivity (B) Variable co-




PNN-expressing neurons in the dorsal-IMG received a similar density of cholinergic and 
serotonergic inputs (cholinergic, 2.0 ± 0.7 %; serotonergic, 2.8 ± 0.9 %, Figure 3.7B-C).  The 
density of GABAergic synaptic boutons contacting PNN-expressing neurons was much higher 
(27.9 ± 5.0 %, Figure 3.7A, Summary Figure 3.20).  There was no correlation between the 
density of PNN labelling and the density of synaptic input to PNN-expressing neurons in the 




Figure 3.7.  Synaptic inputs to PNN-expressing neurons in the dorsal-IMG  
The relationship between synaptic inputs to PNN-expressing neurons and density of WFA 
labelling was assessed.  (A) Neurons in the dorsal-IMG that express WFA-labelled PNNs 
receive moderate levels of inhibitory input (GAD67).  (B) The density of serotonergic 
boutons in contact with these neurons is low.  (C) PNN-expressing neurons receive sparse 
cholinergic input.  (D-F) No correlation was observed between the density of inhibitory, 
serotonergic or cholinergic inputs to individual PNN-expressing neurons and the density of 
PNN labelling neurons (linear regression). 
 
3.2.3.2 PNN expression in lamina X 
Lamina X consists of a small region of grey matter surrounding the central canal.  A 
population of small diameter neurons in lamina X were surrounded by a dense, WFA-
labelled PNN.  These neurons can be observed in horizontal sections of spinal cord, in small 
columns that are found parallel to the central canal (Figure 3.8A).  LN1 or neurocan labelling 
in lamina X was generally much weaker compared with WFA (Figure 3.8C, E).  Some LN1 or 
neurocan-containing PNNs could be detected in lamina X, however, labelling was generally 
weak.  Few of the WFA-labelled PNNs contained LN1 (23%) or neurocan (21%). 
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Figure 3.8.  Neurons in lamina X expresses dense WFA-labelled PNN.   
(A) A population of neurons in lamina X located parallel to the central canal were 
surrounded by WFA-labelled PNNs when spinal cord was cut in the horizontal plane.  (B-C) 
WFA-labelled PNNs in lamina X were weakly immunopositive for LN1.  (D-E) Neurocan 
labelling was weak in these PNNs. Scale bars; A = 200 m, B-E = 20 m. 
 
Lamina X is the location of a cholinergic population of neurons known as central canal 
cluster neurons (Barber et al., 1984; Miles et al., 2007).  To determine whether the PNN-
expressing neurons were part of this neuronal population, sections were double-labelled 
with WFA and ChAT.  PNN-expressing in lamina X neurons were non-cholinergic and the 
density of cholinergic immunoreactive terminals contacting these neurons was low (Figure 
3.9A, B).  The density of serotonin immunoreactive terminals contacting individual PNN-
expressing neurons was also low (Figure 3.9C), but higher numbers of inhibitory boutons 
contacted these neurons (Figure 3.9E).  Double fluorescent labelling was performed using 
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WFA lectin and antibodies against calbindin or parvalbumin to determine whether the 
lamina X PNN-expressing neurons were immunopositive for either of these proteins.  
Occasional calbindin immunoreactive neurons were observed in lamina X, however, none 
were surrounded by a WFA-labelled PNN (Figure 3.9D).  Interestingly, a proportion of PNN-
expressing neurons were found to contain parvalbumin (Figure 3.10, arrows). 
 
Figure 3.9.  Density of synaptic terminals contacting lamina X PNN-expressing neurons. 
(A-B) Neurons with a dense, WFA-labelled PNN in lamina X were non-cholinergic, and a low 
proportion of the cell body had cholinergic bouton contacts.  (C) The density of serotonergic 
terminals contacting PNN-expressing neurons was low.  (D) The calcium-binding protein 
calbindin was not expressed by these neurons.  (E) The density of inhibitory boutons 
contacting lamina X PNN-expressing neurons was relatively high. 
 
Figure 3.10.  Colocalisation of parvalbumin and PNN immunolabelling in lamina X 
To assess whether the lamina X PNN-expressing neurons contained the calcium binding 
protein parvalbumin (PV), sections were double-labelled for WFA and antibody against PV 
Some of the PNN-expressing neurons were positive for parvalbumin (arrows). 
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A second neuronal population expressing strong WFA-labelled PNNs was present in lamina X 
(Figure 3.11A, arrows).  These neurons were large in diameter, with cell bodies near or at 
the midline, which projected to both sides of the spinal cord.  However, there was a sparse 
number of these neurons with only one or two observable neurons per section of spinal 
cord (intermediate grey).  These neurons had PNNs that were weakly immunopositive for 
LN1 (Figure 3.11B) or neurocan (Figure 3.11C).  The density of inhibitory synaptic boutons 
contacting the neurons was low (Figure 3.11D), as was the density of serotonergic or 
















Figure 3.11.  Large diameter neurons in lamina X expresses a dense WFA-labelled PNN 
(A) A small population of large neurons in lamina X were surrounded by a WFA-labelled PNN 
(arrows).  The cell body of these neurons was close to the spinal midline.  (B) These PNN-
expressing neurons in lamina X were weakly immunopositive for LN1.  (C) These neurons 
were also weakly immunopositive for neurocan (C’’).  (D-F) The density of GABAergic, 




3.2.3.3 PNN expression in the ventral IMG 
Throughout the ventral IMG, PNN-labelled neurons were immunopositive for LN1 or 
neurocan which could be detected by WFA labelling (Figure 3.12A-C, respectively).  No 
difference was observed in the percentage of neurons expressing a LN1 or a neurocan-
positive PNN (LN1, 11.1 ± 1.9 %; neurocan, 12.7 ± 3.5%) or those labelled by WFA (14.5 ± 0.9 
%, Figure 3.12D).  No difference was observed in the densities of PNNs or the size of 
neurons expressing PNNs (Figure 12E, Supplementary Figure 1C, respectively).  
 
Figure 3.12. PNN-expressing neurons in the ventral IMG. 
(A-C) PNNs labelled with LN1, neurocan or WFA were observed in the ventral IMG.  (D) 
Quantification of the percentage of neurons with a PNN revealed no difference between the 
three PNN markers examined.  (E) Quantification of the area of the neuronal cell body 
occupied by PNN labelling revealed no significant difference between LN1, neurocan or 
WFA-labelled PNNs (n=3, p>0.05, one-way ANOVA).  Scale bar = 100 m. 
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WFA labelling of individual PNNs varied in intensity (Figure 3.13).  The proportion of WFA-
labelled PNNs expressing high levels of LN1 immunoreactivity was 62.3% (Figure 3.13A, 
arrows).  Similar numbers of PNNs (59.8%) had high neurocan immunoreactivity (Figure 
3.13B, arrows, Summary Figure 3.20). 
 
Figure 3.13. Co-localisation between various PNN components in the neurons located in 
the ventral IMG.   
(A) WFA-labelled and LN1-positive PNNs show a partial overlap in the ventral IMG.  WFA-
labelled PNNs contained a mixture of strong (arrows) or weak LN1-immunolabelling 
(asterisks).  (B) WFA-labelled PNNs can also co-localise with neurocan immunolabelling. 
Scale bar = 100 m.     
 
The density of inhibitory boutons in contact with ventral IMG PNN-expressing neurons was 
24% ± 1.9% (Figure 3.14A). By comparison, the densities of serotonergic (5.1 ± 1.2%) and 
cholinergic (7.0 ± 1.3%) terminals were relatively low (Figure 3.14B-C, Summary Figure 3.20).  
There was no correlation between the density of the PNN and the density of synaptic 
terminals contacting PNN-expressing neurons (GAD67 R2=-0.07, 5-HT R2=0.09, ChAT 
R2=0.002, linear regression, Figure 3.14D-F). 
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Figure 3.14.  Synaptic inputs to PNN-expressing neurons in the ventral IMG   
(A-C) Representative photomicrographs showing synaptic inputs to PNN-expressing neurons 
in the ventral-IMG.  (A) The density of inhibitory boutons contacting PNN-expressing 
neurons in the ventral IMG was relatively high.  (B) PNN-expressing neurons were contacted 
by low numbers of serotonergic terminals.  (C) Similarly, the density of cholinergic boutons 
contacting PNN-expressing neurons was low.  (D-F) There was no correlation between the 
density of inhibitory, serotonergic or cholinergic boutons on individual PNN-expressing 
neurons and the density of WFA immunolabelling. (linear regression).  Scale bar = 100 m.   
 
 
3.2.4 PNN expression in the ventral horn 
Ventral horn neurons had the highest proportion of PNNs, compared with other regions of 
the spinal cord (Figure 3.15).  No significant difference was observed between the 
percentage of neurons with a LN1 (14.3 ± 1.5 %) or neurocan (16.3 ± 2.1 %) containing PNN 
or those labelled by WFA (17.8 ± 0.4 %, Figure 3.15D).  Low magnification images revealed a 
difference in PNN expression throughout the ventral horns (Figure 3.15A-C).  Bright LN1 and 
neurocan immunolabelling was found around motor neurons, identified based on their large 
cell body size and location in the lateral regions of the ventral horns (Figure 3.15A-B).  
Interneurons were identified based on their smaller cell body.  Weak WFA-immunolabelling 
was present around motor neurons, but stronger WFA-immunolabelling surrounded 
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smaller-diameter interneurons located in the medial region of the ventral horns (Figure 
3.15C).   
 
Figure 3.15. PNN-expressing neurons in the ventral horn. 
Neurons in the ventral horn were surrounded by LN1 (A), neurocan (B) or WFA-labelled PNN 
(C).  (D) The percentage of neurons with a PNN was not significantly different for all three 
PNN markers (n=3, p>0.05, one-way ANOVA). 
 
 107 
Due to the apparent difference in PNN expression between motor neurons and 
interneurons in the ventral horns, the density of PNNs was analysed separately for both 
neuronal cell types.  No significant difference was observed between the densities of LN1 
(18.7 ± 2.5 %) or neurocan-positive (20.5 ± 1.4 %) PNNs surrounding motor neurons (Figure 
3.16A, B, G).  The density of WFA-labelled PNNs on motor neurons was significantly lower 
than those positive for LN1 or neurocan (6.8 ± 0.9 %, p<0.01, one-way ANOVA, Figure 
3.16C,G).  No significant difference was observed in the densities of PNNs surrounding 
interneurons (Figure 3.16D-F, H).  There was no difference in the average size of either 
motor- or interneurons expressing LN1, neurocan or WFA-labelled PNNs in the ventral horn 
(Supplementary Figures 1D-E). 
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Figure 3.16.  PNNs surrounding motor neurons and interneurons in the ventral horn. 
(A-C) Ventral horn motor neurons are surrounded by PNNs positive for LN1 or neurocan, or 
labelled by WFA.  (D-F) Interneurons in the ventral horn have LN1 or neurocan-positive 
PNNs, and some are labelled by WFA.  (G) Density of individual WFA-labelled PNNs was 
significantly lower than those positive for LN1 or neurocan (n=3, **p<0.01, one-way 
ANOVA). (H) No difference was observed in the densities of individual PNNs found on 
interneurons (n=3, p>0.05, one-way ANOVA). 
 
As previously mentioned, the density of WFA-labelled PNNs on motor neurons was 
significantly lower than the density of LN1 or neurocan immunopositive PNNs.  To evaluate 
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whether motor neurons surrounded by weakly-labelled WFA PNNs contained LN1 or 
neurocan, double fluorescent labelling was performed.  WFA-labelled PNNs were found on 
mostly large motor neurons and almost all of these (94%) were immunopositive for LN1 
(Figure 3.17A) or neurocan (88%, Figure 3.17B, Summary Figure 3.20).  A large proportion of 
WFA-labelled PNNs found on interneurons were immunopositive for LN1 (63%, Figure 
3.17C) or neurocan (54%, Figure 3.17D, Summary Figure 3.20).       
 
Figure 3.17.  Co-localisation between WFA and LN1 or neurocan immunolabelling of PNN-
expressing neurons in the ventral horn 
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(A) WFA-labelled PNNs were found around motor neurons in the ventral horn and almost all 
of these PNNs were immunopositive for LN1.  (B) Many of the PNNs surrounding motor 
neurons were immunopositive for neurocan.  (C-D) WFA-labelled PNNs on interneurons 
were immunopositive for LN1 and neurocan. Scale bar = 100 m. 
 
 
The density of GABAergic terminals in contact with PNN-expressing motor neurons was 20.0 
± 1.3%. (Figure 3.18A).  The density of serotonergic and cholinergic boutons was much lower 
(5-HT, 8.1 ± 1.1 %; ChAT, 9.5 ± 1.7 %, Figure 3.18B-C, summary Figure 3.20).  There was no 
correlation between the density of synaptic inputs to individual PNN-expressing motor 
neurons and the density of WFA labelling (GAD67 R2= 0.05; 5-HT R2= 0.11 and ChAT R2 = 
0.003, linear regression, Figure 3.18D-F). 
 
Figure 3.18.  Density of synaptic boutons in contact with PNN-expressing motor neurons in 
the ventral horn. 
Representative photomicrographs illustrating the density of synaptic inputs to PNN-
expressing motor neurons in the ventral horn.  (A-C) The density of inhibitory boutons in 
contact with PNN-expressing motor neurons was relatively high.  Conversely, the density of 
serotonergic and cholinergic terminals in contact with these neurons was considerably 
lower.  (D-F) There was no correlation between the density of inhibitory, serotonergic or 
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cholinergic inputs to PNN-expressing neurons and the density of WFA labelling on motor 
neurons (linear regression).  Scale bar = 100 m. 
 
The density of GABAergic contacts to PNN-expressing interneurons was 26.2 ± 2.3% (Figure 
3.19A), while serotonergic and cholinergic inputs were again much lower (5-HT 3.5 ± 0.3 %, 
ChAT 2.3 ± 0.2 %, Figure 3.19B,C, summary Figure 3.20).  There was no correlation between 
the density of synaptic inputs to PNN-expressing interneurons in the ventral horn and the 
density of WFA immunolabelling (GAD67 R2= 0.21; 5-HT R2= 0.09 and ChAT R2 = 0.03, linear 
regression, Figure 3.19D-F). 
 
Figure 3.19.  Density of synaptic boutons in contact with PNN-expressing interneurons in 
the ventral horn. 
Representative photomicrographs illustrating the density of synaptic inputs to PNN-
expressing interneurons in the ventral horn.  (A-C) The density of inhibitory boutons 
contacting with PNN-expressing interneurons was relatively high.  Conversely, the density of 
serotonergic and cholinergic terminals in contact with these neurons was considerably 
lower.  (D-F) There was no correlation between the density of inhibitory, serotonergic or 
cholinergic inputs to PNN-expressing neurons and the density of WFA labelling on inter 






Figure 3.20.  Summaries of the density of synaptic inputs to PNN-expressing neurons and 
the overlap of PNN components. 
 (A) Summary of the percentage of the cell body of PNN-expressing neurons contacted by 
specific types of synaptic inputs.  At all spinal cord regions examined there was a significant 
difference in the density of GAD65-labelled boutons contacting neurons, compared with 
boutons labelled with 5-HT or ChAT. (B) Summary of the proportion of WFA-labelled PNNs 
double-labelled with LN1 or neurocan antibodies. There was no significant difference in the 
proportion of WFA-labelled PNNs labelled with LN1 compared with those labelled with 
neurocan. Significance was determined using a two-way ANOVA, ** denotes p < 0.01, *** 
denotes p < 0.001 and **** denotes p < 0.0001. 
 
3.3 Discussion 
3.3.1 PNNs are heterogeneously distributed throughout the cervical spinal cord 
In the cervical spinal cord of adult Wistar rats there was a heterogeneous distribution of 
WFA-labelled PNNs throughout the grey matter.  There was a dorso-ventral increase in the 
proportion of neurons ensheathed by PNNs detected by WFA, LN1 and the CSPG neurocan.  
However, there was in general no difference in the percentage of neurons expressing PNNs 
that were labelled with WFA, LN1 or neurocan in all spinal cord regions examined, with one 
notable exception in the more dorsal region of the intermediate grey matter.  In contrast to 
previously published observations, the proportion of neurons with a PNN did not exceed 
20% for any of the examined markers.  Previous data suggests that between 20 and 40% of 
neurons express WFA-labelled or LN1-containing PNNs in the intermediate grey matter and 
the ventral horn (Galtrey et al., 2008).  The disparity between the data in this study and 
others may be explained by the use of different rat strains; such that this study used Wistar 
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rats, while the published study by Galtrey and co-workers used Sprague Dawley rats.  
Although there is currently no data available concerning the difference in the extracellular 
matrix, or more specifically, the PNN, in different rat strains, Sprague Dawley and Wistar 
rats are known to exhibit differences in their behaviour and response to neuronal insult 
(Mills et al., 2001; Walberer et al., 2006).  Therefore, it is reasonable to suggest there may 
also be strain-related differences in the extracellular matrix.  Moreover, other factors that 
could have contributed to the differential results observed could be the age of the animals, 
the use of antibodies from different suppliers, in addition to the method of tissue 
preparation and the method of histological staining.  It should also be noted that to date, 
the only other available study that investigated the distribution of extracellular matrix 
molecules in the spinal cord subdivided the cord into distinct anatomical regions, as 
classified by Rexed (Watson et al., 2008).  The purpose of this study was to investigate the 
distribution of PNN molecules throughout broad distinct regions of the spinal cord, namely; 
dorsal horn, intermediate grey matter (either dorsal or ventral) and ventral horn, thus 
rendering it difficult to perform direct comparisons between the published study and this 
one.    
In the dorsal horn, the density of neurocan-immunopositive PNNs was significantly lower 
than those detected by LN1 or WFA.  This result concurs with other published studies, which 
have also noted weaker neurocan labelling in the dorsal horn, when compared with WFA or 
LN1 immunostaining (Galtrey et al., 2008).  Although neurocan levels were generally low in 
the dorsal horn, we noted stronger neurocan immunostaining in PNNs found in other 
anatomical regions of the spinal cord.  Interestingly, other studies have revealed consistent 
low levels of neurocan immunostaining in all PNNs found throughout all regions of the 
spinal cord, whereas immunolabelling for other CSPGs, such as aggrecan and phosphacan 
was strong (Galtrey et al., 2008). The differences between our results and those obtained in 
other studies may be explained by the use of a different supplier of neurocan primary 
antibody, or again, may be explained by the difference in rat species used. 
Interestingly, there was a remarkable difference in the expression of PNNs in the ventral 
horns observed in this study.  Neurons in the ventral horn can be broadly classified as 
motor- or interneurons.  Alpha motor neurons were identified in this study by their large cell 
body size and their location in the motor neuron pools at the lateral grey matter of the 
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ventral horns.  These motor neurons, located in lateral motor neurons pools, were densely 
immunolabelled using LN1 and neurocan antibodies, but poorly labelled by WFA.  
Conversely, PNNs surrounding smaller interneurons in the ventral horns were strongly 
labelled by WFA and weakly immunostained for LN1 or neurocan.  Motor neuron pools are 
found both medially and laterally in the spinal cord, in lamina IX.  Only one published study 
has characterised the intensity of PNN immunostaining in lamina IX of the rat cervical spinal 
cord.  Similarly to the findings in this study, Galtrey and co-workers also noted ‘weak’ WFA 
staining intensity and ‘strong’ neurocan labelling intensity surrounding neurons in lamina IX.  
Interestingly, in contrast with our observations in this study, neurocan intensity was defined 
as ‘weak’ in lamina IX.  Unfortunately, the terms ‘weak’ or ‘strong’ were not clearly defined 
in the published methodology, which makes it difficult to identify the cause for this 
variability.  However, similar results were also obtained in another study (Vitellaro-
Zuccarello et al., 2007).  
 
3.3.2 No correlation between PNN density and the density of synaptic inputs to PNN-
expressing neurons 
As the detailed phenotypes of PNN-expressing neurons have been explored by other groups 
(Vitellaro-Zuccarello et al., 2007), this was not examined in this study.  Instead, this study 
aimed to characterise the relative amounts of synaptic inputs to PNN-expressing neurons in 
the spinal cord and whether this correlated with the density of WFA-immunostaining.  In all 
examined spinal cord regions, the density of individual WFA-binding PNNs was not 
correlated with the density of specific types of synaptic boutons (GABAergic, serotonergic or 
cholinergic) that made contact with these PNN-expressing neurons. 
 
3.3.3 A subpopulation of neurons in lamina X express dense PNNs 
A small proportion of neurons in lamina X, a region of the spinal cord grey matter located 
surrounding the central canal, were surrounded by a thick, WFA-labelled PNN.  Previous 
studies have also observed PNN immunostaining in lamina X, however, the neurons 
expressing these structures has not been characterised.  Using a variety of cellular and 
synaptic markers, this study determined these cells to be negative for ChAT and the calcium 
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binding protein, calbindin, however, a small proportion of these neurons were 
immunopositive for parvalbumin.  Cholinergic and serotonergic inputs to these neurons 
were low, but they received a moderate level of inhibitory (GAD67) inputs.   
Although information is lacking regarding the function of lamina X neurons as a whole, a 
number of different neuronal phenotypes and some of their associated functions have been 
identified in the spinal cord.  Some of the best characterised neurons in lamina X are 
positive for ChAT and were termed the central canal cluster neurons (Barber et al., 1984; 
Miles et al., 2007).  These neurons are found throughout the entire rostrocaudal extent of 
the spinal cord bilaterally, adjacent to the central canal.  The lack of ChAT expression in 
PNN-expressing neurons indicates that these neurons do not belong to the cluster neuron 
population.  Additional studies have revealed dense networks of propriospinal neurons in 
lamina X (Masson et al., 1991; Siebert et al., 2010a; Siebert et al., 2010b), in addition to a 
population of neurons in the thoracic and lumbar regions of the spinal cord, which are 
activated during stimulated fictive locomotion (Dai et al., 2005).  
 
3.4 Conclusions 
In summary, this is the first concise study regarding the expression of PNNs within the 
cervical spinal cord.  We have shown that PNNs, namely WFA, LN1 and neurocan are 
present around neurons and that the levels of each PNN differs between different locations 
of the spinal cord, including dorsal horn, intermediate laminae and ventral horn.  Further 
study with others PNN components may aid our understanding of the PNN distribution and 
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Chapter 4: Investigation of the relationship between PSA and the 
PNN in vitro 
 
4.1 Introduction 
In vivo studies have been widely used to study the temporal development of PNNs and how 
these structures can regulate plasticity in the nervous system.  Cells can be simply modified 
in vitro using techniques such as gene silencing (using, for example, shRNA or siRNA) 
genome editing, enzyme treatments and injury modalities.  Thus, in vitro models provide a 
good system to investigate factors that can alter the structure or development of PNNs, 
without the expense or ethical concerns of in vivo animal experimentation.  To date, there 
have been a number of cell culture systems used to model PNNs, including primary neurons 
isolated from the embryonic rodent brain, organotypic slice cultures and cell lines.  Each of 
these culture models will be discussed in turn, below.  
 
4.1.1 Primary neuronal cultures 
Two main types of primary dissociated cultures have been used to model the development 
of PNNs in vitro: cortical and hippocampal neurons.  Cortical neurons can be isolated from 
the embryonic or early postnatal brain and survive well in culture when they adhere onto a 
two dimensional substrate.  One of the most common methods of isolating cortical neurons 
is to use embryonic day 18 rat pups, which results in a heterogeneous population of cells, 
including neurons and astrocytes.  Cultured cortical neurons can form PNNs during the 
second week in vitro, and can be labelled by WFA lectin, in addition to antibodies raised 
against CSPGs such as neurocan and phosphacan, and the supporting molecule hyaluronan 
(Miyata et al., 2005).  Cortical neurons can also be isolated from mouse pups (embryonic 
day 16), which are at a similar stage of development to embryonic day 18 rat pups.  
Similarly, PNNs formed in these cultures contain CSPGs and the supporting molecule 
hyaluronan (Giamanco and Matthews, 2012).  These studies have helped to reveal 
interesting details regarding the cellular contributions to the PNN. For example, the removal 
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of astrocytes from cortical cultures did not lead to alterations in WFA labelling of PNNs 
(Miyata et al., 2005). 
Similarly to cortical neurons, neurons isolated from the hippocampus for in vitro modelling 
of the PNN are generally collected from the brain of either embryonic day 18 rat, or 
embryonic day 16 mouse pups (John et al., 2006; Geissler et al., 2013).  While little is known 
about the precise cellular components of these cultures, some studies have noted a 
proportion of NG2-positive cells, in addition to low numbers of nestin-positive cells at 7 and 
14 days in vitro (DIV).  It is likely that at least a fraction of these cells correspond to 
oligodendrocyte progenitors, however, this has not yet been confirmed in studies looking at 
PNN development (Pyka et al., 2011; Geissler et al., 2013).  PNNs form in dissociated 
hippocampal cultures during the second week in vitro, and are found associated with 
neurons, where they ensheathe the cell body, proximal dendrites and axon initial segment 
(John et al., 2006).  Sharing a similar composition to those observed in vivo, hippocampal 
PNNs contain CSPGs, can be labelled by WFA lectin and also contain the supporting 
molecules hyaluronan and tenascin-R (Pyka et al., 2011; Geissler et al., 2013).  Cultured 
hippocampal neurons have been used to investigate the effect of ChABC-mediated 
degradation of PNNs on synaptic plasticity and synaptogenesis (Pyka et al., 2011). 
 
4.1.2 Cell lines 
While commonly used cell lines such as the human embryonic kidney 293 (HEK293) line can 
express PNN components such as aggrecan, tenascin-R and LN1, they do not typically 
secrete a pericellular matrix.  Transfecting cells with plasmids encoding a hyaluronan 
synthase enzyme (HAS3) and LN1 can result in the formation of a PNN-like structure that 
binds WFA lectin, similar to those observed in vivo and in primary neuronal cultures (Kwok 
et al., 2010).   This culture system has been used to investigate the components of the PNN 
in more detail, such as which molecules are necessary for PNN formation and maintenance 
in vitro (discussed in  chapter 1.1.1, (Kwok et al., 2010)). 
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4.1.4 Slice cultures 
Organotypic slice cultures can be generated from CNS tissue, typically obtained either 
during embryonic or early postnatal development, from a number of regions of the nervous 
system (Lein et al., 2011; Humpel, 2015).  Cultures survive well in vitro, can easily be 
manipulated using a variety of compounds or genome editing techniques and are widely 
used for electrophysiological recordings.  Organotypic cultures provide a more sophisticated 
cell culture model than dissociated cultures which adhere onto a two-dimensional 
substrate, and more accurately represent the environment observed in vivo, due to their 
heterogeneous cellular composition and three-dimensional architecture (Lein et al., 2011).  
Slice cultures derived from regions of the nervous system that typically express PNNs in vivo, 
such as the hippocampus and the cortex, express PNNs, which contain CSPGs and can be 
detected by WFA labelling (Bruckner et al., 2004; Bruckner et al., 2006).     
 
4.1.5 Aims 
The primary aims of this chapter were to investigate the development of PNNs in primary 
neuronal cultures, and to assess whether premature removal of PSA led to an increase in 
the proportion of neurons with PNNs.  Additionally, to examine whether PSA removal could 
affect synapse formation in vitro.  
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4.2 Results 
4.2.1 Optimisation and characterisation of primary cortical cultures 
Previous studies modelling PNNs in vitro commonly used high density cultures derived from 
the embryonic brain (Miyata et al., 2005; Giamanco et al., 2010).  To identify the optimal 
plating density of cortical cultures required in this study, cultures were plated at 50,000 or 
100,000 cells/cm2, onto poly-D-lysine (PDL) coated coverslips.  At 1 DIV, neuronal cells from 
both plating densities were strongly adherent to the coverslips and exhibited small neurites.  
After 7 DIV, neurons in lower density cultures were homogenously distributed across the 
coverslip and neurites had extended in length, which could be clearly observed with bright 
field microscopy (Figure 4.1A).  Conversely, neurons in higher density cultures at 7 DIV had 
aggregated into large cellular clumps and presented long and thick neurites (Figure 4.1B).  
To assess whether the formation of clumps in higher density cultures was due to insufficient 
PDL coating of coverslips, 3 concentrations of PDL were tested; 10, 50 and 100 g/ml.  
Neurons plated on coverslips coated with either 50 or 100 g/ml PDL adhered to coverslips 
and extended short neurites after 1 DIV.  After 7 DIV, neurons in the lower density cultures 
had extended long neurites and were homogeneously distributed across coverslips pre-
treated with the various concentrations of PDL used (Figure 4.1A, C, E).  Conversely, higher 
density cultures formed large cellular clumps, which extended long and thick bunches of 
neurites, irrespective of the PDL concentrations used (Figure 4.1B, D, F).  
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Figure 4.1.  Cultured cortical neurons plated at high density formed large cellular clumps 
after 7 DIV. 
To optimise plating density for cultured cortical neurons, two cell densities (50,000 and 
100,000 cells/cm2) were seeded onto PDL-plated coverslips and examined under light 
microscopy.  (A) Neurons plated at low density were homogenously distributed across the 
coverslip, and extended long neurites by 7 DIV.  (B) Neurons plated at higher density formed 
large cellular clumps by 7 DIV.  (C-F) To determine whether inadequate coverslip coating 
was causing the formation of large cellular aggregates, an additional two concentrations of 
PDL (50 and 100 g/ml) were tested.  The PDL concentration had no effect on the formation 
of cellular clumps.   
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In a separate experiment, cultures were plated on coverslips coated with 100 g/ml PDL 
followed by laminin (2 g/ml), to assess whether this could prevent the formation of clumps 
within high density cultures (Figure 4.2).  Plating with PDL and laminin did not lead to any 
gross improvement in cell distribution in lower density cultures examined under light 
microscopy (Figure 4.2A, C) nor did it prevent the formation of cellular clumps in higher 
density cultures (Figure 4.2B, D).  Based on this data, all subsequent experiments were 
carried out on neurons cultured at the lower density (50,000 cells/cm2), on coverslips 
coated with 100 μg/ml PDL only. 
 
Figure 4.2.  Treating coverslips with PDL and laminin did not affect the formation of 
cellular aggregates. 
(A, C) Plating dissociated cortical cultures at lower density on PDL and laminin coated glass 
coverslips did not grossly alter cell survival or neurite outgrowth compared to PDL only.  (B, 
D) Higher density cultures still formed large cellular clumps when plated on PDL and laminin 
coated coverslips compared to PDL only.  
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Previously published research has suggested that PNN components can be produced by 
neurons and astrocytes in vitro.  To identify whether the cultures used in this study were of 
a heterogeneous cellular composition, including neurons and astrocytes, cells were fixed at 
various time points (7, 14 and 21 DIV), then immunolabelled for microtubule-associated 
protein 2 (MAP2) and glial fibrillary acidic protein (GFAP) to identify neurons and astrocytes, 
respectively (Figure 4.3).  After 7 DIV, neurons can be identified in the cultures using MAP2 
(Figure 4.3A), which labels both the neuronal cell body and dendrites.  By 14 DIV, the 
number of MAP2-positive neurons had remained qualitatively consistent, but the dendrites 
protruding from the neuronal cell body had increased in length and were entangling 
dendrites from other neurons (Figure 4.3B).  Neurons in 21 DIV cultures appeared similar to 
those in 14 DIV cultures (Figure 4.3C).  Astrocytes have been shown to secrete a number of 
proteoglycans that compose PNNs in the adult CNS, therefore it was important to study 
whether astrocytes were present in these cultures (Miyata et al., 2005).  A common 
astrocyte marker, GFAP, was used to identify astrocytes (Figure 4.3 D-F).  After 7 DIV, 
qualitative assessment detected only a few GFAP-positive cells in culture, which exhibited a 
typical astrocytic fibrous and branched morphology (Figure 4.3A).  By 14 DIV, the numbers 
of these astrocytic cells had increased (Figure 4.3B), and at 21 DIV it had increased further 
(Figure 4.3C).    
Figure 4.3.  Neurons and astrocytes are present in dissociated primary cortical cultures. 
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(A-C) MAP2-labelled neurons could be observed in dissociated cortical cultures at 7, 14 and 
21 DIV.  (A) At 7 DIV, neurons with extended neurites were observed.  (B,C) Neurite length 
had dramatically increased by 14 and 21 DIV.  (D-F) GFAP immunostaining revealed the 
continued presence and a temporal increase in the number of astrocytes in dissociated 
primary cortical cultures. Scale bar = 100 m. 
 
4.2.2 Characterisation of PNNs in dissociated primary cortical cultures 
As previously mentioned, PNNs can be detected both in vivo and in vitro, using antibodies 
raised against the supporting protein LN1 or CSPGs such as neurocan, and using a 
biotinylated lectin, WFA.  Double-fluorescent labelling using PNN markers and MAP2 was 
performed, to verify PNN production in dissociated cortical cultures (Figure 4.4). 
LN1 labelling was predominantly co-localised with MAP2 immunostaining of the neuronal 
cell body, and on some MAP2-labelled proximal dendrites (Figure 4.4A, arrows).  
Interestingly, LN1 labelling was also observed on a neurite-like structure, originating from 
the cell body that was not MAP2-positive (arrowhead).  Neurocan labelling was similar in 
morphology to that of LN1, and co-localised with MAP2 immunolabelling of the neuronal 
cell body and proximal dendrites (Figure 4.4B, arrows).  Similarly, neurocan labelling was 
commonly observed on a MAP2-negative structure (arrowheads).  Conversely, WFA labelling 
was different in morphology to that observed with LN1 and neurocan antibodies and was 
granular in appearance (Figure 4.4C).  WFA labelling co-localised with MAP2-positive 
neuronal cell bodies and some dendrites (arrows).  
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Figure 4.4.  PNN labelling was observed on primary cultured cortical neurons. 
(A) LN1-labelled PNNs were observed around some cortical neurons.  LN1 labelling co-
localises with MAP2 labelling of the neuronal cell body and proximal dendrites (arrows), and 
was also found on a neurite-like structure, that was not labelled by MAP2 (arrowheads).  (B) 
Similarly to LN1 immunostaining, neurocan labelling was observed in PNNs surrounding 
cultured cortical neurons, and showed partial co-localisation with MAP2 immunostaining.  
(C) WFA labelling was granular in appearance and was also present on the neuronal cell 
body.  Scale bar = 25 m. 
 
Previous studies have indicated two types of WFA-labelling are observed in cultures derived 
from the cortex, termed granular and pericellular labelling (Miyata et al., 2005).  However, 




Upon closer examination of the cultures from this study at 14 DIV, only pericellular labelling 
could be identified with the LN1 antibody (Figure 4.5A, arrows).  Interestingly, however, 
neurocan-labelled PNNs could be classified as pericellular (Figure 4.5B, arrows) or granular 
(arrowheads).  WFA labelling was observed as a granular morphology only (Figure 4,5C).  
Similarly, in 21 DIV cultures LN1 was observed as a pericellular morphology only (Figure 
4.5D) and only neurocan labelling was observed as being both pericellular or granular 
(Figure 4.5E, arrows and arrowheads, respectively).  WFA was observed in granular PNNs 
only (Figure 4.5F).  It was not determined whether granular labelling was intracellular or 
extracellular.   
Figure 4.5.  PNNs were observed in cortical cultures at 14 and 21 DIV. 
PNN immunolabelling could be observed at both 14 and 21 DIV using LN1 or neurocan 
antibodies and WFA lectin.  (A, D) LN1 labelling was classified as pericellular (arrows).  (B, E) 
Neurocan labelling was observed to be either pericellular (arrows) or granular (arrowheads).  
(C, F) Interestingly, only WFA labelling was observed as granular at both 14 and 21 DIV 
(arrowheads).  Scale bar = 50 m. 
 
To assess the co-localisation between LN1 or neurocan PNNs, and those labelled with WFA, 
cells were double-labelled with either LN1 or neurocan antibodies, and WFA.  Neurocan and 
LN1 double labelling was not performed due to cross-species reactivity between the two 
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primary antibodies.  As previously mentioned, neurocan and WFA labelling were both 
observed as a granular morphology in some of the cultured cortical neurons.  Double-
fluorescent labelling revealed a partial co-localisation of neurocan and WFA labelling within 
these granular PNNs (Figure 4.6A).  Conversely, granular LN1 labelling was not observed in 
vitro and thus, was not observed as co-localising with WFA-labelled granular PNNs (Figure 
4.6B).  Since WFA labelling was absent in a pericellular form, there was no co-localisation 
between neurocan pericellular labelling and WFA (Figure 4.6C).  Similarly, there was no co-
localisation observed between LN1 pericellular staining and WFA labelling (Figure 4.6.D).  
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 Figure 4.6.  WFA labelling co-localised with neurocan in granular PNNs of primary 
cortical neurons. 
(A) WFA labelling was only observed in a granular morphology.  Neurocan immunostaining 
partially co-localised with WFA labelling within these granular PNNs. (B) No co-localisation 
between WFA and LN1 in granular PNNs was observed.  (C) WFA labelling was absent in 
pericellular PNNs that could be labelled by neurocan antibody. (D) Similarly, WFA was also 
absent in LN1-labelled pericellular PNNs.  Highlighted areas are magnified in the top right 
corner of each image.  Scale bar = 10 m (A, B) or 100 m (C, D). 
 
 
4.2.3 Characterisation of PNNs in dissociated primary hippocampal cultures 
As previously described in chapter 4.1.2 above, it has been reported that PNNs can also be 
observed in dissociated hippocampal cultures isolated from the embryonic rat brain (Pyka et 
al., 2011).  Therefore, the purpose of this study was to determine whether the expression of 
PNNs was similar between neurons from different anatomical regions of the embryonic rat 
brain.  Similarly to those observed in cortical cultures, PNNs can be labelled with LN1 or 
neurocan antibody or WFA and show a partial co-localisation with MAP2 immunostaining in 
hippocampal cultures (Figure 4.7).  At 14 DIV, LN1-labelled PNNs predominantly exhibited a 
pericellular morphology, and were found on the neuronal cell body and proximal dendrites 
(Figure 4.7A, arrows).  A MAP2-positive neurite was also labelled by LN1 (arrowhead).  
Likewise, neurocan-labelled PNNs were found on the neuronal cell body and proximal 
dendrites at 14 DIV (Figure 4.7B, arrows).  There was also neurocan labelling on a neurite 
that was not labelled by MAP2 (arrowhead).  WFA labelling in hippocampal cultures had a 
granular morphology, and co-localised with MAP2 immunostaining (Figure 4.7C, arrow).  In 
21 DIV cultures, all 3 PNN markers appeared similar in morphology, and showed a partial co-
localisation with MAP2 immunostaining (Figure 4.7D-F). 
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Figure 4.7.  PNN immunolabelling in dissociated primary hippocampal cultures. 
(A) After 14 DIV, hippocampal neurons identified by MAP2 labelling exhibited PNNs that 
were detected by the LN1 antibody.  This showed co-localisation on the neuronal cell body 
and occasional dendrites (arrows), but additionally could be found on a MAP2-negative 
neurite (arrowhead).  (B) Similarly, neurocan labelling was observed in PNNs surrounding 
the hippocampal neuronal cell body and dendrites (arrows) and on a neurite-like structure 
that was not labelled by MAP2 (arrowhead).  (C) WFA immunostaining was granular in 
morphology and was found primarily on the neuronal cell body. (D-F) After 21 DIV there was 
no gross morphological difference in PNNs examined for LN1, neurocan or WFA.  Scale bar = 
20 m. 
 
Similarly to PNNs observed surrounding neurons isolated from the cortex, PNNs in 
hippocampal cultures could be classified as either granular or pericellular, based on their 
morphology (Figure 4.8).  Granular labelling appeared as a punctate labelling pattern, which 
was predominantly observed on the neuronal cell body, with weaker dendritic staining 
(Figure 4.8A, C).  On the other hand, pericellular labelling was observed as a diffuse labelling 
pattern, found closely associated with the cell body and with strong dendritic staining 
(Figure 4.8B, D).  Interestingly, both LN1 and neurocan could be observed as granular and 
pericellular PNNs, which contradicted data observed in cortical cultures, in which LN1 was 
absent from granular PNNs (Figure 4.8).  WFA labelling was absent in pericellular PNNs, and 
was only found as a granular labelling pattern (Figure 4.7C, F). 
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Figure 4.8. Granular and pericellular PNNs were present on primary cultured hippocampal 
neurons. 
Diffuse and granular PNNs were observed in hippocampal cultures.  (A) LN1 labelling was 
observed in granular PNNs.  (B) LN1 labelling was also observed in pericellular PNNs, which 
exhibited prominent dendritic staining.  (C, D) Similarly, neurocan was observed in granular 
and pericellular PNNs.  Scale bar = 100 m. 
 
4.2.4 Addition of endoneuraminidase N can selectively remove PSA from the surface of 
cultured hippocampal neurons 
Polysialic acid (PSA) can be observed surrounding cultured hippocampal neurons at 7, 14 
and 21 DIV.  Previous research has shown that an enzyme, endoneuraminidase N (endo-N), 
can be used in vitro to selectively remove PSA from the surface of cultured cells (Dityatev et 
al., 2004).  To identify the optimal concentration of endo-N needed to remove PSA from the 
cultures, cells were treated with 40, 80 or 100 ng/ml endo-N after 4 DIV for an additional 
three days.  Cultures were fixed at 7 DIV and immunolabelled for PSA.  Untreated cultures 
showed robust PSA labelling (24.9  2.0 %, Figure 4.9.A, E).  As expected, Endo-N treatment 
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resulted in a drastic reduction in PSA labelling (Figure 4.9B-D).  Quantification of the density 
of PSA labelling in endo-N treated cultures revealed a significant reduction in the area 
occupied by PSA labelling, at all endo-N concentrations examined (40 ng/ml;  0.01  0.003%, 






 Figure 4.9.  PSA expression in primary hippocampal cultures treated with endo-N.   
(A) PSA labelling was robust following 7 DIV.  (B-D) Endo-N treatment resulted in a drastic 
reduction in PSA labelling, at all concentrations tested.  (E) Quantification of the density of 
PSA labelling following endo-N treatment revealed a significant reduction in the area 
occupied by PSA immunostaining.  n=3 independent experiments.  ****denotes p<0.0001, 
one-way ANOVA, Bonferroni’s post-hoc test).  Scale bar = 100 m. 
 
To investigate whether treating cultured hippocampal neurons with endo-N could affect 
neuronal survival, cells were treated with endo-N as above, and immunolabelled using the 
MAP2 antibody.  Untreated cultures contained a high density (45.1 ± 1.2 cells/field of view, 
Figure 4.10A, E) of MAP2-labelled neurons at 7 DIV, from which long MAP2 labelled 
dendrites had covered a large proportion of the coverslip.  Treating cultures with endo-N, at 
all concentrations, resulted in a strong and dose-dependent reduction in the average 
number of MAP2-labelled neurons per field of view (40 ng/ml; 19.2  1.1, 80 ng/ml 5.2  




Figure 4.10.  Reduction of MAP2-positive neurons following endo-N treatment. 
(A) At 7 DIV, there was a high number of MAP2-positive neurons in culture.  (B-D) After 
endo-N treatment, the numbers of MAP2-immunolabelled neurons were reduced in a dose-
dependent manner.  (E) Quantification of the number of MAP2-positive neurons per field of 
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view in the presence of endo-N.  A significant decrease in the number of neurons in culture 
was observed with increasing endo-N concentrations.  n=3 independent experiments. 
***p<0.001, one-way ANOVA, Bonferroni’s post-hoc test.  Scale bar = 100 m. 
 
As endo-N concentrations from 40 - 100 ng/ml resulted in a significant reduction in the 
number of MAP2-immunopositive neurons in vitro, a concentration of 20 ng/ml was tested 
in a subsequent study.  Strong PSA labelling was observed in untreated hippocampal 
cultures after 14 DIV (39.6  3.1 %, Figure 4.11A, E), and less in 21 DIV cultures (29  3.6%, 
Figure 4.11 C, E).  Treating cultures with 20 ng/ml endo-N significantly reduced the density 





Figure 4.11.  Treating hippocampal cultures with 20 ng/ml endo-N reduced PSA labelling at 
14 and 21 DIV. 
(A) Strong PSA labelling was observed in hippocampal cultures at 14 DIV.  (B) Continuous 
endo-N treatment from 4 DIV almost completely ablated PSA immunolabelling in 14 DIV 
cultures.  (C) PSA labelling in 21 DIV hippocampal cultures was strong; however, it was 
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reduced in comparison to 14 DIV cultures.  (D) PSA labelling was drastically reduced in 21 
DIV cultures following endo-N treatment.  (E) Quantification of the percentage area 
occupied by PSA labelling following endo-N treatment.  PSA labelling was significantly 
reduced at both 14 and 21 DIV following endo-N treatment.  n=3 independent experiments.  
****p<0.0001, two-way ANOVA.  Scale bar = 100 m. 
 
The previous examination of endo-N concentrations at 40 – 100 ng/ml showed that the 
treatment resulted in neuronal cell death.  To check that the continuous treatment with 20 
ng/ml endo-N did not affect neuronal survival, cells were fixed at 14 and 21 DIV and 
immunolabelled with MAP2 antibody (Figure 4.12).  At 20 ng/ml endo-N, no significant 
difference was observed in the average number of MAP2-positive cells at 14 DIV in control 
(57.3  2.1 cells/field of view) or treated cultures (57.9  2.5, Figure 4.12 A-B, E).  Similarly 
the number of MAP2-positive cells at 21 DIV was unchanged with endo-N treatment 
(control 61.4  1.8; treated 62  0.9, Figure 4.12C-E).  This data suggests endo-N at a 
concentration of 20 ng/ml was sufficient to reduce PSA expression without having any 
detrimental effect on the neuronal cells in culture. 
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Figure 4.12.  Treating hippocampal cultures with 20 ng/ml endo-N did not affect neuronal 
survival. 
(A-D) Representative photomicrographs illustrating MAP2 immunostaining of 14 and 21 DIV 
hippocampal cultures, with or without endo-N treatment.  (E) Quantification of the number 
of MAP2-positive cells per field.  The number of MAP2-positive cells was not significantly 
different following endo-N treatment, at both 14 and 21 DIV.  n=3 independent 
experiments.  p>0.05, two-way ANOVA.  Scale bar = 100 m. 
 
4.2.4 Treating cultures with endo-N does not alter the development of the PNN  
Previous unpublished data from our laboratory indicated that there may be an inverse 
relationship between PSA expression and the formation of the PNN in the postnatal rat CNS.  
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To assess whether removing PSA from the cultured cells could alter the proportion of 
neurons with a PNN in vitro, cultures were continuously treated with 20 ng/ml endo-N 
starting after 4 DIV, then fixed at 14 or 21 DIV.  This endo-N concentration was selected 
from previous experiments that showed a significant reduction in PSA labelling in treated 
cultures, without a reduction in the number of neurons.  To quantify the proportion of 
neurons with a PNN, cells were double-labelled with the MAP2 antibody and either 
LN1/neurocan antibody or WFA.  After 14 DIV, the percentage of neurons with a PNN was 
different between the three PNN markers examined in this study.  While a similar 
percentage of neurons had PNNs immunolabelled with LN1 (4.7  1.2%, Figure 4.13A) or 
neurocan (3.3  0.7%, Figure 4.13B), a slightly higher percentage had WFA labelling (8.1  
2.4%, Figure 4.13C).  Following endo-N treatment, there was no change in the average 
percentage of neurons with a PNN, labelled with LN1 (3.3  1.0%, Figure 4.13A), neurocan 
(2.7  0.4, Figure 4.13B) or WFA (11.5  4.1, Figure 4.13C).  Interestingly, between 14 and 21 
DIV, there was a slight, but non-significant increase in the proportion of neurons with a LN1 
or neurocan-labelled PNN in untreated cultures (21 DIV untreated; LN1 7.0  0.8%; 
neurocan 6.1  0.4%, Figure 4.13A,B).  There was no significant difference in the percentage 
of neurons with a WFA-labelled PNN between 14 and 21 DIV cultures (21 DIV untreated; 8.7 
 1.4%, Figure 4.13C).  Quantification of the percentage of neurons with a PNN in 21 DIV 
cultures revealed no significant change following endo-N treatment compared to control 
cultures (LN1 5.2  1.1%; neurocan 5.6  0.6%; WFA 11.4  2.1%). 
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Figure 4.13.  Endo-N treatment does not alter the proportion of neurons with PNNs in 
vitro. 
Quantification of the percentage of neurons with either a LN1, neurocan or WFA labelled 
PNN, following continuous treatment with endo-N.  (A) The proportion of neurons with a 
LN1-labelled PNN was marginally increased between 14 and 21 DIV.  Treating cells with 
endo-N from 4 DIV did not alter the proportion of neurons with a LN1-labelled PNN, at 
either time point.  (B) Similarly, the percentage of cultured hippocampal neurons with a 
neurocan-labelled PNN increased between 14 and 21 DIV.  The percentage of neurons with 
a neurocan-labelled PNN was unchanged following endo-N treatment.  (C) There was no 
change in the proportion of neurons with a WFA-labelled PNN, at either 14 or 21 DIV 




Figure 4.14.  Endo-N treatment does not alter the density of PNN immunolabelling.   
(A-D) Representative photomicrographs showing the density of individual PNNs following 
endo-N treatment.  (E) Quantification of the density of individual LN1-labelled PNNs.  There 
was no difference in the density of individual LN1 PNNs at either 14 or 21 DIV following 
endo-N treatment (p>0.05, two-way ANOVA).  (F) Similarly, there was no difference in the 
density of neurocan labelled PNNs following endo-N treatment.  n=3 independent 
experiments.  p>0.05, two-way ANOVA.  Scale bar = 50 m. 
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4.2.5 Endo-N treatment does not alter the density of synaptophysin immunolabelling in 
vitro 
To assess whether the general density of synaptophysin labelling was altered following 
endo-N treatment, cells were immunolabelled with an antibody raised against 
synaptophysin.  The immunolabelling was robust in both control and endo-N treated 
cultures, at both 14 and 21 DIV (Figure 4.15A-D).  Quantification of synaptophysin 
immunostaining revealed no difference between the area occupied by labelling in endo-N 
treated cultures, at either 14 or 21 DIV.  There was, however, a moderate increase in 
synaptophysin immunolabelling between 14 and 21 DIV (Figure 4.15E). 
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Figure 4.15.  The density of synaptophysin immunostaining in vitro is unchanged by endo-
N treatment. 
(A-D) Representative photomicrographs showing the global density of synaptophysin 
labelling in control hippocampal cultures and following endo-N treatment.  (E) 
Quantification of the density of synaptophysin labelling.  There is a moderate increase in the 
area occupied by synaptophysin immunostaining between 14 and 21 DIV.  Endo-N 
treatment did not affect the density of synaptophysin immunolabelling at either examined 
time point.  n=3 independent experiments.  p>0.05, two-way ANOVA.  Scale bar = 100 m. 
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4.2.6 The density of synaptic inputs to PNN-expressing neurons is unchanged following 
endo-N treatment  
Although the global density of synaptophysin labelling appeared to be unchanged following 
endo-N treatment when compared with control cultures, it was possible that the density of 
synaptic inputs to individual PNN-expressing neurons may be altered.  To assess this, cells 
were triple immunostained using antibodies raised against MAP2, synaptophysin and either 
LN1 or neurocan.  WFA, MAP2 and synaptophysin triple immunolabelling could not be 
reliably performed, due to the difference in buffers required for WFA and synaptophysin 
staining.  At 14 DIV, neurons surrounded by LN1-positive PNNs received sparse contact from 
synaptophysin-immunopositive boutons (0.5  0.1%, Figure 4.16A, E). This was increased by 
21 DIV (1.0  0.2%, Figure 4.16B, E).  There was no difference in the density of 
synaptophysin labelling contacting PNN-expressing neurons following endo-N treatment 
(14DIV 0.2  0.2%; 21DIV 0.8  0.1%, p>0.05, two-way ANOVA, Figure 4.16C-E).  Similarly, 
neurons surrounded by neurocan-labelled PNNs received sparse contact from 
synaptophysin-positive boutons at 14 DIV (0.3  0.04%, Figure 4.17A), which was marginally 
increased by 21 DIV (0.6  0.1%, Figure 4.17C).  Following endo-N treatment, there was no 
difference in the density of synaptophysin labelling contacting neurons with a neurocan-
labelled PNN at either 14 or 21 DIV (14DIV 0.3  0.1%, 21DIV 0.5  0.1%, p>0.05, two-way 
ANOVA, Figure 4.17C-E). 
 145 
 
Figure 4.16.  The density of synaptophysin-positive inputs to neurons with a LN1-positive 
PNN was unchanged following endo-N treatment. 
(A-D) Representative images showing the density of synaptophysin-immunopostive boutons 
in contact with neurons expressing LN1-labelled PNNs after 14 DIV.  (E) There was a 
moderate increase in the density of synaptophysin boutons contacting PNN-expressing 
neurons between 14 and 21 DIV.  There was no difference between control and endo-N 




Figure 4.17.  The density of synaptophysin-positive inputs to neurons with a neurocan-
labelled PNN was unchanged following endo-N treatment. 
(A-D) Representative images showing the density of synaptophysin-immunopositive 
boutons in contact with neurons expressing neurocan-labelled PNNs after 14 DIV.  (E) There 
was a moderate increase in the density of synaptophysin boutons contacting PNN-
expressing neurons between 14 and 21 DIV.  There was no difference between control and 
endo-N treated cultures.  n=3 independent experiments.  p>0.05, two-way ANOVA.  Scale 




To summarise the data presented in this chapter, PNNs were observed in dissociated 
primary cell cultures originating from the embryonic rat cortex and hippocampus.  These 
PNNs were detected using WFA lectin, in addition to antibodies raised against PNN 
components LN1 and neurocan.  Treating hippocampal cells with endo-N to remove PSA 
from the surface of cultured cells did not affect the percentage of neurons with a PNN, as 
hypothesised, or affect the density of individual PNNs.  Finally, endo-N treatment did not 
reduce the density of synaptophysin immunolabelling in hippocampal cultures.  
 
4.3.1 Characterisation of PNNs in vitro 
The development of PNNs in primary cultures isolated from the developing cortex or 
hippocampus has been established previously (Miyata et al., 2005; Pyka et al., 2011).  
Similar to those observed in brain and spinal cord tissue sections, PNNs in vitro have 
previously been shown to bind WFA lectin, as in this study, in addition to supporting 
molecules, such as tenascin-R and LN1, and CSPGs such as brevican, phosphacan and 
neurocan (Miyata et al., 2005; John et al., 2006; Giamanco and Matthews, 2012).  In both 
cortical and hippocampal cultures, PNNs were observed on the neuronal cell body and 
proximal dendrites, as demonstrated by co-localisation between PNN immunolabelling and 
MAP2 immunoreactivity.  Additionally, PNN labelling was observed on another neurite-like 
structure, that was devoid of MAP2 staining.  This probably corresponds to the axon initial 
segment, which has previously been shown to be ensheathed by a dense pericellular matrix, 
both in vitro and in tissue sections (Bruckner et al., 2006; John et al., 2006).  Neuronal 
phenotypes expressing PNNs in vitro have been well established and thus were not 
examined in this study.  Generally, PNNs are observed surrounding parvalbumin-positive 
interneurons in cultures originating from the embryonic cortex, which also corroborates 
findings from tissue sections (Pizzorusso et al., 2002; Miyata et al., 2005).  It is likely that at 
least a proportion of the neurons in the hippocampal cultures used in this study are positive 
for parvalbumin, and that a fraction of these neurons express PNNs. 
Previous research has suggested the formation of two types of WFA-labelled PNNs in 
cortical cultures, which have been termed granular and pericellular PNNs (Miyata et al., 
2005).  It could be speculated that granular PNNs represent less developed structures, while 
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pericellular PNNs are more mature.  In the data presented in this chapter, WFA labelling was 
exclusively found as granular PNNs.  Conversely, neurocan was found as both granular and 
pericellular PNNs, and partially co-localised with WFA in granular structures.  Co-localisation 
between WFA and LN1 was not observed in either cortical or hippocampal cultures, despite 
LN1 being observed in both pericellular and granular structures.  Double-labelling of PNNs 
by neurocan and WFA has been observed in other studies (Miyata et al., 2005), as has 
double-labelling by LN1 and WFA (Giamanco et al., 2010).  The lack of co-localisation 
between LN1 and WFA in this study may explain the absence of pericellular WFA-labelled 
PNNs.  LN1 is believed to stabilise connections between hyaluronan and CSPGs (Tsien, 2013) 
and mounting evidence supports a crucial role for this protein in the development of the 
PNN.  For example, one study noted the production of a condensed, pericellular matrix 
following expression of LN1, in combination with hyaluronan synthase, which was not 
produced following expression of hyaluronan synthase alone (Kwok et al., 2010).  
Furthermore, transgenic mice lacking LN1 expression in the brain, have a drastic reduction 
in both the number and density of WFA-labelled PNNs in the cortex (Carulli et al., 2010; 
Suttkus et al., 2014).  Taken together, these experiments suggest a key role for LN1 in the 
development of a pericellular matrix, such as PNNs.  Double-labelling for LN1 and neurocan 
could not be performed in this study due to cross-reactivity between primary antibodies.  
Co-localisation between LN1 and other CSPGs, such as brevican, has been observed in 
pericellular PNNs in vitro, previously (Giamanco et al., 2010).  Thus, it is likely that there 
would be some degree of LN1 and neurocan co-localisation in these cultures, probably in 
pericellular PNNs. 
4.3.2 The relationship between PSA expression and development of the PNN in vitro 
In vivo, PNNs develop after the critical period for neuroplasticity, and are believed to act to 
stabilise synaptic connections and also to restrict experience-dependent plasticity, for 
example ocular dominance plasticity (Pizzorusso et al., 2002; Wang and Fawcett, 2012).  
Conversely, it has been noted in a separate study that PSA expression, abundant during the 
late stages of embryonic development, and in the early postnatal development is down-
regulated towards the end of the critical period.  It has been proposed that PSA down-
regulation may regulate the onset of ocular dominance plasticity in the visual cortex (Di 
Cristo et al., 2007b).  Unpublished data from our laboratory has revealed a spatiotemporal 
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relationship between PSA down-regulation and expression of PNNs in the postnatal rat 
nervous system.  In the spinal cord, for example, PSA expression was widespread 
throughout the first two weeks of postnatal development, following which, levels declined 
and occasional WFA-labelled PNNs were formed (unpublished observations, Dr Xuenong Bo 
and Dr Yi Zhang).  Between the second and third postnatal weeks, PSA expression was 
down-regulated and the number of PNNs increased (unpublished observation).  This led to 
the hypothesis that PSA down-regulation may act as a molecular switch for the 
development of the PNN in vivo.  The initial data presented in this chapter may also support 
a role for PSA down-regulation in the development of PNNs.  After 14 DIV, PSA expression 
was robust in hippocampal cultures. While occasional PNNs could be observed at this time 
point, the percentage of neurons with a PNN had increased by 21 DIV.  Within the same 
timeframe, PSA expression had decreased and the density of synaptophysin 
immunolabelling had increased.  A gradual increase in the density of synaptophysin labelling 
in hippocampal cultures has been identified previously, and is believed to reflect the 
maturation of cultures with time (Fletcher et al., 1991; Harrill et al., 2015).  While there is no 
current data to suggest a correlation between the density of synaptic proteins and PNN 
markers in vitro, it is likely that the increase in synaptophysin immunostaining and the 
change in the proportion of neurons with a PNN, are linked.  Previous studies have revealed 
the close association between PNNs and synaptic boutons in vitro, suggesting the PNNs 
have a crucial role in the development and stabilisation of synapses (Miyata et al., 2005; 
Geissler et al., 2013).  
To assess the hypothesised relationship between PSA and PNNs in more detail, hippocampal 
cultures were treated with endo-N, starting after 4 DIV.  Endo-N has been widely used in 
vivo to selectively remove PSA from the surface of the neural cell adhesion molecule, to 
investigate the role of PSA in axon guidance and synaptogenesis in specific brain regions 
(Daston et al., 1996; McRae et al., 2007).  As expected, PSA labelling in endo-N treated 
cultures was almost completely absent.  The concentration of endo-N used in this study was 
selected based on a series of experiments that noted a dose-dependent death of cultured 
hippocampal neurons at higher concentrations of endo-N.  Interestingly, there was no 
difference in the percentage of neurons with a PNN, or the density of PNN labelling on 
individual neurons, following endo-N treatment.  To date, this is the first study to directly 
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investigate whether PSA can regulate PNN formation in vitro.  While it is now generally 
believed that neuronal activity can modulate PNN formation both in cultures and also in 
vivo, for example in the rodent visual cortex and the barrel cortex (Pizzorusso et al., 2002; 
McRae et al., 2007), the molecular mechanisms underlying PNN development are poorly 
understood.  Recently, it has been proposed that LN1 upregulation underlies the formation 
of PNNs in the rat cerebellum and visual cortex (Carulli et al., 2007; Carulli et al., 2010).  It 
has also been suggested that closure of the critical period, and thus, PNN formation, can be 
modulated by the ratio of chondroitin-4 to chondroitin-6 sulphation in vivo (Miyata et al., 
2012).   
From the data presented in this thesis, although PSA down-regulation apparently 
corresponds to an increase in the proportion of neurons with a PNN in vitro, it is likely that 
PSA down-regulation is not a critical factor for the development of PNNs, at least in vitro, as 
endo-N treated cultures showed no difference in PNN formation.  Nonetheless, it would still 
be interesting to investigate PNN formation in mice lacking the polysialyltransferase 
enzymes PST and STX.  Mice devoid of both polysialyltransferase enzymes have a complete 
loss of PSA in vivo and have gross abnormalities in brain structure (Weinhold et al., 2005).  
At present, there is no data available as to whether these mice show any abnormalities in 
the extracellular matrix.  It would be interesting to investigate this at different time points 
during postnatal development.  
4.3.3 The relationship between PSA expression and synaptogenesis in vitro 
We speculated here that early removal of PSA from primary hippocampal cultures would 
lead to an increase in the proportion of PNNs.  We also hypothesised that if there was an 
increase in PNNs, this may restrict the formation of synapses on PNN-expressing neurons 
and consequently, lead to a reduction in the density of synaptophysin immunolabelling in 
vitro.  Although there was no alteration in either the number or density of PNNs with endo-
N treatment, as PSA has a crucial role in axonal pathfinding and synaptogenesis, we 
hypothesised that endo-N-mediated PSA removal could still affect synapse formation in 
vitro.  Currently, the only other study investigating the density of synaptic labelling in endo-
N treated hippocampal cultures noted a reduction in the density of synaptophysin-labelled 
boutons contacting neuronal dendrites, compared to control cultures (Dityatev et al., 2004).  
In a heterogeneous culture system, containing hippocampal neurons isolated from NCAM+/+ 
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and NCAM-/- mice, a lower density of synapses was found on NCAM+/+ neurons after 
treatment of the cultures with endo-N (Dityatev et al., 2004).  In the data presented in this 
thesis, endo-N treatment did not affect the general density of synaptophysin labelling in 
vitro, or the density of synaptophysin-labelled boutons contacting individual PNN-expressing 
neurons.  There are a number of crucial differences between the Dityatev et al. study and 
the data presented in this thesis, which may explain the conflicting results obtained, namely, 
differences in the species and age of animals used for culture (rat embryonic day 18 here, 
and mouse postnatal day 1-3 in the study by Dityatev and collaborators).  Furthermore, 
Dityatev et al., quantified inputs to neuronal dendrites, which could not be performed in 
this study due to limitations with the Image J script used for quantification; this script only 
allowed quantification of inputs to the neuronal cell body.  Additionally, their study used a 
higher (10-fold difference) concentration of endo-N (Dityatev et al., 2004).  Such a high 
endo-N concentration was not assessed in the study presented in this thesis.  However, 
treating cells with endo-N, diluted to half of this concentration, resulted in a strong 
reduction in the number of MAP2-positive neurons observed in culture, indicating that high 
concentrations of endo-N led to significant neurotoxicity.  This has also been observed in 
another study (Vutskits et al., 2001).  It must also be taken into consideration that while the 
concentration of endo-N drastically reduced PSA labelling in vitro, there was some residual 
PSA expression observed, which may have promoted synapse formation. 
In this study, synaptophysin immunolabelling was used to identify synapses, due to its 
robust use in other studies, in addition to strong localisation at presynaptic terminals.  While 
synaptophysin is still considered a good marker for the labelling of synapses both in vitro 
and in vivo, it is becoming increasingly common is to use dual fluorescent labelling, with pre- 
and post-synaptic markers, such as bassoon and PSD-95, respectively (Pyka et al., 2011).  
Quantification of the number of double-labelled boutons is hypothesised to give a more 
accurate estimate of the number of active synapses, compared to the use of synaptophysin 
immunolabelling alone.  However, this dual staining technique, like synaptophysin labelling, 
cannot distinguish between excitatory or inhibitory synaptic boutons.  This requires specific 
antibodies, raised against vesicular transporters for either glutamate (VGLUT) or GABA 
(VGAT).  This may be an interesting future experiment, to investigate whether PSA removal 
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from hippocampal neurons can affect the density of different types of synaptic inputs to 
PNN-expressing neurons in vitro.  
The experiments to investigate the effect of PSA removal on the development of PNNs in 
this thesis were performed using primary hippocampal neurons, as opposed to cortical 
neurons or organotypic slice cultures, for two main reasons.  Firstly, hippocampal cultures 
are widely used to model synaptogenesis in vitro.  Secondly, previous research has 
suggested chemical digestion of parts of PNNs can increase the number of synapses in 
hippocampal cultures (Pyka et al., 2011).  As the hypothesis of this chapter was to 
investigate whether PSA can modulate the structure of PNNs, and thereby alter the number 
of synapses, this seemed an appropriate model.  However, it must also be noted that using a 
two-dimensional culture system has its flaws, and does not accurately represent the 
environment in vivo.  For example, neurons in vivo are surrounded by a network of glial cells 
and ECM molecules, which is impossible to replicate using a two-dimensional culture 
system.  Moreover, PSA expression in vitro, at least in the cellular model used in this study, 
does not follow the same developmental pattern observed in vivo.  For example, in vivo, PSA 
expression in the hippocampus is down-regulated during early post-natal development, with 
the exception of the dentate gyrus (Seki and Arai, 1991; Di Cristo et al., 2007a).  Conversely, 
cultured hippocampal neurons maintain strong PSA expression during the third week in 
vitro, beyond the time-point at which PSA would normally be down-regulated in vivo.  For 
these reasons, it may be prudent to repeat this study using organotypic slice cultures, which 
more accurately represent the natural spatiotemporal expression of PSA in vivo, in addition 
to maintaining the complex cytoarchitecture of the brain in vitro. 
One of the main caveats of this study is the lack of short time-points for quantification of 
the proportion of neurons with a PNN and the density of synaptophysin immunolabelling.  
The main reason that 14 DIV was selected as the earliest time-point is due to the poor PNN 
and synaptophysin immunostaining prior to this in vitro.  Very few PNN-bearing neurons 
were observed at 7 DIV, which made accurate quantification extremely difficult.  Moreover, 
synaptophysin labelling was weak at 7 DIV, and detection of synaptophysin-positive boutons 
by the quantification program used in this study was poor, rendering quantification 




Taken together, the results from this study indicate that although the timing of PSA 
reduction in cultured hippocampal neurons that have not been treated with endo-N 
seemingly corresponds to an increase in the proportion of neurons with a PNN, it is unlikely 
that PSA down-regulation has a direct role in PNN formation, at least in vitro, as treating 
cultured neurons with endo-N did not alter either the proportion of neurons expressing 
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The data generated in the previous chapter of this thesis showed no difference in either the 
proportion of neurons with a PNN, or the density of PNNs on individual neurons following 
removal of PSA from cultured hippocampal neurons.  However, there were a number of 
limitations with this study, as discussed in chapter 4.3, which may have affected the results 
from these experiments.  One of the most likely caveats, is the two-dimensional cell cultures 
used for these experiments, which do not represent the complex cytoarchitecture of the 
brain.  Consequently, it was decided to further investigate the proposed relationship 
between PSA and the PNN in vivo, using a viral vector to selectively express the 
polysialyltransferase gene in neurons and subsequently use immunolabelling to examine the 
effect of induced PSA expression on both the number and density of PNNs.  Before 
undertaking these experiments, there were a number of factors to be deliberated, such as 
the type and pseudotype of viral vector used, in addition to the delivery method of viral 
vectors, to ensure robust transgene expression in the desired cell type and region of the 
CNS.  These factors will be discussed in more detail below. 
 
5.1.1 The use of lentiviral vectors in the CNS 
The use of viral vectors to selectively express a gene of interest in the CNS is increasing in 
popularity.  While different vectors are principally used for other tissues, the most 
commonly used in the CNS are derived from the adeno-associated virus, or lentivirus.   
Lentiviral (LV) vectors consist of a genome formed of single-stranded RNA, which is 
surrounded by the viral capsid and then ensheathed by an envelope (Baron, 1996).  
Following entry into the host cells, the RNA genome is reverse transcribed into double-
stranded DNA, which subsequently integrates into the host genome, resulting in long-term 
transgene expression (Baron, 1996).  Unfortunately, some vectors show a preference for 
integration into the sites of regularly active genes, which carries a high risk of insertional 
mutagenesis.  Consequently, a group of non-integrating retroviral vectors have been 
 156 
engineered, which retain the ability to successfully transduce neurons and glial cells in vivo 
(Rahim et al., 2009).   
Including the human immunodeficiency virus (HIV), simian immunodeficiency virus (SIV) and 
feline immunodeficiency virus (FIV), LV vectors can transduce both dividing and non-dividing 
cells and produce long-lasting transgene expression (Azzouz et al., 2004).  Interestingly, 
some vectors can be uptaken by either the neuronal cell body or the axon terminal, 
facilitating their use as neuroanatomical tracers (Beier et al., 2011; Hutson et al., 2012).   
Commonly, LV vectors are pseudotyped using glycoprotein from the vesicular stomatitis 
virus (VSV-G), allowing transduction of a broad range of cell types (Liehl et al., 2007; Yaguchi 
et al., 2013).  Cell-type specific targeting can be achieved by altering the cellular tropism, 
using different envelope proteins; for example, pseudotyping with glycoprotein from the 
rabies virus resulted in selective transduction of astrocytes (Liehl et al., 2007).  What is far 
more common, however, is to drive gene expression in target cells using a cell-type specific 
promoter sequence.  The use of a ubiquitous promoter sequence, such as that from 
cytomegalovirus (CMV), will drive transgene expression in a number of CNS cell types, 
including neurons and astrocytes (Li et al., 2010).  Conversely, using cell-type specific 
promoters, such as synapsin I or GFAP, results in transgene expression in exclusively 
neurons or astrocytes, respectively (Hioki et al., 2007; Li et al., 2010; Yaguchi et al., 2013). 
LV vectors have previously been used to either induce expression of a gene of interest, or as 
a delivery system for small hairpin RNA (shRNA) to suppress the expression of target genes 
in the CNS (reviewed by (Parr-Brownlie et al., 2015).  Coupled with the ability to direct 
transgene expression to pre-determined cell types, in addition to improvements in the 
safety of viral vectors, this has led to a surge of research attempting to harness this 
technology to deliver drug treatments to the injured or diseased nervous system (Yip et al., 
2006; Weishaupt et al., 2014).  
5.1.2 Methods of lentiviral vector administration to the CNS 
Many studies, particularly those that use viral vectors to deliver drug treatment to the 
injured CNS require the precise delivery of vectors to specific regions of the brain or spinal 
cord.  The most common method of focal delivery is the direct injection of vectors into the 
CNS parenchyma.  One of the main advantages of this method, is that it allows the precise 
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delivery of vectors to specific regions of the CNS, thereby allowing targeting to pre-
determined neuronal populations (Cetin et al., 2006).  Additionally, this technique is highly 
reproducible and causes very little damage to the CNS (Cetin et al., 2006).  However, 
diffusion of vectors away from the initial injection site is often limited, and multiple 
injections may be required to deliver vectors to large regions of the CNS (Parr-Brownlie et 
al., 2015). 
Other types of viral vector, namely adeno-associated vectors, can transduce a wide area of 
the CNS following delivery into either (i) the cerebrospinal fluid (CSF), typically via the lateral 
ventricles or cisterna magna, or (ii) the periphery (using intravenous injections) (Stone et al., 
2008; Shen et al., 2013).  This is not possible with LV vectors, which require direct delivery to 
the parenchyma to allow the robust transduction of CNS cell types. 
 
5.1.3 Aims 
The work presented in this chapter had the following aims; i) to generate LV vectors carrying 
the transgene for the polysialyltransferase (PST) enzyme or the control transgene GFP; ii) to 
optimise the methodology for LV vector delivery to the CNS suitable for use in vivo; iii) to 
optimise the promoter sequence needed to drive high levels of transgene expression in 
neurons; iv) to conduct a pilot study, investigating whether induced expression of PSA in the 
adult sensorimotor cortex can reduce WFA-binding within the PNN. 
 
5.2 Results 
5.2.1 Generation of lentiviral vectors  
The methodology for the production and titration of LV vectors, is described in chapter 2.2.  
A total of 3 LV vectors were generated in this study: i) carrying the transgene for GFP, under 
the control of a CMV promoter (LV/CMV-GFP), to act as the control vector; ii) carrying the 
transgene for GFP under the control of a human synapsin I promoter (LV/Synapsin I-GFP), to 
provide a second control for the overexpression of PST via the synapsin I promoter; iii) 
carrying the transgenes for PST, fused to GFP, and mCherry, under the control of two 
separate human synapsin I promoters (LV/Synapsin I-PST), to provide expression of PST. 
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5.2.2 Optimisation of the viral vector delivery method 
There are several methods through which LV vectors have been delivered directly into the 
CNS, in particular via a Hamilton syringe with a 33G steel needle or a glass micropipette 
(Cetin et al., 2006; Yip et al., 2006).  To compare these delivery methods, rats received 
bilateral injections of LV/GFP into the sensorimotor cortex, delivered using either a steel 
needle or glass micropipette (one hemisphere received LV/CMV-GFP injection, the other 
received LV/Synapsin-1 injection).  Injections delivered by either the steel needle or the 
glass micropipette resulted in successful transduction of cortical cells, which could be 
observed 2 weeks post-injection as large regions of GFP-positive cells (Figure 5.1).  The 
injection performed using the steel needle resulted in a clearly identifiable needle tract, 
which was filled with autofluorescent cells (Figure 5.1A, arrowheads).  By contrast, no clear 
needle tract could be observed following injection delivered using the glass micropipette, 
and no autofluorescent cells were identified (Figure 5.1B).  This data suggests that delivering 
LV vectors using a glass micropipette resulted in very limited tissue damage compared to a 
steel needle; thus, subsequent injections were performed using this methodology.  
 
 
Figure 5.1.  Intraparenchymal injections delivered using a steel needle resulted in greater 
damage to the cortex compared to a glass micropipette. 
(A) Delivery of LV vector to the sensorimotor cortex using a steel needle resulted in strong 
transduction of cells near the injection site, which could be identified by GFP expression 2 
weeks post-injection.  A distinct needle tract damage to the cortical parenchyma was 
observed, indicated by autofluorescent cells along the needle tract (arrowheads).  (B) 
Similarly, delivering LV vector to the cortex using a glass micropipette resulted in 
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transduction of cells at the injection site, identified by GFP expression, with minimal needle 
tract damage to the cortical parenchyma.  Scale bar = 100 m.  
 
5.2.3 Cell types transduced by lentiviral vectors following injection to the cortex 
As mentioned in chapter 5.1.1, targeted expression of LV vectors can be obtained using cell-
type specific promoter sequences to drive transgene expression.  For this study, it was 
important to obtain robust and specific transgene expression in neurons.  Previous research 
has noted strong transgene expression in neurons, and also glial cells, when driven by a 
CMV promoter sequence, or exclusive transgene expression in neurons when expression 
was driven by synapsin I promoter sequence.  To study the effect of different promoters and 
to determine the optimal promoter sequence for high transgene expression in neurons, rats 
received bilateral injections of LV/CMV-GFP and LV/Synapsin I-GFP to the sensorimotor 
cortex.  Coronal brain sections of the injection sites were immunolabelled with antibodies 
raised against GFAP (astrocytes), NeuN (neurons) or Iba1 (microglia) to identify cell types 
transduced by each vector. 
Two weeks following injection of the viral vectors, large areas of GFP-positive cells could be 
identified in the cortex, indicating successful transduction of, and strong transgene 
expression in cortical cells, by both LV/CMV-GFP and LV/Synapsin I-GFP (Figure 5.2).  The 
LV/CMV-GFP injection resulted in transgene expression in a heterogeneous population of 
cells, including both neurons and astrocytes.  A large number of GFP-positive cells was 
strongly co-labelled with GFAP, indicating that a large proportion of these cells were 
astrocytes (Figure 5.2A’-A’’’, arrowheads).  However, co-localisation between GFP-positive 
cells and NeuN was weak, with only occasional double-labelled cells observed (Figure 5.2B’-
B’’’, arrowheads).  No co-localisation could be observed between Iba1 and GFP (Figure 
5.2C’-C’’’), suggesting that transgene expression in microglial cells did not occur.  
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Figure 5.2.  Expression of LV/CMV-GFP reporter gene was strong in astrocytes following 
injection into the sensorimotor cortex  
Qualitative assessment was used to identify the type of cells with expression of LV/CMV-GFP 
reporter gene, 2 weeks following injection into the sensorimotor cortex. (A’-C’) Strong 
expression of the viral reporter gene (GFP) was observed at 2 weeks post injection.  (A’-A’’’) 
Frequent co-localisation was observed between GFP-positive cells and GFAP 
immunolabelling (arrowheads).  (B’-B’’’) Weak co-localisation was observed between GFP 
and NeuN labelling, but some double-labelled cells could be identified (arrowhead).  (C’-C’’’) 
No co-localisation between GFP and Iba1 labelling was observed.  Scale bar = 100 m. 
 
Similarly to LV/CMV-GFP, LV/Synapsin I-GFP injection resulted in a large area of transduced 
cells in the cortex, which could be identified by strong GFP expression (Figure 5.3).  
Fluorescent immunostaining using cell-type specific antibodies revealed no co-localisation 
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between GFP and GFAP labelling (Figure 5.3A’-A’’’).  Conversely, strong co-localisation could 
be observed between GFP and NeuN labelling (Figure 5.3B), indicating that LV/Synapsin I-
GFP could drive strong transgene expression in transduced cortical neurons.  No co-
localisation was also observed between Iba1 labelling and GFP, suggesting poor reporter 
gene expression in cortical microglial cells (Figure 5.3C’-C’’’). 
Figure 5.3.  Expression of LV/Synapsin I-GFP reporter gene was exclusively neuronal. 
Qualitative assessment was used to identify the type of cells with expression of LV/Synapsin 
I-GFP reporter gene at 2 weeks following injection into the sensorimotor cortex.  (A’-C’) 
Expression of the viral reporter gene (GFP) was strong at 2 weeks post injection.  (A’-A’’’) No 
co-localisation was observed between GFP and GFAP immunostaining.  (B’-B’’’) GFP co-
localised exclusively with NeuN-immunopositive neurons (arrowheads).  (C’-C’’’) No co-
localisation was observed between GFP and Iba1 labelling.  Scale bar = 100 m. 
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In a separate study, animals received unilateral injections of LV/Synapsin I-PST, which can 
independently express PST and the red mCherry fluorescent protein into the sensorimotor 
cortex.  To identify the cell types transduced by LV/Synapsin I-PST, brains were harvested 2 
weeks post-injection, and coronal sections were immunolabelled with primary antibodies 
raised against GFAP, NeuN or Iba1.  LV/Synapsin I-PST injection resulted in successful 
reporter gene expression in cortical cells, which could be identified by strong mCherry 
expression (Figure 5.4A’-C’).  No co-localisation was observed between mCherry-positive 
cells and GFAP immunolabelling, suggesting that Synapsin I promoter sequence did not drive 
transgene expression in cortical astrocytes (Figure 5.4A’-A’’’).  Conversely, strong co-
localisation was observed between mCherry-positive cells and NeuN labelling (Figure 5.4B’-
B’’’), indicating strong transgene expression in cortical neurons.  No co-localisation was 
observed between Iba1 labelling and mCherry (Figure 5.4C’-C’’’). 
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Figure 5.4.  Expression of LV/Synapsin I-PST reporter gene was exclusively neuronal. 
Qualitative assessment was used to identify the type of cells containing expression of 
LV/Synapsin I-PST reporter gene at 2 weeks following injection into the sensorimotor cortex.  
(A’-C’) Strong expression of the viral reporter gene (mCherry) was observed at 2 weeks post 
injection.  (A’-A’’’) No co-localisation was observed between GFAP immunostaining and 
mCherry.  (B’-B’’’) mCherry co-localised exclusively with NeuN-positive neurons.  (C’-C’’’) No 
co-localisation was observed between Iba1 labelling and mCherry.  Scale bar = 100 µm. 
 
In summary, these experiments suggest that following injection into the adult rat cortex, LV 
vectors under the control of a CMV promoter restricted transgene expression to astrocytes, 
with weak transgene expression in neurons.  Conversely, LV vectors under the control of the 
human synapsin I promoter restricted transgene expression to neurons, as expected, 
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illustrated by the strong co-localisation between GFP- or mCherry-positive cells and NeuN 
immunolabelling. 
 
5.2.4 Cell types transduced by lentiviral vectors following injection to the cervical spinal 
cord  
 
5.2.4.1 Uninjured spinal cord 
Previous research suggests that different promoter sequences are required to drive 
transgene expression in neurons in different regions of the CNS.  For example, using LV 
vectors with the transgene under the control of the CMV promoter results in low transgene 
expression in cortical neurons, compared to the use of LV vectors with the transgene under 
the control of the PGK promoter.  Conversely, the opposite is true with cerebellar granular 
neurons (Li et al., 2010).  To assess whether transgene expression driven by the CMV 
promoter was higher in the spinal cord, compared to previous data obtained in the 
sensorimotor cortex, rats received a unilateral injection of LV/CMV-GFP into the 
intermediate grey matter and ventral horn at C6/C7 spinal cord level.  Horizontal spinal cord 
sections containing the injection site were collected at 2 weeks post injection and 
immunolabelled for neurons, astrocytes and microglia using the cell-type specific markers 
NeuN, GFAP and Iba1, respectively.  Similarly to data obtained following cortical injection, 
LV/CMV-GFP intraspinal injection resulted in strong co-localisation of GFP-positive cells and 
GFAP (Figure 5.5A’-A’’’, arrowheads).  Co-localisation between NeuN labelling and GFP-
positive cells was weak, however, occasional double-labelled cells could be identified (Figure 
5.5B’-B’’’, arrowheads).  Furthermore, a few of these double-labelled neurons were motor 
neurons, based on their size and location within the ventral horn. Co-localisation between 
Iba1 and GFP-positive cells was absent, suggesting that CMV promoter cannot drive 
transgene expression in spinal cord microglial cells (Figure 5.5C’-C’’’).   
As this data supports previous findings using LV/CMV-GFP in the sensorimotor cortex, it was 
decided to continue future experiments using LV vectors with the transgene under the 




Figure 5.5.  Expression of LV/CMV-GFP reporter gene was strong in neurons and astrocytes 
in the uninjured cervical spinal cord. 
Qualitative assessment was used to identify the type of cells transduced by LV/CMV-GFP at 
2 weeks following injection into the sensorimotor cortex.  (A’-C’) Strong expression of the 
viral reporter gene (GFP) was observed at 2 weeks post injection.  (A’-A’’’) Frequent co-
localisation between GFAP labelling and GFP was observed (arrowheads).  (B-B’’’) GFP co-
localised with NeuN immunolabelling, but was relatively scarce (arrowheads).  (C’-C’’’) No-
localisation was observed between GFP and Iba1-labelled cells.  Scale bar = 100 m.  
 
5.2.4.2 Injured spinal cord 
To assess transgene expression in cell types following injury to the spinal cord, and to 
ensure this was consistent with data obtained from the uninjured animals, rats received a 
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lateral hemisection lesion at C5/C6 spinal cord level and injections of LV/Synapsin I-GFP 
(control) and LV/Synapsin I-PST (containing a mCherry driven by an independent synapsin I 
promoter) were carried out rostrally and caudally to the injury site.  The spinal cords were 
harvested 2 weeks after surgery and horizontal sections containing the injury and injection 
sites were immunolabelled for astrocytes, neurons and microglia using the cell-type 
antibodies, GFAP, NeuN and Iba1, respectively.  A dense network of GFP-positive cells 
expressed by LV/Synapsin I-GFP was observed rostral to the lesion site, and a similar sized 
area of mCherry-positive cells expressed by LV/Synapsin I-PST was observed caudal to the 
lesion (Figures 5.6 and 5.7, respectively).  These cells were found exclusively in the grey 
matter, ipsilateral to the lesion site, in the intermediate grey matter and in the ventral horn.  
None of the GFP or mCherry-positive cells exhibited co-localisation with GFAP or Iba1 
immunolabelling, indicating these cells were not astrocytes or microglia, respectively (Figure 
5.6A & C, 5.7 A & C).  As expected, strong co-localisation was observed between GFP and 
mCherry with NeuN positive neurons (Figure 5.6B & 5.7B).   
This data suggests that LV/Synapsin I-GFP or LV/Synapsin 1-PST can selectively express 
transgenes in neurons in the injured cervical spinal cord.  Furthermore, the hemisection 






Figure 5.6.  Expression of LV/Synapsin I-GFP reporter gene was strong in neurons in the 
injured cervical spinal cord. 
Qualitative assessment was used to determine the cell types expressing LV/Synapsin I-GFP 
reporter gene at 2 weeks following injection to the injured cervical spinal cord.  LV/Synapsin 
I-GFP and LV/Synapsin I-PST was injected rostrally and caudally, respectively, to a mid-
cervical hemisection lesion and immunolabelling was used to assess the cell types 
transduced by each vector.  (A’-A’’’) GFP-positive cells did not co-localise with GFAP 
labelling.  (B’-B’’’) Strong co-localisation was observed between GFP and NeuN, suggesting 
that transduced cells were neurons. (C’-C’’’) No co-localisation between Iba1 and GFP was 




Figure 5.7.  Expression of LV/Synapsin I-PST reporter gene was strong in neurons in the 
injured cervical spinal cord. 
Qualitative assessment was used to determine the cell types expressing LV/Synapsin I-PST 
reporter gene at 2 weeks following injection to the injured cervical spinal cord.  (A’-A’’’), 
mCherry-positive cells expressed no co-localisation with GFAP labelling.  (B’-B’’’) Strong co-
localisation was observed between mCherry and NeuN, suggesting that transduced cells 
were neurons.  (C’-C’’’) No co-localisation between Iba1 and mCherry was observed.  Scale 
bar = 100 m. 
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5.2.5 Polysialic acid production by the lentiviral vectors 
To investigate whether the injection of LV vectors into the CNS resulted in polysialic acid 
(PSA) expression, tissue sections were immunostained and analysed at 2 weeks post-
injection. 
5.2.5.1 Cortex 
PSA expression is weak in the sensorimotor cortex of the adult rat brain, following down-
regulation during early stages of postnatal development (Di Cristo et al., 2007b).  After 2 
weeks post-injection of LV/Synapsin I-GFP (control), PSA labelling was indeed absent from 
the cortex and no immunolabelling was observed surrounding transduced neurons (Figure 
5.8A’-A’’’).  Conversely, at 2 weeks post-injection of LV/Synapsin I-PST, PSA labelling was 
observed in the cortex surrounding neurons transduced by LV (Figure 5.8B’-B’’’).  A separate 
population of transduced neurons contained intracellular PSA labelling, which co-localised 
with mCherry (Figure 5.8C’-C’’’).  As the LV/Synapsin I-PST contained a transgene for GFP 
which is fused to the C-terminus of the PST gene, it was possible that this perceived 
intracellular PSA labelling could be GFP signal rather than true PSA immunostaining.  To 
investigate this, tissue sections were incubated with PSA secondary antibody only, with the 
primary antibody omitted from the immunostaining.  The data showed mCherry-positive 
neurons did not contain any intracellular labelling (Figure 5.8D), suggesting that the 




Figure 5.8.  LV/Synapsin I-PST induced PSA expression in neurons. 
(A’-A’’’) No PSA immunolabelling was observed surrounding neurons transduced by 
LV/Synapsin I-GFP following delivery to the cortex.  (B’-B’’’) Some neurons transduced by 
LV/Synapsin I-PST expressed a ring-like PSA immunostaining that surrounded the neuronal 
cell body (arrows).  (C’-C’’’) A separate population of transduced neurons had intracellular 
PSA immunolabelling (arrows).  (D’-D’’’) GFP expression mediated by LV/Synapsin I-PST was 
not detected when the PSA primary antibody was excluded from the immunostaining.  Scale 
bar = 50 m. 
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5.2.5.2 Injured spinal cord 
In the uninjured adult rat spinal cord, PSA expression in grey matter is generally confined to 
the superficial dorsal horns and surrounding the central canal (lamina X) (Bonfanti et al., 
1992).  In this study, PSA immunolabelling was absent around neurons when transduced by 
LV/Synapsin I-GFP (control, Figure 5.9A’-A’’’).  Conversely, PSA immunolabelling was 
abundant surrounding neurons when transduced by LV/Synapsin I-PST (Figure 5.9B’-B’’’).   
 
Figure 5.9.  LV/Synapsin I-PST induced PSA expression in neurons of the injured spinal cord 
(A’-A’’’) PSA labelling was absent around neurons transduced by LV/Synapsin I-GFP at 2 
weeks post-delivery to the injured cervical spinal cord.  (B’-B’’’) Conversely, strong PSA 
labelling was found surrounding mCherry-positive neurons in the grey matter at 2 weeks 
post-delivery of LV/Synapsin I-PST.  Scale bar = 100 m. 
 
5.2.6 Perineuronal net intensity following injection of lentiviral vectors into the 
sensorimotor cortex 
Preliminary data from our laboratory suggested that re-expressing PSA in the spinal cord 
could reduce WFA labelling in PNNs (unpublished observation).  To assess whether 
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overexpressing PSA in the adult sensorimotor cortex could reduce WFA binding to the PNN, 
adult rats received bilateral injections of LV vectors into the sensorimotor cortex; one 
cerebral hemisphere was injected with LV/Synapsin I-GFP, the other hemisphere was 
injected with LV/Synapsin I-PST.  Brains were collected at 4 and 6 weeks post-injection and 
coronal sections containing the bilateral injection sites were labelled with WFA, which was 
visualised with streptavidin-conjugated Alexa Fluor 647. 
At 4 weeks post-injection, transduction of neurons by LV/Synapsin I-GFP (control) or 
LV/Synapsin I-PST was strong (Figure 5.10).  A fraction of neurons transduced by 
LV/Synapsin I-GFP were surrounded by WFA-labelled PNNs, suggesting that LV/Synapsin I-
GFP can transduce PNN-expressing neurons in vivo (Figure 5.10A’-A’’, arrows).  Production 
of mCherry by LV/Synapsin I-PST was strongly observed using the red channel (excitation 
wavelength 543 nm) which also bled-through to the far red (excitation wavelength 647 nm) 
channel on an epifluorescence microscope (Figure 5.10B’-B’’) and confocal microscope 
(Figure 5.10C’-C’’).  Several attempts were made to carry out WFA labelling using 
streptavidin-conjugated AMCA (using another excitation wavelength of 350 nm), but were 
all unsuccessful.  Consequently, neither the number of transduced neurons with a PNN, or 
the density of individual PNNs were quantified.  In summary, the issue of whether induced 




 Figure 5.10.  The relationship between induced PSA expression and the PNN was 
investigated in vivo. 
(A’-A’’) A large area of GFP-positive neurons was observed following LV/Synapsin I-GFP 
(control) delivery into the cortex.  GFP-positive neurons were surrounded by WFA-labelled 
PNNs (arrows).  (B-C) A large region of mCherry-positive neurons was observed following 
LV/Synapsin I-PST delivery into the cortex.  mCherry fluorescence bled through to the far 
red channel on both an epifluorescence and confocal microscope (arrowheads), thus the 
effect of PSA expression on the PNN could not be investigated.  Scale bar = 100 m 
 
5.3 Discussion 
5.3.1 Generation of lentiviral vectors and delivery into the CNS 
The use of LV vectors to drive gene expression in the CNS is becoming increasingly common, 
and vectors have been engineered to express enzymes, growth factors, receptors and 
siRNAs (reviewed by (Parr-Brownlie et al., 2015)).  An increasing number of studies are using 
cell-type specific promoters to drive expression of transgenes in required cell types.  The 
primary aim of this study was to generate two high-titre LV vectors, one to overexpress the 
polysialyltransferase (PST) gene, and a control vector to express the GFP only.  A number of 
properties were required for these vectors for use in future studies, including the ability to 
(i) transduce specific neuronal cells in the CNS, (ii) transduce high numbers of neurons, (iii) 
produce high expression of PSA in vivo when using the LV/Synapsin I-PST and, (iv) result in 
long-term transgene expression. 
In this chapter, three LV vectors were generated, all of which produced robust transgene 
expression at 2 weeks following intraparenchymal delivery into the CNS.  Two LV vectors 
were driven by the human synapsin I promoter; LV/Synapsin I-GFP (control) and 
LV/Synapsin I-PST, the other one was driven by a CMV promoter (LV/CMV-GFP).  Following 
delivery of viral vectors to the sensorimotor cortex, using a steel needle, there was visible 
needle tract damage as indicated by the presence of autofluorescent cells along the tract.  
However, this was not observed following LV delivery using a glass micropipette, thus this 
procedure was used for subsequent injections into both the sensorimotor cortex and the 
spinal cord.  Using a glass micropipette to perform the injections allowed the precise 
delivery of viral vectors into the sensorimotor cortex, using stereotaxic coordinates, as 
previously described (Cetin et al., 2006).    
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There are many advantages that support the use of LV vectors in this study, compared to 
other types of viral vector.  Firstly, previous studies from our laboratory, and others, have 
successfully used LV vectors carrying the PST gene to overexpress PSA in the injured nervous 
system, including rodent models of spinal cord injury (Zhang et al., 2007b; Zhang et al., 
2007c).  These studies showed the robust, long-term transgene expression following 
delivery of LV/PST into the injured spinal cord, and the resulting high-levels of PSA.  
Additionally, LV vectors are relatively easy to produce and purify in the laboratory, and it is 
simple to engineer the virus to transduce specific cell-types using specific promoter 
sequences.  However, one downside to the use of LV vectors is that they are only able to 
transduce a relatively small area of the CNS.  This is believed to be due (at least in part), to 
the relatively large size of the virion, compared to the size of the extracellular space of the 
rodent CNS (Cetin et al., 2006).  This was also observed in this study, as transduced cells 
were often only found within a small region and in close vicinity to the injection site.  Thus, 
it was necessary that multiple injections be used in future studies (at least 2 injections per 
site), to allow viral transduction of a wider area of the CNS.  However, while delivering 
vectors using a glass micropipette causes considerably less tissue damage, compared to 
delivery using a steel needle, there will still be some minor damage to the CNS following 
injections using glass micropipettes.  With multiple injections of LV vectors necessary to 
transduce a wide area of the CNS, this may cause some small, local areas of tissue damage 
that may affect the outcomes of any future experiments.  
 
5.3.2 Cell types transduced by lentiviral vectors with a CMV promoter 
As previously discussed, one of the LV produced in this study contained a CMV promoter, to 
non-specifically drive transgene expression in a number of CNS cell-types.  Following direct 
microinjection into the sensorimotor cortex, transduction of neurons by LV/CMV-GFP was 
weak.  Interestingly, however, transgene overexpression was robust in astrocytes, but 
absent in microglia.  While it is well documented that CMV promoter sequences are able to 
transduce a wide range of cell types found in the CNS, the extent of neuronal transduction is 
disputed.  In a similar study, Yaguchi et al., noted strong transduction of cortical neurons by 
VSV-G pseudotyped LV with GFP under the control of a CMV promoter.  Approximately 85% 
of transduced cells were reported to be immunolabelled with the neuronal marker NeuN, 
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and the remaining 10% of cells were astrocytes (Yaguchi et al., 2013).  However, conflicting 
data was obtained from another study, by Hioki et al., which noted approximately half of all 
transduced cells were neurons (Hioki et al., 2007).  The disparity between our results 
compared to those obtained by other groups, may be explained by differences in viral titres, 
since some data suggests that the cellular tropism of LV vectors may change as a function of 
the titre of the viral vector (Yaguchi et al., 2013).  Moreover, studies have noted that the pH 
of the medium used to harvest LV vectors can affect their tropism following delivery to the 
brain (Torashima et al., 2006).   
Similarly, following LV/CMV-GFP injection into the cervical spinal cord, the transduction of 
neurons was poor, but transduction of astrocytes was high.  This is consistent with other 
studies that have also noted strong transduction of spinal astrocytes (over 70% transduced 
cells) following delivery of a CMV promoter-driven LV into the rodent spinal cord (Hendriks 
et al., 2007; Peluffo et al., 2013) and weak or no transduction of microglia (Hendriks et al., 
2007).  A relatively low number of neurons were transduced by LV/CMV-GFP in the work 
presented in this study; a proportion of these were classified as motor neurons, based on 
their morphology and distribution.  Similar findings have also been recently described by 
others (Peluffo et al., 2013). 
Following completion of the GFAP labelling, it was found that the majority of GFP cells in 
both the cortex and the spinal cord were astrocytes, thereby it was decided to cease the 
further analysis of this tissue, and investigate LV vectors under the control of a neuronal-
specific promoter. 
 
5.3.3 Cell types transduced by synapsin I  
In order to obtain selective neuronal cell transduction, LV with a synapsin I promoter was 
used in this study.  Following microinjection into the cortex, both LV/Synapsin I-GFP 
(control) and LV/Synapsin I-PST selectively transduced cortical neurons at 2 weeks following 
injection.  No transduction of either astrocytes or microglia was observed, but neuronal 
transduction was strong with either LV vector.  These data are in agreement with a number 
of other published studies, that have noted almost exclusive transduction of neurons by 
synapsin I-driven LV following delivery into the CNS (Yaguchi et al., 2013).  In the data 
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presented in this study, importantly, both LV/Synapsin I-GFP and LV/Synapsin I-PST could 
transduce PNN-expressing neurons following injection into the cortex.  While no phenotypic 
analysis of the types of neurons transduced by LV/Synapsin I-GFP was carried out in this 
study, the presence of PNNs surrounding these neurons, suggests, at least in the cortex, 
these cells may be parvalbumin-positive inhibitory neurons, which have previously been 
documented to express high levels of WFA-labelled PNNs in vivo (Pizzorusso et al., 2002; 
Orlando and Raineteau, 2015).  Additionally, based on the large size and ventral horn 
localisation of a population of transduced neurons in the spinal cord, it is clear that 
LV/Synapsin I-GFP can also transduce motor neurons, following intra-spinal delivery.  While 
a strict analysis of the phenotypes of neurons transduced by LV vectors following delivery to 
the CNS was not performed here, this will be necessary in future studies if LV/Synapsin I-PST 
promotes functional recovery in a model of spinal cord injury. It will be important to 
investigate the neuronal circuitry responsible for this recovery of function. 
5.3.4 PSA production by lentiviral vectors 
Following injection of LV/Synapsin I-PST into the cortex or the cervical spinal cord, 
expression of PSA was widespread, and was found on the surface of transduced neurons in 
both regions of the CNS.  Interestingly, in the cortex only, intracellular PSA immunostaining 
could also be observed.  This may be due to the autopolysialylation of the PST enzyme, 
which has previously been shown to occur in vivo (Close and Colley, 1998).  There was no 
PSA immunostaining present in the areas surrounding the control LV/Synapsin-GFP in either 
the cortex or the spinal cord, suggesting that the PSA produced in the CNS is due to 
expression of the PST enzyme.  This data concurs with a number of other studies, that have 
noted selective PSA expression in the CNS following delivery of LV/Synapsin I-PST (Zhang et 
al., 2007b; Zhang et al., 2007c; Zhang et al., 2007a).  Many of these studies have done so 
with the aim of assessing whether re-expressing PSA in the CNS can lead to enhanced 
regeneration of damaged axons in models of SCI, which is the focus of this thesis in Chapter 
6.   
One of the main aims of this chapter was to conduct a pilot study to investigate whether 
induced PSA expression in the cortex can lead to a reduction of WFA binding to its site 
within the PNN.  As previously mentioned, there were some problems associated with this 
experiment, namely, the bleed-through of mCherry fluorescence (from LV/Synapsin I-PST) 
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onto other channels of both epifluorescence and confocal microscopes.  This prevented the 
analysis of this tissue, due to the expression of GFP (as a consequence of LV/Synapsin I-GFP 
injection) in the other cerebral hemisphere rendering the use of FITC (or similar)-conjugated 
antibodies inadequate.  Immunolabelling using AMCA-conjugated secondary antibody was 
attempted, however, staining was poor and was not strong enough for quantification.  At 
this point, it was decided to replicate this study in the spinal cord, using separate animals for 




In this study, we have demonstrated successful generation of three high-titre LV vectors 
that can successfully transduce a high number of cells following stereotaxic injections into 
the cortex or cervical spinal cord.  Two of these vectors (LV/Synapsin I-GFP and LV/Synapsin 
I-PST) that contain the neuron-specific promoter synapsin I, can result in selective transgene 
expression in neurons.  Furthermore, LV/Synapsin I-PST, but not the control LV/Synapsin I-
GFP can overexpress PSA in vivo.  Therefore, these two vectors were used to assess the 
relationship between PSA and the PNN in the uninjured cervical spinal cord, in the following 
studies, and also to investigate whether PSA overexpression in a rodent model of SCI can 
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Chapter 6: Investigating whether induced PSA expression can 
promote locomotor recovery and neuroplasticity in a rodent model 
of spinal cord injury  
 
6.1 Introduction 
In the previous chapter of this thesis, a lentiviral (LV) vector encoding the 
polysialyltransferase (PST) and mCherry genes under the control of two separate synapsin I 
promoters was generated (LV/PST).  2 weeks following delivery to either the naïve or injured 
cervical spinal cord, strong transduction of the grey matter was apparent, which was 
observed as numerous mCherry-positive neurons.  Moreover, robust PSA expression was 
observed in the regions surrounding the mCherry-positive neurons.  A control vector was 
also developed, which carried the gene for GFP only under the control of synapsin I 
promoter (LV/GFP).  Following delivery to the naïve or injured spinal cord, strong neuronal 
transduction was observed.  In contrast to LV/PST, PSA immunolabelling surrounding the 
injection sites was absent.  
 
6.1.1 PSA-induced behavioural improvement in rodent models of SCI 
As reviewed in chapter 1.4.4, a number of studies have investigated the effects of PSA in 
promoting functional improvements in models of SCI.  For the most part, PSA expression has 
been achieved using a viral vector to induce expression of one of the polysialyltransferases 
that catalyses the formation of PSA in vivo (El Maarouf et al., 2006; Zhang et al., 2007b).  A 
further set of studies have developed PSA mimetic peptides, that are delivered to the CNS 
via intrathecal catheters (Marino et al., 2009; Pan et al., 2014).  All of these studies have 
utilised thoracic-level models of injury, and only a fraction of these have relied on 
behavioural testing to assess the extent of locomotor recovery.  In the studies that used 
behavioural testing, a significant improvement in hindlimb locomotor function was observed 
in animals treated with PSA mimetic peptide, compared to controls.  This recovery may have 
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been due to enhanced sprouting of serotonergic fibres caudal to the lesion site (Marino et 
al., 2009). 
While the data obtained from the above studies is encouraging, there are questions that 
remain to be addressed, such as the efficacy of such treatments in a cervical-level model of 
SCI, and behavioural improvements associated with viral vector-mediated PSA expression.  
In our laboratory, we chose the use of viral vectors encoding the polysialyltransferase gene 
to induce PSA expression in the spinal cord, rather than the use of PSA mimetics.  This 
allows us to direct PSA expression to specific cellular populations, and also, this allows long-
term expression.  The use of this viral vector in a mid-cervical model of SCI was investigated 
in more detail in this chapter.  
 
6.1.2 Proposed relationship between PSA and the PNN in vivo 
As described in chapter 1.5.4, preliminary observations from our laboratory suggest an 
inverse relationship between the expression of PSA and the formation of the PNN in vivo.  
This is based on results from a previous small histological study using sections of postnatal 
rat spinal cords, ranging from postnatal day 3 to day 21.  This study noted the emergence of 
WFA-labelled PNNs following down-regulation of PSA expression in the spinal cord, and the 
lack of double-labelled neurons for both PSA and the PNN marker WFA (unpublished 
observation).   
Thus far in this thesis, a cell culture model using primary neuronal cells was used to 
investigate whether removing PSA from the culture could exacerbate PNN formation, which 
would subsequently restrict synaptogenesis in vitro.  Results from this study were negative, 
and no difference was observed in the proportion of PNNs or the density of synaptophysin-
labelled terminals contacting cells with or without PSA (see Chapter 4).  We hypothesised 
that the limitations of using a two-dimensional culture system may have affected the results 
obtained in this study.  Additionally, in a pilot study, LV/PST and LV/GFP were injected into 
the adult rat sensorimotor cortex to investigate whether induced PSA expression could lead 
to a reduction in WFA labelling of PNNs in vivo (Chapter 5).  Restrictions in immunostaining 
prevented further analysis of this tissue, therefore it was decided to re-examine this in the 
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cervical spinal cord, using the same viral vectors developed in Chapter 5, but only injecting 
one vector to the spinal cord of each animal.  
 
6.1.3 Aims 
Using the LV vectors described in chapter 5, the aims of this chapter were as follows.  First, 
to evaluate whether induced PSA expression rostral and caudal to a cervical spinal cord 
lesion, could promote functional recovery by enhancing axonal sprouting and 
synaptogenesis.  Second, to investigate whether PSA expression in the naïve cervical spinal 
cord can alter the binding of WFA lectin to its site within the PNN.  Third, to see whether 
induced PSA expression in the naïve spinal cord can induce axonal sprouting and 




6.2.1 LV/PST induced functional recovery in rats with a cervical spinal cord injury 
 
6.2.1.1 Open field locomotor assessment 
To evaluate whether induced PSA expression via direct injection of LV/PST into the injured 
spinal cord can promote improvement in locomotor recovery, adult rats received unilateral 
injections of either LV/GFP or LV/PST, rostral and caudal to a lateral hemisection injury 
between the 5th and 6th cervical segments (henceforth known as Hx + LV/GFP and Hx + 
LV/PST, respectively).  In the same study, additional groups of animals received injections of 
either LV/GFP or LV/PST only, in the absence of hemisection lesion, or sham surgery, which 
involved laminectomy only.  Fore- and hindlimb function was assessed using a number of 
behavioural tests, starting 1 day following surgery and continued for the duration of the 
study. 
The open field locomotor assessment can be used to score the forelimb and hindlimb 
locomotor function of rats, using the forelimb locomotor scale (FLS) and the Basso Beattie 
Bresnahan (BBB) scale, respectively.  The FLS was developed as a tool to investigate acute 
recovery of forelimb function in the days following SCI.  Baseline testing before surgery 
revealed normal forelimb function in all animals (FLS score 17  0; consistent plantar 
stepping, parallel paw placement and consistent toe clearance, Figure 6.1A).  1 day post-
surgery, all animals that received lateral hemisection injury had a drastic loss in forelimb 
function (FLS score 1 DPO; Hx + LV/GFP, 2.1  1.0 and Hx + LV/PST, 0.8  0.2, Figure 6.1A).  
Hx + LV/GFP animals showed a gradual improvement in forelimb function, which persisted 
until 16 days post-lesion (FLS score 16 DPO,  10.6  1.4).  There was little change beyond this 
time-point, and scores remained similar at the end of the study (FLS score 42 DPO, 11.3  
1.4, Figure 6.1A).  Conversely, a gradual recovery of forelimb function was observed with Hx 
+ LV/PST animals up to 8 days post-injury (FLS score 8 DPO, 9.7  0.2, Figure 6.1A).  Forelimb 
function remained consistent for approximately 2 weeks, then a moderate improvement 
was observed 26 days post-lesion (FLS score 26 DPO, 11.8  1.7).  A further improvement 
was observed 36 days post-injury (FLS score 36 DPO, 13.0  1.8), then scores plateaued for 
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the remainder of the study.  There was no difference in FLS scores in Hx + LV/PST versus Hx 
+ LV/GFP animals at any examined time-point post-lesion (Figure 6.1A, p > 0.05, two-way 
ANOVA, Tukey’s multiple comparisons test).  Sham animals had a consistent FLS score of 17, 
indicating that the laminectomy procedure did not affect forelimb locomotor function 
(Figure 6.1A). 
The BBB scale was designed to evaluate hindlimb function, ranging from complete hindlimb 
paralysis to normal movement (Basso et al., 1995).  Pre-surgery, all animals in all treatment 
groups had BBB scores of 21, indicating normal hindlimb function (Figure 6.1B).  This 
corresponds to consistent stepping, with paws placed in parallel to the animal’s trunk, no 
toe dragging and consistent fore- and hindlimb coordination (see Figure 6.1).  1 day post-
surgery, all animals that received the lateral hemisection lesion and either LV/GFP or LV/PST 
injections had a drastic loss in hindlimb motor function (BBB scores; LV/GFP, 5.6  1.4 and 
LV/PST, 7.0  1.8, respectively, Figure 6.1B).  Up to 5 days post-lesion, injured animals 
showed a gradual improvement in hindlimb function but no difference was observed in the 
rate of recovery between treatment groups.  By 7 days post-lesion, all Hx animals (in both 
treatment groups) had a BBB score of 11 (occasional stepping and fore- and hindlimb 
coordination).  Hx + LV/GFP animals showed no further improvement in hindlimb function 
beyond the first week post-lesion.  Conversely, hindlimb function of Hx + LV/PST animals 
continued to steadily improve beyond the first week post-injury and a significant 
improvement was observed 30 days post-lesion, compared to Hx + LV/GFP animals (BBB 
scores 30 DPO, 11.6  0.3 vs. 13.8  0.9, LV/GFP vs. LV/PST, p=0.009, two-way ANOVA, 
Tukey’s multiple comparisons test, Figure 6.1B).  This improvement in hindlimb function 
persisted for the remainder of the experiment.  Sham animals had no difference in hindlimb 




Figure 6.1.  Intraspinal injection of LV/PST improved the hindlimb function of animals with 
mid-cervical SCI. 
Open field locomotor testing was used to assess locomotor function of both the fore- and 
hindlimbs post-SCI.  (A) The forelimb locomotor scale (FLS) was used to assess forelimb 
function in SCI-animals.  1 day post-lesion, both LV/PST and LV/GFP treated animals 
displayed a drastic loss in forelimb function.  Animals in both treatment groups gradually 
regained forelimb function during the first 2 weeks, with no difference between groups 
(p>0.05).  LV/GFP treated animals showed minimal improvement after 2 weeks, however, 
there was a minor improvement in function of LV/PST treated animals after 4 weeks.  There 
was no difference between LV/PST and LV/GFP treated animals at any examined timepoint 
(p>0.05).  Forelimb function in sham animals was unaffected.  (B) The BBB scale was used to 
assess hindlimb function. One day post-lesion, both LV/PST and LV/GFP treated animals 
displayed a loss of hindlimb function.  Some improvement was observed during the first 
week after surgery, however, in the LV/GFP group, no further improvement was observed 
after this timepoint.  LV/PST treated animals showed a significant improvement in hindlimb 
function 30 days post-lesion, compared with LV/GFP treated rats (*p<0.05, **p<0.01).  
Hindlimb function in sham animals was unaffected by surgery.  Sham, n=3; Hx + LV/PST, n=6; 
Hx + LV/GFP, n=6; LV/PST only, n=6 and; LV/GFP only, n=6.  
 
6.2.1.2 Montoya staircase test  
Modelling SCI at the cervical level allows assessment of tasks that require skilled 
movements, such as pellet retrieval, which cannot be assessed in models with injuries in the 
thoracic region.  One of the most common behavioural tests for this purpose is the Montoya 
staircase test, a description of which can be found in chapter 2.4.2.  This is a complex 
behavioural task, which requires at least two weeks of training.  Two different outcomes can 
be measured from this behavioural test; first, gross locomotor function can be assessed by 
quantifying the number of food pellets displaced by each animal, and second, skilled 
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locomotor function can be assessed by quantifying the number of food pellets consumed 
per animal.   
In this study, animals in all treatment groups were habituated to the Montoya staircase 
apparatus daily, for 2 weeks before surgery.  Previous research has noted that rats may 
exhibit paw preference in behavioural tasks that involve retrieval of food pellets (Pençe, 
2002).  To ensure this was not the case with the animals used in this study, the number of 
food pellets displaced and consumed using the left (ipsilateral) and right (contralateral) 
paws was examined.  Figure 6.2 shows the mean number of food pellets displaced or 
consumed during the training procedure, for all animals.  There was no difference in the 
number of food pellets displaced by the left and right paws (p=0.96, two-way ANOVA) or 
any difference in the number of food pellets consumed (p=0.91, two-way ANOVA, Figure 
6.2B) during training.  Overall, there was an increase in the number of food pellets displaced 
or consumed during training.  At the end of training, animals were randomly divided into 
treatment groups, thus in Figures 6.2C-F the same data is replotted according to their 
treatment groups.   
On the first day of training, animals in all treatment groups could successfully displace one 
or multiple pellets from the staircase (Figure 6.2C).  Generally, as training progressed, there 
was an increase in the average number of food pellets displaced by each group; one notable 
exception of this was the LV/PST injection only animals, which did not show much 
improvement with training (Figure 6.2C).  There was no difference in the number of food 
pellets displaced by any treatment groups (p>0.05, two-way ANOVA).  The number of food 
pellets consumed on the first day was low for all groups but increased as time progressed 
(Figure 6.2D).  There was no difference in the number of food pellets consumed between 
treatment groups (p>0.05, two-way ANOVA).  This data is replotted in Figures 6.2E and F. 




Figure 6.2.  Animals were trained on the Montoya staircase test for 2 weeks prior to 
surgery. 
The Montoya staircase test was used to assess skilled locomotor recovery following SCI.  
Animals were trained on this test daily for two weeks.  (A, B) Mean ( SEM) number of food 
pellets displaced or consumed, respectively, by all animals during training.  There was no 
difference in the number of pellets displaced or consumed by the left (ipsilateral) or right 
(contralateral) paws.  (C, D) Mean number of food pellets displaced or consumed, 
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respectively, by each treatment group during training.  There was no difference in either the 
mean number of food pellets displaced or consumed between treatment groups (p>0.05).  
(E, F) the data in figures (C) and (D) is presented again here, excluding LV/PST and LV/GFP 
injection only groups, to allow a direct comparison between Hx + LV/PST and Hx + LV/GFP 
animals more clearly.  Sham, n=3; Hx + LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6 and; 
LV/GFP only, n=6. 
 
The day before surgery, all animals were tested on the staircase test to obtain baseline 
values.  No difference was observed between experimental groups in the number of food 
pellets displaced (LV/PST 3.6  0.9, LV/GFP 3.3  0.9, Hx + LV/GFP 3.7  0.8, Hx + LV/PST 4.0 
 0.5, Sham 2.5  1.2, p>0.05, two-way ANOVA, Figure 6.3A).  There was no difference in the 
number of pellets consumed between any experimental group, with one exception; Hx + 
LV/GFP animals consumed significantly more food pellets than sham animals (Hx + LV/GFP 
3.1  0.9, Sham 1.3  0.6, p=0.02, two-way ANOVA, Figure 6.3B).    
3 days post-surgery there was a minor reduction in the number of food pellets displaced by 
the LV/PST and LV/GFP injections only groups, compared to sham animals (LV/PST 2.0  0.5, 
LV/GFP 2.2  0.6, sham 4.3  0.3).  10 days post-surgery, both groups had regained the 
ability to displace food pellets to the same level as baseline testing (Figure 6.3A).  After this 
time point, the number of pellets displaced fluctuated depending on the testing day, 
however, there was a general trend towards an increase in the number of food pellets 
displaced (Figure 6.3A).  There was no difference in the number of pellets displaced 
between the LV/GFP and LV/PST injection only groups throughout the duration of the study 
(p = 0.35, two-way ANOVA, Figure 6.3A).  Moreover, there was no difference in the number 
of pellets displaced compared to sham animals (LV/PST, p = 0.62; LV/GFP, p = 0.99).  
Similarly, there was a minor reduction in the number of food pellets consumed by LV/PST 
and LV/GFP injection only animals, compared to sham, 3 days post-surgery (LV/PST 2.8  
1.0, LV/GFP 2.8  0.9, sham 1.7  0.7, Figure 6.3B).  The number of pellets consumed had 
increased by 7 days, and further by 10 days post-surgery (Figure 6.3B).  Following this there 
was a general trend towards an increase in the number of food pellets consumed over time, 
although there was some fluctuation on certain testing days (Figure 6.3B).  There was no 
difference between the LV/PST and LV/GFP injection only groups in the number of pellets 
consumed following surgery (p= 0.06, Figure 6.3B).  Furthermore, there was no difference in 
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the number of pellets consumed compared with sham animals (LV/PST, p = 0.42; LV/GFP, p 
= 0.97). 
Compared with animals which received injection only or sham surgery, there was a drastic 
reduction in the number of pellets displaced by animals which had received lateral 
hemisection injuries.  To visualise the results obtained from hemisection and sham animals 
more clearly, the data was re-plotted on a separate graph in figure 6.3A.  There was a 
drastic reduction in the number of pellets displaced by both Hx + LV/PST and Hx + LV/GFP 
animals, compared to sham animals, 3 days post-lesion (Hx + LV/GFP 0  0, Hx + LV/PST 0.5 
 0.2, Sham 3.3  1.1).  7 days post-lesion, some animals had regained the ability to displace 
food pellets, which was generally only 1 or 2 food pellets from the top position of the 
staircase.  No difference was observed between treatment groups (Hx + LV/GFP 1.1  0.6, 
Hx + LV/PST 2  0.4, p=0.52, two-way ANOVA).  By 14 days post-lesion, all animals in the Hx 
+ LV/PST and Hx + LV/GFP groups could displace at least 1 food pellet.  At most examined 
time points, the number of food pellets displaced by Hx + LV/PST was higher than the 
number of pellets displaced by Hx + LV/GFP animals.  However, this did not reach statistical 
significance at any examined time (p>0.05, two-way ANOVA, Tukey’s multiple comparisons 
test, Figure 6.3A).  The number of food pellets displaced by hemisected animals was 
significantly lower than sham animals, for the duration of the study (Hx + LV/PST, p = 0.02; 
Hx + LV/GFP, p = 0.003, Figure 6.3A). 
Similarly, the number of food pellets consumed by Hx + LV/PST, Hx + LV/GFP and sham 
animals was plotted on a separate graph in figure 6.3B.  3 days post-lesion, all Hx + LV/PST 
and Hx + LV/GFP animals lost the ability to retrieve food pellets from the staircase (Hx + 
LV/GFP 0  0, Hx + LV/PST 0  0, Sham 1.3  0.6, Figure 6.3B).  By 7 days post-surgery, 14% 
of Hx + LV/GFP and 50% of Hx + LV/PST animals could retrieve at least 1 food pellet (mean 
number food pellets consumed; Hx + LV/GFP 0.1  0.1, Hx + LV/PST 0.7  0.3).  The number 
of food pellets consumed by all animals fluctuated throughout the duration of the study, 
and no difference was observed in the number of food pellets consumed at any time-point, 
between Hx + LV/PST and Hx + LV/GFP animals (p>0.05, two-way ANOVA, Figure 6.3B).  6 
weeks post-lesion, there was, however, a higher percentage of Hx + LV/PST animals that 
could consume at least one food pellet from the staircase, compared to Hx + LV/GFP (83% vs 
57%, respectively).  The number of food pellets than consumed by hemisected animals was 
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significantly lower than sham animals throughout the study (LV/PST, p = 0.01; LV/GFP, p = 
0.04, Figure 6.3B).  This data is replotted in figures 6.3C and D, excluding the injection only 
groups for ease of viewing. 
 
 
Figure 6.3.  The intraspinal injection of LV/PST does not enhance performance on a skilled 
behavioural task, compared to LV/GFP injection. 
The Montoya staircase test was used to assess the recovery of skilled forelimb locomotor 
function following surgery.  (A) The number of food pellets displaced in the staircase can be 
used as a measure of gross forelimb locomotor function.  3 days post-surgery there was a 
reduction in the number of food pellets displaced by injection only and hemisection animals, 
irrespective of which treatment they received, compared to sham.  One week post-surgery, 
animals had regained partial forelimb function.  (B) Similarly, there was a reduction in the 
number of food pellets consumed by animals, 3 days post-surgery, in the injection only and 
hemisection groups, compared with sham animals.  Some animals showed partial recovery 7 
days post-surgery, which persisted for the duration of the study.  (C, D) To visualise the 
results obtained from hemisection animals more clearly, the data presented in figures (A) 
and (B) was re-plotted to only include Hx + LV/PST, Hx + LV/GFP and sham animals.  There 
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was no difference between Hx + LV/PST or Hx + LV/GFP animals in the number of food 
pellets displaced or consumed at any examined time-point (p>0.05, two-way ANOVA).  
Sham, n=3; Hx + LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6 and; LV/GFP only, n=6.   
 
6.2.1.3 Grid exploratory test 
To further evaluate the locomotor function of Hx + LV/PST animals, sensorimotor 
performance of the hindlimbs was assessed using the grid exploratory test.  Animals were 
left to freely explore on a metal grid, and the number of incorrect steps (or missteps, when 
the animals’ paw fell through the bottom of the grid) was quantified.  Baseline testing 
revealed no difference in the number of missteps in any treatment group (Figure 6.4).  As 
expected, one week after hemisection lesion, animals that received either LV/GFP (Hx + 
LV/GFP) or LV/PST (Hx + LV/PST) injections had an increased number of missteps, compared 
to sham and injection only groups.  Interestingly, there was a difference in the number of 
missteps between Hx + LV/PST and Hx + LV/GFP animals one week post-lesion (11.3  1.1 
and 15.6  0.8, respectively, p<0.05, two-way ANOVA, Figure 6.4).  Over the timecourse of 
the study, both Hx + LV/GFP and Hx + LV/PST animals improved their performance at the 
grid exploratory test.  Hx + LV/PST animals performed significantly better at this test 
between 4 and 6 weeks post-lesion, compared to Hx + GFP animals (p<0.05, two-way 
ANOVA, Figure 6.4).  The number of missteps by animals that received sham surgery or 
injection of LV/PST or LV/GFP in the absence of hemisection injury was unaltered by 
surgery, and remained low for the duration of the study (Figure 6.4). 
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Figure 6.4.  Intraspinal injection of LV/PST improved the hindlimb sensorimotor function 
of animals with mid-cervical SCI. 
Animals’ sensorimotor performance was assessed using the grid exploratory test.  Prior to 
surgery, there was no difference observed in the number of missteps between treatment 
groups.  One week post-surgery, however, animals that received lateral hemisection injury 
and injection of either LV/PST or LV/GFP had an increased number of missteps on the grid.  
Interestingly, Hx + LV/PST animals performed significantly better at the grid test one week 
post-lesion, and then between 4 and 6 weeks (*p<0.05, ** p<0.01, two-way ANOVA). 
 
To summarise the behavioural data thus far, Hx + LV/PST animals showed a significant 
improvement in hindlimb locomotion, compared to Hx + LV/GFP animals, starting 4 weeks 
post-lesion and persisting for the duration of the study.  There was no difference in forelimb 
function between Hx + LV/PST and Hx + LV/GFP animals, however there was a trend in both 
the open field locomotor assessment and the Montoya staircase test, which suggests a 
minor improvement in these animals.  This improvement started 35 days post-lesion in the 
staircase test and 24 days post-lesion in the open field locomotor assessment. This data 
indicates there may be subtle improvements in forelimb locomotor, which cannot be 
detected by routine behavioural tests.  To evaluate fine locomotor parameters, such as the 
forepaw print area, the automated gait analysis system Catwalk-XT was used. 
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6.2.1.4 Automated gait analysis  
Animals were habituated to the Catwalk-XT system prior to surgery.  Baseline values were 
obtained 2-3 days before surgery, then testing commenced when the majority of animals 
had regained frequent to consistent plantar stepping (3 weeks post-lesion).  The Catwalk-XT 
system can be used to quantify both the intensity of the impact and the area occupied by 
individual paws, as they contact the glass walkway.  Max contact max intensity is used to 
reveal the maximum intensity exerted by the paws, at the point at which they are in 
maximum contact with the glass walkway (Catwalk-XT User Manual).  3 weeks post-lesion, 
there was a reduction in the intensity of the ipsilateral forepaw placement in both Hx + 
LV/PST and Hx + LV/GFP animals, compared to sham animals, which persisted for the 
remainder of the study (Figure 6.5A).  While no difference could be observed in the intensity 
of paw placement of Hx + LV/PST animals, when compared with Hx + LV/GFP, there was a 
marginal, non-significant improvement at all examined time points (p>0.05, two-way 
ANOVA, Figure 6.5A).  
Following hemisection lesion, there was also a reduction in the print area of the ipsilateral 
forelimb, compared to sham animals.  No difference was observed between the print area in 
Hx + LV/PST animals, compared to Hx + LV/GFP (Figure 6.5B), although the area was larger in 
Hx + LV/PST animals than in those that received Hx + LV/GFP injections, at all examined time 
points (Figure 6.5B). 
Similarly, there was a reduction in the stride length of the ipsilateral forepaw in animals that 
received either Hx + LV/PST or Hx + LV/GFP animals, compared to sham animals.  There was 
no difference between stride length in Hx + LV/PST and Hx + LV/GFP animals at any 
examined time point (Figure 6.5C) 
While BBB scoring does take into account interlimb coordination, this is difficult to discern 
manually, and also relies on the animal completing three full step cycles in a row, without 
pause.  While this is common in naïve animals, those with SCI do not move around the open 
field as frequently as naïve or sham animals, thus making it difficult to accurately gauge 
interlimb coordination.  To assess coordination using the Catwalk-XT system, a parameter 
called ‘regularity index’ is used, which measures the number of normal stepping patterns 
taking place as an animal crosses the walkway, and represents this as a percentage of the 
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total number of stepping patterns.  Baseline recordings for all animals showed a reliability 
index of close to 100%, suggesting constant interlimb coordination.  Sham animals 
maintained this 100% reliability index, which indicates that the laminectomy procedure did 
not alter their ability to maintain consistent interlimb coordination.  3 weeks post-lesion, 
there was a decrease in the regularity index in both Hx + LV/PST and Hx + LV/GFP animals 
(Figure 6.5D); however, the values for Hx + LV/PST animals were closer to 100% than 
animals that received Hx + LV/GFP at all examined time points, suggesting a mild, non-
significant improvement (Figure 6.5D)  
 
 
Figure 6.5.  The LV/PST injections did not alter fine gait parameters, measured using the 
Catwalk-XT system. 
Only animals that regained weight supported stepping were used for Catwalk-XT analysis.  
(A) The intensity of forepaw placement was unchanged between Hx + LV/PST and Hx + 
LV/GFP animals (p>0.05).  (B) The print area of the ipsilateral forepaw was unchanged 
between Hx + LV/PST and Hx + LV/GFP animals (p>0.05).  (C) Similarly, there was no 
difference in stride length between Hx + LV/PST and Hx + LV/GFP animals).  (D) The 
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regularity index was close to 100% in all animals prior to surgery.  After injury, there was a 
reduction in regularity index in both Hx + LV/GFP and Hx + LV/PST animals.  There was no 
difference between Hx + LV/GFP and LV/PST at any examined time point.  Sham, n=3; Hx + 
LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6 and; LV/GFP only, n=6. 
 
6.2.2 LV/PST did not cause abnormal pain sensations  
One of the possible adverse effects of inducing SCI in rodents is autotomy, which involves 
chewing of one or more of the digits of the animals’ paws.  In this study, no animals in the 
Hx + LV/GFP group developed autotomy at any time during the experiment.  Conversely, 3 
animals in the Hx + LV/PST group developed autotomy of the contralateral hindlimb and 
were culled according to Home Office instructions.  The emergence of autotomy beyond the 
first couple of post-operative days suggested that Hx + LV/PST animals may be suffering 
from neuropathic pain.  To investigate this further, animals were subjected to sensory 
testing to ensure that these animals did not have abnormal pain sensations.  It should be 
noted that as animals with autotomy were immediately culled, sensory testing was 
performed on the remaining animals, which did not previously show signs of autotomy. 
Responses to mechanical stimuli were assessed using Von Frey filaments.  After 5 weeks 
post-lesion, there was no difference in the response to mechanical stimuli in Hx + LV/PST 
rats, compared to Hx + LV/GFP, in either the ipsilateral or contralateral hindpaws (Figure 
6.6A, B, respectively).  Similarly, there was no difference in the response to thermal stimuli 
observed 6 weeks post-lesion in either Hx + LV/PST or Hx + LV/GFP animals (Figure 6.6A, B).  
Responses to thermal stimuli were assessed using the plantar heat test (Hargreave’s 
method).  After 5 weeks post-lesion, there was no differences in the response to thermal 
stimuli in Hx + LV/PST animals, compared to those that received Hx + LV/GFP of either the 
ipsilateral or contralateral hindpaws (Figure 6.6C, D, respectively).  Similarly, there was no 
difference in responses to thermal stimuli 6 weeks post-lesion in Hx + LV/PST or Hx + LV/GFP 




Figure 6.6.  Testing of sensory function in animals that received lateral hemisection injury 
and viral vector treatment.   
Following the development of autotomy in three animals that received Hx + LV/PST 
injections, sensory testing was performed to ensure that these animals were not suffering 
from neuropathic pain.  (A-B) Responses to mechanical stimuli were assessed using Von 
Frey filaments.  There was no difference in the response to stimulation with Von Frey 
filaments of either (A) ipsilateral or (B) contralateral hindpaws, in either Hx + LV/PST or Hx + 
LV/GFP animals.  (C-D) Responses to thermal stimuli were assessed using the plantar heat 
test (Hargreave’s method).  There was no difference in the response to temperature of 
either the (C) ipsilateral or (D) contralateral hindpaws in either Hx + LV/PST or Hx + LV/GFP 
animals.  Sham, n=3; Hx + LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6 and; LV/GFP 
only, n=6. 
 
6.2.3 PSA expression was robust six weeks after LV/PST intraspinal injections  
To verify PSA production following intraspinal injection of LV/PST viral vectors at the end of 
the experiment, horizontal sections of the cervical spinal cord containing the injury site (if 
present) and the injection sites, were immunolabelled using an antibody against PSA.  
Animals that received Hx + LV/PST injections had four regions of mCherry-positive cells in 
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the grey matter of the spinal cord, two rostral and two caudal to the hemisection lesion, 
representing the areas injected by the viral vector.  Positive-cells were concentrated in the 
intermediate grey matter, some cells were also found in the dorsal and ventral horns.  
mCherry-positive cells were surrounded by strong PSA immunolabelling, suggesting strong 
expression of PSA by LV/PST, both rostral and caudal to the lesion site (Figure 6.7A, B).  
Conversely, no PSA immunolabelling was observed in animals that received Hx + LV/GFP 
injections.  While large regions of GFP-expressing cells were observed in these animals (2 
rostral and 2 caudal to the lesion site), no PSA labelling was found surrounding these cells 
(Figure 6.7C, D).  Similarly to animals that received Hx + LV/PST injections, those that 
received injections alone had four regions of mCherry-positive cells, indicating the injection 
sites.  Additionally, strong PSA labelling could be observed surrounding these mCherry-
positive neurons (Figure 6.7E, F).  Animals that received LV/GFP injections only showed a 
similar pattern to Hx + LV/GFP animals.  Four regions of GFP-positive cells could be 




Figure 6.7.  PSA labelling in the intermediate grey matter 6 weeks following injection of 
lentiviral vectors. 
(A, B) Regions of mCherry-positive cells were observed in the cervical spinal cords of Hx + 
LV/PST animals, two rostral and two caudal to the lesion site.  PSA labelling was strong 
surrounding mCherry-positive cells, suggesting PSA production by LV/PST.  (C, D) Similarly, 
regions of GFP-positive cells were observed in the spinal cords of Hx + LV/GFP animals, 6 
weeks post-injection.  PSA immunolabelling was absent surrounding these cells.  (E, F) 
LV/PST injection only, in the absence of hemisection injury resulted in mCherry-positive cells 
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in the spinal grey matter.  These cells were surrounded by strong PSA immunolabelling.  (G, 
H) GFP-positive cells were observed in the spinal cord of animals that received LV/GFP 
injection only.  No PSA labelling was observed surrounding these cells.  Scale bar = 100 m. 
 
To evaluate whether PSA expression was similar in Hx and injection only animals, the area 
occupied by PSA immunostaining was quantified 6 weeks following delivery to the spinal 
cord.  As previously shown, there was no PSA expression in animals that received either Hx + 
LV/GFP injections or LV/GFP injections only, in the grey matter, in the areas surrounding the 
injection sites (Figure 6.8C, D and G, H).  The area of PSA expression was high in both Hx + 
LV/PST and LV/PST injection only animals and was fairly variable between animals in the 
same treatment group.  There was no difference between the PSA expression in animals 
that received Hx + LV/PST injection, compared to those that received LV/PST injection only 
(LV/PST 0.79  0.21, Hx + LV/PST 0.46  0.12, p>0.05, one-way ANOVA, Figure 6.8A).  
Moreover, there was no difference in PSA expression in the rostral or caudal injection sites 
in LV/PST injection only animals (Rostral 0.43  0.16; Caudal 0.36  0.1, p > 0.05, two-way 
ANOVA, Figure 6.8B), or rostral or caudal to the lesion in Hx + LV/PST animals (Rostral 0.22  
0.06; Caudal 0.24  0.09, p > 0.05, Figure 6.8B) 
 
 
Figure 6.8.  Quantification of PSA labelling following delivery of lentiviral vectors to the 
spinal cord. 
The area occupied by PSA immunostaining was quantified 6 weeks following injection to the 
cervical spinal cord.  (A) No PSA labelling was observed in sham animals, or those that 
received LV/GFP injections with or without hemisection injury.  Conversely, strong PSA 
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labelling was observed in animals that received LV/PST injections.  There was no difference 
observed between animals that received Hx + LV/PST or LV/PST injections only (p>0.05).  (B) 
There was no difference between the area occupied by PSA labelling rostral and caudal to 
the injury site, in animals that received Hx + LV/PST.  Moreover, there was no difference in 
the area occupied by PSA labelling in the rostral or caudal injections, in animals that 
received LV/PST injections only (p<0.05).  Sham, n=3; Hx + LV/PST, n=6; Hx + LV/GFP, n=6; 
LV/PST only, n=6 and; LV/GFP only, n=6. 
 
6.2.4 LV/PST-mediated PSA expression did not induce neuroplasticity six weeks after 
delivery to the cervical spinal cord 
 
6.2.4.1 Serotonin immunolabelling 
 
The delayed improvement in hindlimb motor function displayed by the LV/PST treated 
animals (starting 30 days post-lesion) may correspond to enhanced axonal sprouting and the 
formation of new spinal cord circuits.  Serotonin is an important neuro-modulator, and 
sprouting of serotoninergic fibres has been demonstrated in a number of rodent models of 
SCI (Camand et al., 2004; Hawthorne et al., 2011).  Moreover, a number of therapeutic 
agents have previously been shown to enhance sprouting of serotonergic fibres, including 
ChABC and PSA mimetic peptides (Barritt et al., 2006; Pan et al., 2014).  To assess whether 
sprouting of serotonergic fibres was responsible for the improvement in motor function in 
LV/PST-treated animals, the spinal cords were immunolabelled using antibody raised against 
serotonin and the density of serotonergic inputs to individual mCherry or GFP-positive 
neurons in the intermediate grey matter-ventral horns was quantified. 
The antibody used in this study strongly labelled serotonergic fibres, which were observed 
throughout the spinal cord, and with high density in the ventral horns.  Serotonergic inputs 
to individual neurons could be clearly observed with a 40x objective on a standard 
epifluorescence microscope (Figure 6.9).  In both Hx + LV/GFP and Hx + LV/PST animals, 
there appeared to be a lower density of serotonergic inputs to transduced neurons located 
caudal to the lesion site, compared to those in the rostral spinal cord (Figure 6.9A, D).  This 
likely reflects the loss of descending serotonergic inputs to the caudal spinal cord, due to 
the hemisection lesion.  There was no apparent difference in the density of serotonergic 
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inputs to mCherry-positive, compared to GFP-positive neurons, in animals that received 
intraspinal injections in the absence of hemisection injury (Figure 6.9E-H).  
 
Figure 6.9.  Representative photomicrographs showing serotonin labelling 6 weeks post-
SCI and following delivery of viral vectors. 
Immunolabelling was used to assess the density of serotonergic labelling onto GFP- or 
mCherry-positive neurons.  (A-B) Strong serotonergic inputs were observed in animals that 
received Hx + LV/PST injections, rostral to SCI.  Neurons located caudal to the injury 
appeared to receive lower levels of serotonergic inputs.  (C-D) Similar results were observed 
in animals that received Hx + LV/GFP injections.  (E-H) Similar levels of serotonergic inputs 
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were observed in animals that received LV/PST or LV/GFP injections only.  Scale bar = 25 
m. 
The quantification of the density of serotonergic labelling showed no difference in the 
density of inputs to either mCherry- or GFP-positive neurons in Hx + LV/PST or Hx + LV/GFP 
animals, respectively, rostral to the lesion (Hx + LV/PST 2.1  0.5; Hx + LV/GFP 1.6  0.4, p > 
0.05, Figure 6.10).  Similarly, there was no difference caudal to the lesion (Hx + LV/PST 1.6  
0.5; Hx + LV/GFP 1.0  0.1, p > 0.05, Figure 6.10).  There was also no difference in the 
density of serotonergic inputs to immunopositive neurons in animals that received 
injections of LV/PST alone, compared to LV/GFP, in the absence of hemisection injury 
(Rostral; LV/PST 2.2  0.1; LV/GFP 2.7  0.2, p > 0.05; Caudal; LV/PST 2.4  0.4; LV/GFP 1.5  
0.2, p > 0.05, Figure 6.10). 
 
Figure 6.10.  Quantification of the density of serotonin-labelled boutons contacting either 
mCherry- or GFP-positive neurons. 
Six weeks following delivery of viral vectors to the cervical spinal cord, animals were culled 
and the spinal cords were assessed for serotonin labelling.  There was no difference in the 
density of serotonergic inputs either rostral or caudal to the lesion site, in Hx + LV/PST and 
Hx + LV/GFP animals.  Moreover, there was no difference between animals which received 
injections of either LV/PST or LV/GFP only and sham animals that received laminectomy (p > 
0.05, two-way ANOVA).  Sham, n=3; Hx + LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6; 
and LV/GFP only, n=6. 
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6.2.4.2 Synaptophysin immunolabelling 
To assess whether induced PSA expression resulted in enhanced synaptic contacts to 
neurons with viral transgene expression, horizontal sections of spinal cord containing the 
intermediate grey matter were immunolabelled using antibody raised against synaptophysin 
and the density of synaptophysin-labelled boutons contacting individual mCherry or GFP-
positive neurons was quantified.  Strong synaptophysin labelling was observed throughout 
the spinal cord of animals in all experimental groups.  There was no clear difference in the 
density of synaptophysin-labelled boutons contacting mCherry-positive, compared to GFP-




Figure 6.11.  Representative photomicrographs showing synaptophysin immunolabelling 
following LV/PST or LV/GFP delivery to the spinal cord. 
Immunolabelling was used to assess the density of synaptophysin-labelled boutons 
contacting GFP- or mCherry-positive neurons.  (A-D) Examples of synaptophysin 
immunolabelling in animals which received Hx + LV/PST or LV/GFP injections.  (E-H) 
Synaptophysin immunolabelling in animals which received injections of LV/PST or LV/GFP in 
the absence of hemisection injury.  Scale bar = 50 m. 
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The quantification of the density of synaptophysin immunolabelling showed no difference in 
the density of synaptic inputs to either mCherry-positive, or GFP-positive neurons in Hx + 
LV/PST or Hx + LV/GFP animals, respectively, rostral to the lesion site (16.1  2.0, 13.4  2.9, 
respectively, p < 0.05, Figure 6.12).  Similarly, there was no difference caudal to the lesion 
(12.2  1.8, 13.6  2.9, respectively, p < 0.05, Figure 6.12).  There was also no difference in 
the density of synaptophysin-labelled boutons to mCherry or GFP-positive neurons in 
animals that received injections of LV/PST alone, compared to LV/GFP, in the absence of 
hemisection injury (Rostral; 18.4  2.5, 20.0  3.2, respectively, Caudal; 17.0  3.2, 16.3  
4.0, respectively, p < 0.05, Figure 6.12). 
 
Figure 6.12.  Quantification of the density of synaptophysin-labelled boutons contacting 
either mCherry- or GFP-positive neurons. 
There was no difference in the density of synaptophysin-positive boutons either rostral or 
caudal to the lesion site in Hx + LV/PST and Hx + LV/GFP animals.  Moreover, there was no 
difference between animals which received injections of either LV/PST or LV/GFP only and 
sham animals that received laminectomy (p > 0.05, two-way ANOVA).  Sham, n=3; Hx + 
LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6 and; LV/GFP only, n=6. 
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6.2.5 LV/PST-mediated PSA expression did not alter the number of density of PNNs six 
weeks after delivery to the cervical spinal cord 
 
6.2.5.1 WFA immunolabelling 
To assess whether induced PSA expression in the spinal cord led to alterations in the PNN, 
sections were immunolabelled using WFA lectin, in addition to antibodies raised against LN1 
and neurocan.  Sham animals had PNNs distributed throughout the grey matter of the spinal 
cord, which were readily labelled by WFA lectin.  Similarly, WFA-labelled PNNs were 
detected in animals in all the other experimental groups (Figure 6.13A).  As previously 
described, Hx + LV/PST and Hx + LV/GFP injected animals had regions of mCherry-positive 
and GFP-positive neurons, respectively, in the intermediate grey matter-ventral horn.  WFA-
labelled PNNs were observed surrounding some mCherry/GFP-positive neurons in those 
animals (Figure 6.13A-D).  Similarly, mCherry and GFP-positive neurons were observed in 
animals that received LV/PST and LV/GFP injections, respectively, in the absence of 
hemisection injury, and were surrounded by WFA-labelled PNNs (Figure 6.13E-H). 
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Figure 6.13.  WFA labelled PNNs in animals injected with lentiviral vectors. 
WFA-labelling was observed throughout the neuropil and condensed in PNNs in the spinal 
cords of animals in all treatment groups.  (A-B) mCherry-positive neurons were surrounded 
by WFA-labelled PNNs rostral and caudal to the lesion in Hx + LV/PST animals.  (C-D) 
Similarly, PNNs were observed surrounding GFP-positive neurons in Hx + LV/GFP animals.  
(E-F) WFA-labelled PNNs were found surrounding mCherry-positive neurons in animals that 
received LV/PST injections in the absence of hemisection injury.  (G-H) GFP-positive neurons 
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were surrounded by WFA-labelled PNNs in LV/GFP injection only animals.  Scale bar = 50 
m. 
 
To evaluate whether there were any differences in WFA-labelled PNNs in animals that 
received LV/PST injections, compared to those that received LV/GFP injections, the 
proportion of transduced neurons with a WFA-labelled PNN, in addition to the density of 
WFA PNN labelling on individual neurons was quantified.   
There was no difference in the proportion of mCherry or GFP-positive neurons with a WFA-
labelled PNN in Hx + LV/PST and Hx + LV/GFP animals, respectively, rostral to the injury site 
(Hx + LV/PST 13.1  3.2; Hx + LV/GFP 23.6  7.0, p > 0.05, Figure 6.14A).  Similarly, no 
difference was observed in animals that received injections of LV/PST or LV/GFP only, or 
sham (LV/PST 19.4  2.4; LV/GFP 20.3  3.1, p > 0.05, Figure 6.14A).  Similar results were 
obtained caudal to the lesion site (Hx + LV/PST 18  4.9; Hx + LV/GFP 16.2  2.3; LV/PST 17.4 
 4.5; LV/GFP 19.2  6.3, p > 0.05, Figure 6.14A).  To assess whether the induced PSA 
expression altered the density of PNN immunolabelling, the area occupied by PNN labelling 
on individual mCherry or GFP-positive neurons was quantified.  There was no difference in 
the area occupied by WFA-PNN labelling in Hx + LV/PST or Hx + GFP animals, either rostral 
or caudal to the lesion site (Rostral; 28.6  2.3 and 25.3  6.7, respectively, p > 0.05; Caudal 
30.2  2.4 and 27  3.8, respectively, p > 0.05, Figure 6.14B).  There was also no difference in 
the density of WFA-PNN immunolabelling in LV/PST or LV/GFP injection only animals, rostral 
or caudal (Rostral; 26.8  2.7 and 25.8 7.8, respectively, Caudal; 27.0  5.3 and 28.9  5.7 




Figure 6.14.  Quantification of WFA labelled PNNs following delivery of LV/PST and LV/GFP 
to the spinal cord. 
(A) No difference was observed in the proportion of mCherry or GFP-positive neurons with a 
WFA-labelled PNN in Hx + LV/PST or Hx + LV/GFP animals, respectively.  Moreover, there 
was no difference between animals that received injections of LV/PST or LV/GFP in the 
absence of injury, or sham animals.  (B) There was no difference in the density of individual 
WFA-labelled PNNs in Hx + LV/PST or Hx + LV/GFP animals, rostral or caudal to the lesion 
site.  Similarly, there was no difference in PNN density in LV/PST or LV/GFP injection only 
animals, or shams.  Sham, n=3; Hx + LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6; and 
LV/GFP only, n=6. 
 
6.2.5.2 LN1 immunolabelling 
LN1-labelling was observed throughout the neuropil, and was concentrated in PNN 
structures in animals from all experimental groups (Figure 6.15).  In all groups, a proportion 
of the mCherry or GFP-positive neurons were surrounded by LN1-labelled PNNs, which were 
found closely associated with the neuronal cell body.  PNNs were also observed surrounding 
neurons devoid of mCherry or GFP labelling, but adjacent to those with expression of viral 




Figure 6.15.  LN1-labelled PNNs were detected in the spinal cords of animals injected with 
viral vectors. 
LN1 immunolabelling was observed throughout the cervical spinal cords of animals in all 
experimental groups, in both the neuropil and in PNNs.  (A-B) PNNs were observed 
surrounding mCherry-positive neurons, and also neurons devoid of mCherry labelling, in 
animals that received Hx + LV/PST injections.  (C-D) Similarly, LN1-labelled PNNs were found 
in GFP-positive, or negative, neurons in animals that received Hx + LV/GFP injections.  (E-H) 
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PNN labelling was observed in animals that received injections of viral vectors only, in the 
absence of hemisection lesion.  Scale bar = 50 m. 
 
To assess whether there was any difference in PNN immunolabelling in animals that 
received LV/PST injections, compared to those that received control viral vector (LV/GFP), 
the proportion of mCherry or GFP-positive neurons with a LN1-labelled PNN, in addition to 
the density of PNN immunolabelling was quantified.  
There was no difference in the proportion of mCherry or GFP-positive neurons with a LN1-
labelled PNN in Hx + LV/PST and Hx + LV/GFP animals, respectively, either rostral or caudal 
to the injury site (Rostral; Hx + LV/PST 14.3  2.2 and Hx + LV/GFP 22.0  2.3, Caudal; Hx + 
LV/PST 18.0  2.3 and Hx + LV/GFP17.5  2.9, p > 0.05, Figure 6.16A).  Similarly, no 
difference was observed in animals that received injections of LV/PST or LV/GFP only, or 
sham animals (Rostral; LV/PST 20.0  3.2 and LV/GFP 19.4  3.2, Caudal; LV/PST 19.4  3.2 
and LV/GFP 17.5  2.8, p > 0.05, Figure 6.16A). To assess whether the induced PSA 
expression altered the density of PNN immunolabelling, the area occupied by LN1-PNN 
labelling on individual mCherry-positive or GFP-positive neurons was quantified.  There was 
no difference in the area occupied by LN1-PNN labelling in Hx + LV/PST or Hx + GFP animals, 
either rostral or caudal to the lesion site (Rostral; 20.0  1.2 and 18.3  3.1, respectively, p > 
0.05; Caudal 22.5  3.3 and 20.1  1.4, respectively, p > 0.05, Figure 6.16B).  There was also 
no difference in the density of LN1-PNN immunolabelling in LV/PST or LV/GFP animals, 
rostral or caudal (Rostral, 21.5  6.2 and 22.4  5.2, respectively; Caudal, 23.0  7.3 and 20.8 




Figure 6.16.  Quantification of LN1-labelled PNNs following delivery of LV/PST and LV/GFP 
to the spinal cord. 
(A) No difference was observed in the proportion of mCherry or GFP-positive neurons with a 
WFA-labelled PNN in Hx + LV/PST or Hx + LV/GFP animals, respectively.  Moreover, there 
was no difference between animals that received injections of LV/PST or LV/GFP in the 
absence of injury, or sham animals.  (B) There was no difference in the density of individual 
WFA-labelled PNNs in Hx + LV/PST or Hx + LV/GFP animals, rostral or caudal to the lesion 
site.  Similarly, there was no difference in PNN density in LV/PST or LV/GFP injection only 
animals, or shams.  Sham, n=3; Hx + LV/PST, n=6; Hx + LV/GFP, n=6; LV/PST only, n=6 and; 
LV/GFP only, n=6.   
 
6.3 Discussion 
To summarise the data obtained in this chapter, first, a significant improvement in hindlimb 
locomotor function was observed following delivery of LV vector carrying the transgene for 
polysialyltransferase (LV/PST) rostral and caudal to a mid-cervical spinal cord lesion (Hx + 
LV/PST), compared to animals that received injections of control virus following injury (Hx + 
LV/GFP).  This was not associated with an increase in the density of synaptophysin-positive 
boutons contacting neurons showing successful viral transgene expression, or an increase in 
the density of serotonergic inputs to these neurons.  Moreover, no alterations were 
observed in either the proportion of neurons with a PNN, or the density of PNN 
immunolabelling on individual neurons.  In a separate group of animals, injection of LV/PST 
in the absence of injury did not alter the proportion of neurons with a PNN, or the density of 
PNN immunolabelling.  Furthermore, there was no increase in the density of synaptophysin-
positive or serotonergic boutons contacting neurons showing viral transgene expression.  
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6.3.1 Locomotor function following delivery of lentiviral vectors 
Targeted therapeutic interventions aiming to increase neuroplasticity in the injured spinal 
cord are increasing in popularity, due to the observation that the generation of novel spinal 
circuits may induce significant locomotor recovery, in the absence of long distance axonal 
regeneration (Bareyre et al., 2004).  While regeneration of damaged axons across the glial 
scar may contribute to functional improvement in rodent models of SCI, in humans, the 
chances of this occurring are considerably lower due to the large distances (multiple 
centimetres) that regenerating axons must grow to cross the lesion site in order to reform 
functional connections.   
In this study, hindlimb recovery was primarily assessed using the BBB scale, which is widely 
used in SCI research and has been used in a range of injury models including hemisection, 
contusion and compression lesions, in either cervical or thoracic spinal cord regions (Basso 
et al., 1995; García-Alías et al., 2011; Liu et al., 2015).  One of the main benefits of this test is 
that it allows the investigation of a wide range of hindlimb movements, such as the 
individual movement of the ankle, knee and hip joints, interlimb coordination and the 
direction of paw placement (Basso et al., 1995).  This allows monitoring of hindlimb 
locomotor function immediately following injury, which is generally not possible with other 
behavioural tests such as the grid exploratory test, or the automated gait analysis systems, 
as these tests typically require at least weight support or weight supporting stepping for 
accurate results. 
Interestingly, hindlimb recovery following hemisection injury occurred at a similar rate in 
animals that received LV/PST or LV/GFP injections, for the first 4 weeks post-lesion.  After 
this point, no further recovery was observed in Hx + LV/GFP animals.  However, animals that 
received Hx + LV/PST injections continued to improve.  A significant improvement in 
hindlimb function was observed starting 29 days post-lesion in Hx + LV/PST animals, 
compared to controls.  This was due to an improvement in BBB scores from 11 to 14, which 
corresponds to an improvement in interlimb coordination.  Additionally, there was a 
significant improvement observed in the hindlimb sensorimotor function of Hx + LV/PST 
animals, assessed using the grid exploratory test, compared to those that received Hx + 
LV/GFP.  While the BBB scale is widely used in SCI research, there are a number of caveats 
with this test, one of which is the way in which interlimb coordination is assessed.  To 
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examine this, an assessor must count the number of completed passes each animal 
undertakes (one completed pass equates to three complete step cycles), and observe 
whether fore and hindlimb placement occurs sequentially (Basso et al., 1995).  This can be 
quite difficult to observe, especially as animals generally move around the open field 
apparatus at relatively fast speeds.  Therefore, to obtain a quantified measure of interlimb 
coordination, in addition to other details regarding the animals locomotor performance, the 
automated gait analysis system Catwalk-XT was used.   
Interestingly, there was no significant difference between the coordination (regularity 
index) of Hx + LV/GFP and Hx + LV/PST animals when assessed using the Catwalk-XT.  There 
was, however, a trend to suggest a minor improvement in the regularity index.  The 
differences observed in the BBB scores and Catwalk-XT regularity index values may have 
occurred for two reasons.  First, as previously mentioned, the interlimb coordination 
measurement using the BBB scale may be inaccurately measured.  Second, automated gait 
analysis systems, such as the Catwalk-XT, generally require a large number of animals for 
accurate results (Koopmans et al., 2007).  Only 3-5 animals from each treatment group 
could perform weight-supported plantar placement of all four limbs, and thus it was only 
these animals that could be tested on the Catwalk.  It is likely, therefore, that the Catwalk-
XT study was underpowered, which may have affected the final results. 
The FLS was developed as the forelimb counterpart to the BBB scale, and it measures similar 
parameters, such as paw placement, in addition to movement of the joints of the forearm 
(Cao et al., 2008).  Interestingly, there was no improvement observed in forelimb locomotor 
function in Hx + LV/PST animals, compared to those that received LV/GFP injections.  Similar 
to the BBB test, the FLS has a number of caveats, one of which is the broad criteria used to 
score the animals ((Cao et al., 2008) Supplementary Figure 2).  Therefore, to complement 
the FLS, the forelimb locomotor function was also assessed using the Montoya staircase; 
however, no difference in locomotor function was observed between treatment groups.  
Moreover, forelimb function was examined using the Catwalk-XT system; however, no 
improvement was observed in any of the examined parameters.   
While there was no drastic improvement observed in locomotor function following delivery 
of LV/PST after SCI, there was a trend to suggest a minor (non-significant) improvement in 
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all behavioural tests.  This suggests that LV/PST delivery has caused a subtle improvement in 
locomotor function, but not such a large improvement as to reach statistical significance.  
Nonetheless, the behavioural data obtained in this study is still promising.  Towards the end 
of this study (35 days post-lesion), Hx + LV/PST begin to show a slight improvement in the 
ability to retrieve food pellets in the Montoya staircase.  It may be interesting to examine a 
longer timepoint, to see if the animals’ performance on the staircase test continues to 
improve.  Furthermore, mounting evidence suggests that rehabilitation used in combination 
with a targeted therapy can improve locomotor function beyond that observed with use of 
drug treatment alone ((Wang et al., 2011; Dietz and Fouad, 2014).  There are a number of 
studies that have tried different paradigms of rehabilitation, including treadmill training, 
enriched cages, and task-specific rehabilitation, for example, pellet retrieval.  Rehabilitation 
is also clinically relevant, as SCI patients are given a program of physiotherapy prior to their 
initial release from hospital after injury, and which they are encouraged to continue at 
home.  Therefore, it would also be interesting to combine LV/PST injections with 
rehabilitation to see if this elicits a stronger behavioural improvement following SCI.  In this 
case, it would be interesting to use a task-specific rehabilitation program, such as daily use 
of a pellet retrieval test (for example the Montoya staircase) to see if this leads to an 
improvement in forelimb locomotor function. 
This study is the first to investigate the therapeutic benefit of PSA in the injured cervical 
spinal cord.  Moreover, this is the first study to investigate the behavioural changes 
associated with LV/PST intraspinal injection in rats with SCI.  To date there has been a 
number of studies investigating the therapeutic benefit of PSA expression in the injured 
thoracic spinal cord.  Early research used a pseudotyped LV vector to engineer expression of 
polysialyltransferase in astrocytes in the injured spinal cord, which drives production of PSA 
(El Maarouf et al., 2006).  Unfortunately, behavioural testing was not performed so 
comparisons between that study and ours cannot be performed.  More recently, a couple of 
groups have developed PSA mimetic peptides, which can be continuously infused into the 
injured spinal cord using an osmotic minipump.  So far, studies using these peptides have 
relied on contusion or corticospinal tract transection injuries in the thoracic spinal cord.  The 
differences between the studies using the PSA mimetic and our study make direct 
comparisons difficult.  Nonetheless, a significant recovery of motor function is observed in 
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our study with LV/PST treatment, and in studies using the PSA mimetic, compared to mice 
that received control peptide (Marino et al., 2009; Mehanna et al., 2010; Pan et al., 2014). 
 
6.3.2 Autotomy in Hx + LV/PST animals 
One of the possible adverse outcomes in experimental models of SCI is the emergence of 
autotomy, a behaviour during which the animal will consume part of its digits.  Generally, 
two patterns of autotomy can be observed in rodent models of SCI (Hankenson, 2013).  
Firstly, autotomy can occur shortly after the initial injury (during the first few post-operative 
days), and is believed to be a direct consequence of the loss of sensation resulting from the 
damage to the spinal cord.  Secondly, autotomy can also develop weeks after the injury, 
which is believed to be linked to the development of neuropathic pain.  In this study three 
Hx + LV/PST animals developed autotomy of the digits of the contralateral hindlimb.  This is 
in contrast to Hx + LV/GFP animals that did not exhibit any of this behaviour.  The 
emergence of autotomy in Hx + LV/PST animals was observed between 2 and 3 weeks post-
injury, which suggested that this might be caused by the development of neuropathic pain.   
Interestingly, however, responses to both thermal and mechanical stimuli were unaltered in 
Hx + LV/PST animals, compared to Hx + LV/GFP.  Furthermore, animals that received Hx + 
LV/PST injections did not show any behavioural signs of pain (for example, unkept fur, 
weight loss), suggesting that these animals were not suffering from neuropathic pain.  
However, it should be noted that the animals that developed autotomy were not included in 
the sensory testing, as per Home Office requirements they were culled as soon as autotomy 
penetrated beyond the superficial skin of the digits.  For this reason, it is likely that the data 
obtained from the sensory tests is not an accurate representation of all the animals in the 
Hx + LV/PST group.    
The incidence of autotomy in other studies investigating PSA and SCI (using either viral 
vector-induced PSA expression, or PSA mimetic peptide) has not been reported, nor has any 
examination of sensory function.  Previous data from our laboratory has, however, noted 
enhanced regeneration of sensory fibres following dorsal column lesion (Zhang et al., 
2007b), so it could be speculated that in this study, enhanced regeneration/sprouting of 
sensory fibres in some Hx + LV/PST animals led to the development of neuropathic pain. 
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It is clear that this topic requires further research, as the emergence of neuropathic pain 
following therapeutic intervention to the spinal cord could be devastating and is an 
undesirable treatment outcome.  If repeated, future studies should contain extensive 
sensory testing, including the plantar heat test (Hargreave’s method) and the Von Frey test, 
and should include baseline testing and then regular testing following injury.  Moreover, 
spinal cords from these animals could be immunolabelled to assess the sprouting of pain-
related sensory axons.  To investigate this at a cellular level, a relatively simple experiment 
could be to induce PSA expression in cultured dorsal root ganglion neurons, to examine (i) 
whether PSA induced significant neurite outgrowth (ie sprouting) of sensory neurons, and 
(ii) if so, which molecular factors may be responsible for this.  Data from these studies would 
then provide robust evidence as to whether induced PSA expression in the injured spinal 
cord can result in the development of neuropathic pain.  
 
6.2.3 LV/PST delivery resulted in strong PSA expression in the spinal cord 
6 weeks following delivery of LV/PST to both the injured or uninjured spinal cord, multiple 
regions of mCherry-positive cells were observed, throughout most regions of the spinal 
cord, but concentrated in the intermediate grey matter.  Following immunolabelling using 
an antibody against PSA, these cells were shown to be surrounded by strong PSA staining.  
This PSA labelling was not present in either injured or uninjured animals injected with 
LV/GFP.  Previous studies using either viral vectors carrying the PST, or the STX transgene 
have also noted strong PSA labelling for up to six weeks (El Maarouf et al., 2006; Zhang et 
al., 2007b; Zhang et al., 2007c).  It is likely that PSA expression will persist beyond six weeks, 
however, this has not yet been determined in vivo. 
 
6.2.4 Induced PSA expression did not alter PNN structure or numbers  
One of the primary aims of this thesis was to investigate the proposed relationship between 
PSA and the PNN in more detail.  Thus far in this thesis, removing PSA from cultured 
hippocampal neurons during the first week in vitro did not affect the formation of PNNs.  
Moreover, a preliminary study using LV vectors to induce expression of PSA in the 
sensorimotor cortex was discontinued, due to the difficulty of analysing the tissue.   
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In the data described in this chapter, induced PSA expression using LV/PST in naïve rats, or 
animals that received lateral hemisection injury, did not affect either the number of neurons 
surrounded by either WFA or LN1-labelled PNNs, or the density of PNN immunostaining on 
individual neurons.  The hypothesis that PSA expression may affect PNN development was 
based on preliminary data generated in the Bo laboratory, that noted (i) the down-
regulation of PSA labelling prior to the formation of the PNN in the postnatal rat spinal cord 
and (ii) a reduction in WFA binding to its site within the PNN following induced PSA 
expression in vivo.  Based on the evidence obtained in this study, it is unlikely that induced 
PSA expression can modulate the structure of the PNN in vivo, in either uninjured animals, 
or animals with a cervical level spinal cord injury. 
 
6.2.5 Induced PSA expression does not enhance synaptogenesis in vivo 
Six weeks following delivery of LV/PST to the injured spinal cord (Hx + LV/PST) there was no 
change in the density of synaptophysin- or serotonin-labelled boutons contacting neurons 
with viral transgene expression, compared to neurons in Hx + LV/GFP animals.  
Synaptophysin is a widely used marker of presynaptic terminals and a number of studies 
have shown an increase in the density of synaptophysin immunolabelling in the spinal cord 
to be associated with locomotor recovery following injury.  Similarly, various studies are 
showing that enhanced sprouting of serotonergic neurons can also promote locomotor 
recovery from SCI (Barritt et al., 2006; Liu et al., 2015).  
While there are no studies investigating sprouting of serotonergic fibres following LV-PST-
mediated PSA expression after SCI, studies using PSA mimetic peptides have shown 
enhanced sprouting of serotonergic fibres following treatment with the mimetic, compared 
to control treatments (Marino et al., 2009; Pan et al., 2014).  The study presented in this 
thesis did not assess the overall density of serotonergic fibres in the spinal cord, due to the 
limited area of induced PSA expression following delivery of LV/PST.  Instead, the density of 
serotonin-labelled boutons contacting neurons with viral transgene expression was 
assessed.  As previously mentioned in this thesis, there was no difference in the density of 
serotonergic boutons contacting neurons in Hx + LV/PST animals, compared to Hx + LV/GFP.  
While data from animals treated with PSA mimetic peptides suggests this treatment 
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enhances sprouting of serotonergic fibres, it may be possible that either (i) intraspinal 
delivery of LV/PST does not result in enhanced sprouting or increase synaptogenesis of 
serotonergic fibres in vivo, or (ii) LV/PST delivery may result in enhanced sprouting of 
serotonergic fibres, similar to treatment with PSA mimetic; however, these fibres do not 
form synaptic connections.  Further work is required to assess this. 
Currently, there is no other data available regarding synaptophysin immunolabelling 
following delivery of LV/PST to the injured spinal cord.  Similarly, studies utilising PSA 
mimetic peptides have not investigated synaptophysin immunostaining.  What is far more 
common, is the examination of specific types of synaptic markers, such as serotonin, 
VGLUT1 and ChAT (Mehanna et al., 2010).  As previously mentioned, it has been reported 
that treatment with a PSA mimetic increases sprouting of serotonergic fibres following 
compression injury in mice.  In a separate study, it was found that the density of both 
VGLUT1 and ChAT terminals were increased caudal to a thoracic-level injury in mice 
(Mehanna et al., 2010).  It is likely that if synaptophysin immunolabelling were examined in 
these animals, the increase in the density of both VGLUT1 and ChAT-positive boutons would 
also be correlated with an increase in synaptophysin immunolabelling.  
It is possible that the relatively limited expression of PSA following delivery of LV/PST to the 
spinal cord, in the data presented in this thesis, is responsible for both the lack of functional 
improvement and synaptogenesis in these animals.  In other studies, the subdural 
administration of PSA mimetics allows the circulation of these peptides throughout the 
spinal cord (Marino et al., 2009; Mehanna et al., 2010; Pan et al., 2014), whereas the focal 
delivery method used in this study resulted in PSA expression in a relatively small area.  It is 
likely that the number of injections of viral vector in this study was not sufficient to induce 
widespread PSA expression, which may explain both the limited behavioural recovery and 
limited synapse formation observed in Hx + LV/PST injected animals. 
There was also no difference in the density of synaptophysin or serotonin-labelled boutons 
in animals injected with LV/PST only, in the absence of hemisection injury, compared to 
those injected with LV/GFP.  This is not surprising, given that other studies investigating 
plasticity-promoting molecules, for example, ChABC, have not shown any alterations in 




In this study, we have demonstrated a mild improvement in locomotor function following LV 
vector-mediated PSA expression in a mid-cervical model of SCI.  This slight improvement in 
locomotor function was not associated with an increase in the density of synaptophysin or 
serotonin-labelled boutons contacting neurons with transgene expression.  Moreover, there 
was no difference in the number of PNNs or the density of PNN immunolabelling in animals 
treated with induced PSA expression.  This study is the first to examine induced PSA 
expression mediated by LV vectors in a cervical-level model of SCI.  Moreover, this is the 
first study to use behavioural testing to examine the efficacy of LV vector-mediated PSA 
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Chapter 7: General discussion and conclusions 
 
7.1 Conclusions 
There are several conclusions that can be drawn from the data presented in this thesis.   
Firstly, PNNs detected by WFA labelling, in addition to antibodies raised against molecules 
LN1 and neurocan, are ubiquitously distributed throughout the cervical spinal cord.  Using 
double-immunofluorescent labelling it was found that WFA-labelled PNNs do not always 
contain LN1 or neurocan, and vice versa.  Moreover, the proportion of neurons surrounded 
by PNNs is highly variable, depending on their location in the spinal cord. For example, the 
percentage of neurons with PNNs gradually increases as you move through the dorsal-
ventral axis.  It was also revealed that PNN-expressing neurons receive differing levels of 
serotonergic, cholinergic and inhibitory synaptic inputs. 
Secondly, it was found that to allow high transgene expression in neurons in the cervical 
spinal cord and the sensorimotor cortex, lentiviral vectors should be driven by a synapsin I 
promoter, rather than a ubiquitous cell type promoter such as CMV.  This results in strong 
transgene expression in neurons, but not astrocytes or microglial cells, 2 and 6 weeks 
following delivery to the CNS.  Furthermore, using immunohistochemistry, it was shown that 
a lentiviral vector carrying the PST gene results in robust and long-term expression of PSA 
following delivery to the spinal cord and sensorimotor cortex.   
Next, it was determined that while a decrease in PSA expression in cultures of embryonic 
hippocampal neurons corresponds to an increase in the proportion of cultured neurons with 
a PNN, enzymatic removal of PSA during the first week in vitro does not alter the 
development of PNNs.  Moreover, removal of PSA does not affect the formation of 
synapses.  Following on from this data, it was also shown that induced PSA in the adult 
spinal cord does not alter WFA binding to PNNs, or the detection of PNNs using LN1 
antibody. 
Finally, it was found that induced PSA expression above and below cervical SCI leads to a 
general improvement in hindlimb, but not forelimb locomotor function.  No anatomical 
basis for this locomotor improvement could be determined in this thesis, as induced PSA 
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expression did not correspond to a reduction in the number of PNNs and did not alter the 
density of serotoninergic boutons contacting PSA-expressing neurons in vivo.  
 
7.2 Discussion 
Previous research has revealed the heterogeneous distribution and composition of PNNs in 
the spinal cord (Vitellaro-Zuccarello et al., 2007; Galtrey et al., 2008).  In chapter 3 of this 
thesis, more neurons were surrounded by PNNs in the ventral regions of the spinal cord, 
compared to the dorsal horn, and dorsal regions of the intermediate grey matter.  Some 
PNNs lacked labelling for the supporting molecule LN1, which is interesting considering that 
previous studies using LN1 knockout mice, in addition to in vitro studies, have suggested 
LN1 expression is critical for the production of condensed PNNs (Carulli et al., 2010; Kwok et 
al., 2010).  Similarly, some PNNs also lacked labelling for the CSPG neurocan, which is 
unsurprising, given that other studies have noted relatively low expression of neurocan in 
the spinal cord compared to expression of other CSPGs (Galtrey et al., 2008).  Thus, it is 
likely that the PNNs devoid of neurocan labelling contain other CSPGs, such as versican, 
aggrecan or phosphacan.  
To date, there is relatively little available data regarding the phenotype and function of 
neurons located in lamina X of the spinal cord.  In data presented in chapter 3 of this thesis, 
a population of neurons in lamina X were surrounded by dense, WFA-labelled PNNs, that 
showed little LN1 or neurocan labelling.  Phenotypic analysis of these neurons suggested 
some were positive for the calcium-binding protein parvalbumin, but not for calbindin, or 
the cholinergic neuronal marker ChAT, and received low serotonergic and cholinergic inputs.  
Some studies have suggested that a population of lamina X neurons may be activated during 
stimulated locomotion, and others have suggested the presence of propriospinal neurons in 
lamina X (Dai et al., 2005; Siebert et al., 2010b).  It would be interesting to further 
characterise these neurons, to try to elucidate their phenotype. 
While previous studies have  characterised the types of PNN-expressing neurons in the 
spinal cord, there is little available data regarding the types and relative amounts of synaptic 
inputs received by these cells.  With mounting research suggesting that modulation of PNNs 
can promote neuroplasticity and locomotor recovery after SCI (Alilain et al., 2011; Dyck and 
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Karimi-Abdolrezaee, 2015), it is therefore vital to understand the circuitry of PNN-expressing 
neurons, to be able to accurately predict the consequences of manipulating inputs to these 
neurons after injury.  This study revealed that PNN-expressing neurons receive varying 
levels of serotonergic, cholinergic and GABAergic inputs, depending on their location in the 
spinal cord.  Moreover, there was no correlation observed between the density of specific 
types of synaptic inputs to PNN-expressing cells and the density of PNN immunolabelling.  
Although the development of PNNs coincides with the stabilisation of synapses in vivo, it 
may be that the amount of matrix deposited on the neuronal surface is not dependent on 
the density, or type of synaptic inputs to these neurons.  
Currently, there is little data available regarding the molecular cues or interactions 
responsible for initiation of PNN formation in vivo.  Based on preliminary data from our 
laboratory, we proposed that down-regulation of PSA may correspond to the time at which 
PNN formation is commenced in the spinal cord.  This was addressed further in chapter 4, 
and to a lesser extent, chapters 5 and 6 of this thesis.  In chapter 4, it was found that 
cultured hippocampal neurons expressed high levels of PSA during the first two weeks in 
vitro, following which levels declined.  Conversely, few PNNs were found in culture until the 
second week in vitro, but they increased during the third week.  While these observations 
are consistent with preliminary data obtained in this laboratory, attempts to validate a 
causal relationship between PSA down-regulation and PNN formation by enzymatically 
removing PSA from culture were unsuccessful.  While two-dimensional cultures, like the 
system used in chapter 4 of this thesis, are commonly used in research, the cells share little 
similarity with those found in vivo.  This is partly based on the complex, three-dimensional 
cytoarchitecture of the CNS, which consists of closely-associated neurons and glial cells, 
ensheathed by the interstitial extracellular matrix.  Consequently, in chapters 5 and 6 of this 
thesis, the proposed relationship between PSA and PNNs was addressed in vivo.   
Based on preliminary data, it was hypothesised that induced PSA expression in vivo can 
reduce WFA binding to its site within the PNN (unpublished observation, Dr Xuenong Bo and 
Dr Yi Zhang).  The data presented in chapter 5 of this thesis showed strong PSA expression 
following delivery of a lentiviral vector carrying the PST transgene to the sensorimotor 
cortex.  Due to problems with the immunolabelling of this tissue, the number and density of 
PNNs in the area of induced PSA expression could not be reliably analysed, thus this study 
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was discontinued and was repeated in the cervical spinal cord.  In chapter 6, it was found 
that induced PSA expression in the spinal cord did not affect either the proportion of 
neurons with a PNN, or the density of PNN labelling on individual neurons.  This, coupled 
with the data presented in chapter 4, suggests that PSA is unable to affect the development, 
or the maintenance, of PNN expression either in vitro or in vivo.  This is interesting, 
considering the preliminary data obtained from this laboratory suggesting an inverse 
relationship between PSA expression and PNN formation in vivo, in addition to published 
studies from other laboratories suggesting contrasting functions of PSA and PNNs in the 
regulation of neuroplasticity in the visual cortex (Pizzorusso et al., 2002; Di Cristo et al., 
2007a).   
While the data presented in this thesis did not support a direct relationship between PSA 
and the PNN, at least in the adult CNS, chapter 6 of this thesis aimed to address whether 
induced expression of PSA using LV/PST could still promote neuroplasticity and locomotor 
recovery following cervical-level SCI.  While there was no improvement in forelimb 
locomotor function in animals with LV/PST, there was a minor improvement in hindlimb 
function, observed from four weeks following injury.  It was also found that enhanced 
synaptogenesis, and specifically, involving serotonergic neurons, was not responsible for 
this functional improvement.  While no other studies have investigated serotonergic 
sprouting following LV/PST delivery to the injured spinal cord, enhanced sprouting has been 
observed following delivery of PSA mimetic peptide (Pan et al., 2014).  What has been 
observed, however, is enhanced sprouting of corticospinal neurons (El Maarouf et al., 2006).  
In the study presented in this thesis, BDA was injected into the contralateral sensorimotor 
cortex, to assess the sprouting of corticospinal fibres post-injury.  Unfortunately, however, 
BDA labelling was very poor and was difficult to observe in the grey matter of both Hx + 
LV/GFP and Hx + LV/PST animals (Supplementary Figure 4), but could be seen in the dorsal 
columns (Supplementary Figure 5).  For this reason, corticospinal axons could not be 
quantified here, however, it could be proposed that enhanced axonal sprouting of 
corticospinal neurons, and the formation of new spinal circuits could be responsible for the 
recovery of function observed in this study.  
Enhanced regeneration of sensory neurons in a dorsal column transection lesion, following 
delivery of LV/PST has previously been observed by the Bo laboratory (Zhang et al., 2007b).  
 226 
In the final results chapter, it was found that hemisected animals with LV/PST delivery had a 
higher incidence of autotomy, compared to those injected with control viral vector.  Some 
studies indicate that autotomy in experimental models of SCI may be due to the 
development of neuropathic pain, a common adverse effect of SCI in rodents and humans 
alike (Zhang et al., 2005; Wang et al., 2016).  While no signs of neuropathic pain were 
observed in animals treated with LV/PST in this study, the animals with severe autotomy 
were not included in this behavioural testing, thus the data is not an accurate 
representation of all LV/PST treated animals and is likely skewed.  As LV/PST delivery has 
been shown to enhance regeneration of sensory neurons following SCI (Zhang et al., 2007b), 
one hypothesis that could be drawn from this data is that LV/PST delivery has resulted in the 
enhanced sprouting of sensory neurons, which has led to the development of neuropathic 
pain.  
 
7.3 Future work 
While the data presented in chapter 3 of this thesis has provided a detailed characterisation 
of LN1 and neurocan labelled PNNs in the cervical spinal cord, what is lacking from this 
study is information regarding other components of the PNN, such as additional members of 
the CSPG family (aggrecan, versican and phosphacan), in addition to other supporting 
molecules such as hyaluronan and tenascin-R.  Recent work has identified the 
chemorepulsive protein semaphorin 3A as a component of PNNs in the rodent brain.  It 
would be interesting to include semaphorin 3A in future studies, as little information is 
currently available regarding this molecule and PNNs in the spinal cord.  The reasons LN1 
and neurocan were selected for analysis in this thesis were, firstly, previous research has 
shown LN1 expression to be vital for the development of PNNs both in vivo and in vitro 
(Carulli et al., 2010; Kwok et al., 2010).  Secondly, both LN1 and neurocan expression has 
been shown in PNNs in the spinal cord, in addition to in cultures of embryonic neurons 
(Miyata et al., 2005; Galtrey et al., 2008).  Future work, building on the data presented in 
this thesis, should therefore, examine other components of PNNs, and could also examine 
the distribution of PNNs in the thoracic and lumbosacral spinal cord, to examine whether 
there are differences in PNNs along the rostrocaudal axis of the spinal cord. 
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Chapter 3 also showed the heterogeneous distribution of PNNs throughout the dorsoventral 
axis of the spinal cord.  One region of particular interest in this study was lamina X, where a 
population of neurons expressing dense, WFA-labelled PNNs, were located.  While the data 
presented here showed that a proportion of these neurons are positive for the calcium-
binding protein parvalbumin, the phenotype of other lamina X PNN-expressing neurons is 
still unknown.  It would be interesting to investigate these neurons in more detail, to 
elucidate the phenotype of the parvalbumin-negative, PNN-expressing neurons in lamina X.    
The in vitro experiments performed in chapter 4 provided no evidence to suggest a causal 
relationship between PSA down-regulation and the formation of PNNs.  However, as 
previously mentioned, two-dimensional cultures do not accurately represent the 
environment in vivo, therefore may not have been the optimal cellular model.  For example, 
in the data presented in this thesis, removal of PSA from cultured neurons did not alter the 
formation of synapses to PNN-expressing neurons or affect the global density of 
synaptophysin labelling.  Interestingly, however, removing PSA from the cortex in 
organotypic slice cultures has been shown to promote early maturation of inhibitory 
synapses, and was consistent with additional data obtained in vivo (Di Cristo et al., 2007a).  
For this reason, it would be interesting to repeat the experiments performed in chapter 4, 
using organotypic cultures, which more accurately represent the tissue environment in vivo.  
Moreover, the quantification method used to assess synaptophysin-labelled boutons in 
contact with PNN-expressing neurons in these cultures did not permit the evaluation of 
inputs to dendrites; only boutons in contact with the neuronal cell body could be assessed.  
As previous research has shown endo-N-mediated PSA removal from cultured hippocampal 
neurons resulted in a reduction in the density of synaptic inputs to dendrites, it may be that 
the quantification method used in this thesis was not sufficient. 
Building on this, it would also be interesting to examine the effect of PSA removal in vivo on 
the formation and structure of PNNs.  There are two ways in which this could be performed.  
Firstly, intraventricular or intracortical delivery of endo-N to postnatal animals, to selectively 
cleave PSA from the surface of cells in vivo.  This technique has been performed in a number 
of studies, and results in widespread loss of PSA throughout the brain (Daston et al., 1996; 
Di Cristo et al., 2007a; Battista and Rutishauser, 2010).  Secondly, using knockout mice 
devoid of one or both of the polysialyltransferase enzymes (Eckhardt et al., 2000; Oltmann-
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Norden et al., 2008; Röckle and Hildebrandt, 2016).  Subsequent histological analysis could 
then be performed at different time points to assess whether PSA removal had any effect on 
the development of the PNN.  Performing these experiments would provide additional 
information regarding the proposed relationship between PSA and the PNN in vivo.  
The final results chapter in this thesis showed an improvement in hindlimb locomotor 
recovery in hemisected rats following intraspinal delivery of LV/PST, compared to those that 
received injections of control virus.  While no improvement in the density of synaptophysin 
or serotonergic-labelled boutons was observed contacting neurons which displayed 
expression of viral transgenes, it would be interesting to evaluate other types of synaptic 
markers, including those that have previously been shown to be altered in other studies 
investigating LV/PST delivery to the injured spinal cord, or those using PSA mimetic peptide.  
Examples of these include cholinergic and corticospinal synapses (El Maarouf et al., 2006; 
Mehanna et al., 2010; Pan et al., 2014).   
While no improvement in forelimb function was observed in animals treated with LV/PST, 
there was a general trend towards improvement in all behavioural tests.  This suggests that 
induced PSA expression has a minor effect in spinal cord injured animals, but not enough to 
elicit functional improvement.  Although four intraspinal injections were used in the study 
presented in chapter 6 of this thesis, and PSA expression encompassed a fairly large region 
of the spinal cord, other studies revealing functional improvement have relied on the use of 
PSA mimetic peptide, delivered intrathecally (Mehanna et al., 2010; Pan et al., 2014).  Thus, 
it would be interesting to deliver LV/PST using more injections, to try to cover a wider region 
of the spinal cord, or using a different type of viral vector, such as adeno-associated vectors, 
that are able to transduce a relatively large area of the CNS following direct delivery 
(McCown, 2011).  Moreover, in this study, LV/PST was only delivered to the ipsilateral side 
of the spinal cord.  It is now well-regarded that spontaneous axonal sprouting occurs after 
injury, and axons have been shown to cross across the spinal cord midline, from the 
contralateral to the ipsilateral side of the spinal cord.  Thus, it would be interesting to also 
inject LV/PST into the contralateral side of the spinal cord, as well as rostral and caudal to 
the lesion site, to try encourage the sprouting of axons across the midline.  
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With a strong trend towards locomotor recovery observed in the Montoya staircase test, a 
measure of skilled locomotor function, in animals injected with LV/PST, it could be 
speculated that combining LV/PST administration with daily neurorehabilitation would 
result in more significant improvement in forelimb locomotor function.  Mounting evidence 
is showing the beneficial role of rehabilitation in improving locomotor recovery from SCI, 
particularly when used in combination with targeted therapeutics (García-Alías et al., 2009; 
Wang et al., 2011).   
Although considered a good model for the evaluation of neuroplasticity and axonal 
regeneration in rodents, stab lesions, such as the hemisection model that was used in this 
study are rarely observed in clinical SCI (SpinalResearch, 2016).  Commonly, lesions to the 
spinal cord are a result of compression or contusion injury, resulting from dislodgement of 
one of more of the vertebrae (SpinalResearch, 2016).  Therefore, it would also be interesting 
to evaluate intraspinal delivery of LV/PST following either contusion or compression injury 
in rodents.  A reliable, hemi-contusion model of SCI has been developed for the mid-cervical 
spinal cord, which would allow the evaluation of both fore and hindlimb locomotor function 
following delivery of LV/PST (Dunham et al., 2010; Mondello et al., 2015). 
 
7.4 Concluding remarks 
One of the main aims of this thesis was to evaluate the proposed relationship between 
expression of PSA and the development of PNNs in more detail.  While the data presented 
here does not suggest a link between the two, there are subsequent experiments that could 
be performed to evaluate this in more detail.  This thesis also evaluated the detailed 
distribution of WFA, LN1 or neurocan-labelled PNNs in the cervical spinal cord and the 
relationship between the density of PNN and synaptic immunolabelling.  Finally, induced 
PSA expression using a lentiviral vector was shown to improve locomotor recovery following 
SCI.  However, the cause of this functional improvement has not yet been determined.  This 
study was the first to evaluate any PSA-based therapy in a cervical-level injury, and also the 
first to investigate the behavioural improvements associated with viral vector-mediated 




Supplementary Figure 1.  Average size of PNN-expressing neurons in the cervical spinal 
cord 
 
Supplementary Figure 1.  Average size of PNN-expressing neurons in the cervical spinal 
cord. 
Quantification of the mean size of the cell bodies of neurons expressing LN1, neurocan or 
WFA-labelled PNNs in the (A) dorsal horn, (B) dorsal intermediate grey matter, (C) ventral 
intermediate grey matter, (D) ventral horn (motor neurons) and (E) ventral horn 
(interneurons).  No difference was observed in the mean size of neurons in any region of the 
spinal cord (p>0.05, one-way ANOVA, n=3) 
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Supplementary Figure 3.  FLS scoring system. 
 
Forelimb Locomotor Scale (FLS) 
0. No movements of the forelimb (shoulder, elbow or wrist joints) 
1. Slight movements of one or two joints of the forelimb 
2. Extensive movement of one joint and slight movement of another joint of the forelimb 
3. Slight movement of all three joints of the forelimb 
4. Extensive movement of one joint and slight movement of two joints of the forelimb 
5. Extensive movement of two joints and slight movement of one joint of the forelimb 
6. Extensive movement of all three joints of the forelimb 
7. Plantar placement of the forelimb with no weight support 
8. Dorsal stepping only 
9. Dorsal stepping and/or occasional plantar stepping 
10. Frequent plantar stepping 
11. Continuous plantar stepping 
12. Continuous plantar stepping with paw position rotated (either at initial contact, lift off or 
both) 
13. Continuous plantar stepping with paw position parallel (either at initial contact, lift off or 
both) 
14. Continuous plantar stepping with paw position rotated (either at initial contact, lift off or 
both) and occasional toe clearance 
15. Continuous plantar stepping with paw position parallel (either at initial contact, lift off or 
both) and occasional toe clearance 
16. Continuous plantar stepping with paw position parallel (either at initial contact, lift off or 
both) and frequent toe clearance 
17. Continuous plantar stepping with paw position parallel (either at initial contact, lift off or 
both) and continuous toe clearance  
 
Supplementary Figure 4.  BDA labelling in SCI animals 
Supplementary Figure 4.  BDA labelling in injured animals. 
Quantification of BDA was not possible due to the poor labelling observed in the hemisected spinal cord, 6 weeks post-lesion.  (A) BDA labelling was weak in 
the ipsilateral spinal cord of animals in the Hx + LV/GFP treatment group.  (B) Similarly, BDA labelling was weak in the ipsilateral spinal cord of animals in the 
Hx + LV/PST group.  Scale bar = 100 m.  
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Supplementary Figure 5.  BDA labelling in the dorsal columns of SCI animals. 
 
Supplementary Figure 5.  BDA labelling in the dorsal columns of injured animals. 
As previously shown, BDA labelling was poor in the ipsilateral grey matter and could not be used for quantification.  However, BDA labelling was observed in 
the dorsal columns of both (A) Hx + LV/GFP and (B) Hx + LV/PST treated animals.  Scale bar = 100 m. 
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